"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,S,US D0540606 S,026-857-681-257-06X,2007-04-17,2007,US 23604905 F,2005-08-10,US 23604905 F,2005-08-10,Inflatable lumbar support,,GREENBERG DANIEL;;GREENBERG JONATHAN,GREENBERG DANIEL;;GREENBERG JONATHAN,,https://lens.org/026-857-681-257-06X,Design Right,no,0,4,1,1,0,,,0609;;D 6604,0,0,,,,EXPIRED
2,US,A1,US 2011/0191684 A1,098-638-671-244-451,2011-08-04,2011,US 201113081360 A,2011-04-06,US 201113081360 A;;US 49324809 A;;US 7668808 P;;US 32164310 P,2008-06-29,Method of Internet Video Access and Management,"A system and apparatus for enabling the end user to schedule the display of online videos and dynamically displaying online videos according to a user preference. The system provides an editorially-selected guide to online videos in which videos from existing online video providers are gathered under a single portal and thereby provides the end user a directory through which the user can view recommended videos as presented by the system, or personalize the selections into a dynamically-generated subset of videos. The system also provides a seamless playlist of multiple videos from various websites, and allows the user to manage and re-sequence this playlist.",TV1 COM HOLDINGS LLC,GREENBERG JONATHAN,,https://lens.org/098-638-671-244-451,Patent Application,yes,2,89,1,2,0,G06F3/01;;G11B27/34;;H04N21/8586;;G06F3/01,G06F3/01,715/719,0,0,,,,DISCONTINUED
3,CN,A,CN 114599477 A,090-498-670-126-290,2022-06-07,2022,CN 202080068948 A,2020-03-18,US 201962906522 P;;US 2020/0023438 W,2019-09-26,BACKING MATERIAL FOR WELDING,"A backing plate includes a synthetic diamond portion configured to abut a joint region during a welding operation. The welding jig includes a plurality of gripping blocks, each gripping block including a synthetic diamond portion configured to abut a pipe joint region during a welding operation. Because the back plate and the clamping block each comprise a synthetic diamond portion, the back plate and the clamping block can withstand high welding temperatures without damaging or reducing the quality of the welding.",RING AND BALL MACHINERY LTD COMPANY,GREENBERG JONATHAN E,,https://lens.org/090-498-670-126-290,Patent Application,no,0,0,8,8,0,B23K37/0531;;B23K37/06;;B23K37/0443;;B23K2101/10;;B23K9/035;;B23K37/0531;;B23K37/0443;;B23K2101/06;;B23K2101/10;;B23K37/06,B23K37/053;;F16L13/02,,0,0,,,,PENDING
4,US,A1,US 2009/0327100 A1,011-019-375-342-592,2009-12-31,2009,US 49324809 A,2009-06-29,US 49324809 A;;US 7668808 P,2008-06-29,Method of Internet Video Access and Management,"A system and apparatus for enabling the end user to schedule the display of online videos and dynamically displaying online videos according to a user preference. The system provides an editorially-selected guide to online videos in which videos from existing online video providers are gathered under a single portal and thereby provides the end user a directory through which the user can view recommended videos as presented by the system, or personalize the selections into a dynamically-generated subset of videos. The system also provides a seamless playlist of multiple videos from various websites, and allows the user to manage and re-sequence this playlist.",TV1 COM HOLDINGS LLC,GREENBERG JONATHAN;;EKHAUS DAVID,,https://lens.org/011-019-375-342-592,Patent Application,yes,5,33,1,2,0,G06Q30/0601;;G06Q30/0601;;G06F3/0481;;G06F3/0481;;G06F16/70;;G06F16/70,G06Q30/00;;G06F3/048;;G06F17/30,705/27;;707/102;;715/720;;715/835,0,0,,,,DISCONTINUED
5,US,B1,US 6219814 B1,157-919-641-183-685,2001-04-17,2001,US 77230796 A,1996-12-23,US 77230796 A,1996-12-23,Method and apparatus for selectively varying error correcting code (ECC) power in a direct access storage device (DASD),A method and apparatus are provided for utilizing error correction code (ECC) in a direct access storage device (DASD). A plurality of predetermined file conditions are identified. Each of the plurality of predetermined file conditions are related to a read data raw error rate. An ECC burst control is provided with an ECC engine for varying an ECC correction power of the ECC engine. The ECC correction power is selectively varied responsive to the identified predetermined file conditions.,IBM,COKER JONATHAN DARREL;;GREENBERG RICHARD,INTERNATIONAL BUSINESS MACHINES CORPORATION (1997-02-20);;HITACHI GLOBAL STORAGE TECHNOLOGIES NETHERLANDS B.V (2002-12-31),https://lens.org/157-919-641-183-685,Granted Patent,yes,33,45,2,2,0,G11B20/1833;;H03M13/35;;G11B20/1833;;H03M13/35,G11B20/18;;H03M13/35,714/763;;714/769;;714/774,2,0,,,"Enhanced Addressing Error Detection System, J.M. Karp and S.C. West, IBM Technical Disclosure Bulletin, vol. 34, No. 7B, Dec. 1991, pp. 31-37.;;Fully Self-Contained Memory Card Extended Error Checking/Correcting Hardware Implementation, D.L. Arlington, E.K. Evans, D.A. Kleinman, W.L. Mostowy, and A.F. Weaver, IBM Technical Disclosure Bulletin, vol. 31, No. 5, Oct. 1988, pp. 352-355.",EXPIRED
6,SG,A1,SG 65038 A1,095-739-076-671-655,1999-05-25,1999,SG 1997004390 A,1997-12-08,US 77230796 A,1996-12-23,Method and apparatus for selectively varying error correcting code(ecc) power in a direct access storage device(dasd),,IBM,COKER JONATHAN DARREL;;GREENBERG RICHARD,,https://lens.org/095-739-076-671-655,Patent Application,no,0,0,2,2,0,G11B20/1833;;H03M13/35;;G11B20/1833;;H03M13/35,G11B20/18;;H03M13/35,,0,0,,,,PENDING
7,WO,A1,WO 2002/037297 A1,037-436-757-180-163,2002-05-10,2002,US 0146067 W,2001-10-31,US 70427300 A,2000-11-01,METHOD AND SYSTEM FOR SELECTING ADVERTISEMENT BASED ON USER INTERACTION WITH AN ELECTRONIC PROGRAM GUIDE,"A method and system are described for delivering targeted advertisements in an electronic program guide (24). The method includes the monitoring of the EPG user's actions (26) in the EPG and the determination that the user is paying particular attention (28) to a given program item in the EPG. This determination may be based on the amount of time the user lingers over a given program item or the user's selection of a program item cell. A characteristic (30) of this given program item is then used to select an advertisement (32) having a similar characteristic, which ad is then displayed to the user on the EPG screen (34). This characteristic may also be found through monitoring of other user actions in the EPG, such as performance of a search or sort or selection of a trivia question or news item.",GIST COMMUNICATIONS INC,FINISTER PAUL;;GREENBERG JONATHAN;;ROTH CLIFFORD,,https://lens.org/037-436-757-180-163,Patent Application,yes,5,9,2,2,0,G06Q30/02;;H04N7/163;;H04N21/4331;;H04N21/4532;;H04N21/478;;H04N21/4821;;H04N21/812;;H04N21/44224;;H04N21/44224,G06Q30/00;;H04N5/445;;H04N7/16,,0,0,,,,PENDING
8,CA,A,CA 1080073 A,181-492-629-713-129,1980-06-24,1980,CA 240000 A,1975-11-19,US 52532774 A,1974-11-20,SUTURES WITH REDUCED DIAMETER AT SUTURE TIP,"A needle-suture combination is provided in which the suture has at its tip within a recess at the blunt end of the needle and extending to a segment adjacent the attachment of the suture to the needle, a cross-sectional area and a cross-sectional amount of suture material less than the cross-sectional area and the cross-sectional amount of suture material in the remainder of its length. In one embodiment, the invention provides a weakened segment which permits a surgeon to separate the needle from the suture by a sharp tug. In another embodiment the invention also permits the use of needles having substantially the same external diameter as the suture attached thereto so that the suture in the sewn tissue substantially plugs the needle hole.",ETHICON INC,GREENBERG JONATHAN F;;QUADE ROBERT T,,https://lens.org/181-492-629-713-129,Granted Patent,no,0,0,6,6,0,A61B17/06004;;A61B17/06195;;A61B2090/037;;A61B17/06004;;A61B17/06195;;A61B2090/037,A61B17/06;;A61B19/00,128-124,0,0,,,,EXPIRED
9,US,A,US 3926194 A,091-549-685-052-953,1975-12-16,1975,US 52532774 A,1974-11-20,US 52532774 A,1974-11-20,Sutures with reduced diameter at suture tip,"A needle-suture combination is provided in which the suture has at its tip within a recess at the blunt end of the needle and extending to a segment adjacent the attachment of the suture to the needle, a cross-sectional area and a cross-sectional amount of suture material less than the cross-sectional area and the cross-sectional amount of suture material in the remainder of its length. In one embodiment, the invention provides a weakened segment which permits a surgeon to separate the needle from the suture by a sharp tug. In another embodiment the invention also permits the use of needles having substantially the same external diameter as the suture attached thereto so that the suture in the sewn tissue substantially plugs the needle hole.",ETHICON INC,GREENBERG JONATHAN FRED;;QUADE ROBERT T,,https://lens.org/091-549-685-052-953,Granted Patent,no,4,238,6,6,0,A61B17/06004;;A61B17/06195;;A61B2090/037;;A61B17/06004;;A61B17/06195;;A61B2090/037,A61B17/06;;A61B19/00,128/339,0,0,,,,EXPIRED
10,US,A1,US 2010/0135562 A1,199-224-714-245-780,2010-06-03,2010,US 62549909 A,2009-11-24,US 62549909 A;;US 11858508 P,2008-11-28,COMPUTER-AIDED DETECTION WITH ENHANCED WORKFLOW,"Described herein is a technology for supporting an efficient workflow. In one implementation, a computer system receives at least one image of a subject and at least one corresponding image finding ( 302 ). The image finding identifies one or more regions-of-interest in a subject area of the image. The computer system generates enhanced annotations based on the image finding ( 306 ), overlays the enhanced annotations on the image ( 310 ) and displays ( 312 ) the resulting image to facilitate image assessment by a skilled user.",SIEMENS COMP AIDED DIAGNOSIS L,GREENBERG MICHAEL;;LEICHTER ISAAO;;STOECKEL JONATHAN,SIEMENS ISRAEL LTD (2010-02-07),https://lens.org/199-224-714-245-780,Patent Application,yes,1,46,1,1,0,G06T7/0012;;G06T7/0012;;G06T2200/24;;G06T2200/24;;G06T2207/10072;;G06T2207/10072;;G06T2207/10116;;G06T2207/10116;;G06T2207/10132;;G06T2207/10132;;G06T2207/30068;;G06T2207/30068;;G16H30/20;;G16H30/20;;G16H30/40;;G16H30/40,G06K9/00;;G06K9/46,382/131;;382/195;;382/170;;382/254,0,0,,,,DISCONTINUED
11,AU,A,AU 2002/027166 A,126-292-600-737-492,2002-05-15,2002,AU 2002/027166 A,2001-10-31,US 70427300 A;;US 0146067 W,2000-11-01,Method and system for selecting advertisement based on user interaction with an electronic program guide,,GIST COMMUNICATIONS INC,FINISTER PAUL;;GREENBERG JONATHAN;;ROTH CLIFFORD,,https://lens.org/126-292-600-737-492,Patent Application,no,0,0,2,2,0,G06Q30/02;;H04N7/163;;H04N21/4331;;H04N21/4532;;H04N21/478;;H04N21/4821;;H04N21/812;;H04N21/44224;;H04N21/44224,G06Q30/00;;H04N5/445;;H04N7/16,,0,0,,,,PENDING
12,DE,A1,DE 2552098 A1,142-388-322-205-723,1976-05-26,1976,DE 2552098 A,1975-11-20,US 52532774 A,1974-11-20,NADEL-NAHTMATERIAL-KOMBINATION,,ETHICON INC,GREENBERG JONATHAN FRED;;QUADE ROBERT T,,https://lens.org/142-388-322-205-723,Patent Application,no,4,0,6,6,0,A61B17/06004;;A61B17/06195;;A61B2090/037;;A61B17/06004;;A61B17/06195;;A61B2090/037,A61B17/06;;A61B19/00,,0,0,,,,EXPIRED
13,NZ,A,NZ 584381 A,128-975-486-075-119,2011-10-28,2011,NZ 58438103 A,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 A;;NZ 57150803 A,2002-05-24,Neutralizing human anti-IGFR antibody,"Provided is a method for producing an IGFR antibody peptide with a specified amino acid sequence, comprising introducing the corresponding polynucleotide to Chinese hamster ovary (CHO) cells for cellular production. The expression vector can contain a CMV promoter, DHFR gene and hygromycin B gene with TK promoter.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A,,https://lens.org/128-975-486-075-119,Patent Application,no,0,0,1,1,0,,A61K39/395;;C07H21/04;;C07K16/00;;C12N5/12;;C12N15/00,,0,0,,,,DISCONTINUED
14,CN,A,CN 116284392 A,079-204-901-167-520,2023-06-23,2023,CN 202211558717 A,2017-03-10,US 201662306354 P;;CN 201780022535 A;;US 2017/0021958 W,2016-03-10,Activin type 2 receptor binding proteins and uses thereof,"The present disclosure provides ActRII binding proteins, such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII binding proteins. In certain aspects, the ActRII binding proteins inhibit or antagonize ActRII activity. In addition, the present disclosure provides compositions and methods for diagnosing and treating: diseases and disorders associated with muscle loss; fibrosis conditions; inflammatory diseases or disorders, cardiovascular diseases or disorders, lung diseases or disorders, musculoskeletal diseases or disorders, neurological diseases or disorders, ocular diseases or disorders, skeletal diseases or disorders, autoimmune diseases or disorders, or metabolic diseases or disorders; wound healing; and cancer, as well as other ActRII mediated diseases and disorders.",ACCELERON PHARMA INC;;ADIMAB INC,KUMAR RAVINDRA;;BELK JONATHAN;;GREENBERG ALBERT;;SAKO DIANNE;;CASTONGUAY ROSELYNE,,https://lens.org/079-204-901-167-520,Patent Application,no,0,0,25,25,0,C07K16/2863;;C07K2317/565;;C07K2317/56;;C07K2317/76;;C07K2317/92;;C07K2317/24;;C07K16/2863;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K38/00;;A61P1/16;;A61P11/00;;A61P17/02;;A61P19/00;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P3/00;;A61P3/04;;A61P35/00;;A61P3/10;;A61P37/06;;A61P9/00;;A61P9/04;;A61P9/12;;C07K2317/76;;C07K16/2863;;A61P21/00;;A61P3/00;;C07K2317/92;;C07K2317/21;;A61K2039/505;;C07K16/2863;;C07K2317/92;;C07K2317/76;;C07K2317/55;;C07K2317/21;;C07K2317/34;;A61K38/00;;A61K38/02;;A61K38/16;;C07K5/00;;C07K14/001;;C07K14/47,C07K16/28,,0,0,,,,PENDING
15,US,A1,US 2002/0152224 A1,023-981-289-406-285,2002-10-17,2002,US 8751602 A,2002-03-02,US 8751602 A;;US 27334601 P,2001-03-06,System and method for generating a recommendation guide for use with an EPG,"
   A system and method for generating and displaying customized electronic programming (EPG) data is described. One exemplary method includes the steps of retrieving a plurality of category preferences associated with a user; retrieving a list of displayable program indicators for each of the plurality of category preferences, wherein each of the program indicators included in the list of displayable program indicators is associated with a start time; retrieving program data for each of the program indicators included in the list of displayable program indicators; and providing the retrieved program data for display. 
",ROTH CLIFF;;FINSTER PAUL;;GREENBERG JONATHAN;;RUDERMAN DAVID;;SHINE WILLIAM,ROTH CLIFF;;FINSTER PAUL;;GREENBERG JONATHAN;;RUDERMAN DAVID;;SHINE WILLIAM,GIST COMMUNICATIONS INC (2002-06-17),https://lens.org/023-981-289-406-285,Patent Application,yes,3,154,1,1,0,H04N7/012;;H04N7/163;;H04N21/25891;;H04N21/2668;;H04N21/4668;;H04N21/4821;;H04N21/4826;;H04N21/6581;;H04N21/47;;H04N7/012;;H04N21/4826;;H04N21/6581;;H04N21/4668;;H04N21/4821;;H04N21/25891;;H04N21/2668;;H04N7/163;;H04N21/47,H04N5/445;;H04N7/16;;H04N21/258;;H04N21/2668;;H04N21/466;;H04N21/482;;H04N21/658,707/104.1,0,0,,,,DISCONTINUED
16,AU,A,AU 2001/091116 A,133-088-937-061-120,2002-04-15,2002,AU 2001/091116 A,2001-09-20,US 67059900 A;;US 0129295 W,2000-09-29,Method and system for creating and presenting a recommendation-based guide to television viewing choices,,GIST COMMUNICATIONS INC,FINSTER PAUL;;RUDERMAN DAVID B;;ROTH CLIFF;;GREENBERG JONATHAN;;SHINE WILLIAM,,https://lens.org/133-088-937-061-120,Patent Application,no,0,0,5,5,0,H04N7/17318;;H04N21/252;;H04N21/25883;;H04N21/25891;;H04N21/4524;;H04N21/4532;;H04N21/4622;;H04N21/466;;H04N21/4782;;H04N21/4821;;H04N21/4826;;H04N21/4828;;H04N21/6131;;H04N21/84;;H04N21/44224;;H04N21/44224,H04N5/445;;H04N7/16;;H04N7/173,,0,0,,,,PENDING
17,US,A1,US 2014/0245158 A1,186-481-333-210-512,2014-08-28,2014,US 201313774929 A,2013-02-22,US 201313774929 A,2013-02-22,Virtual Interoperability and Information Sharing Engine,"The present invention includes an emergency management system and method to manage collections of information that provide situation awareness and decision support for specific real world situations, such as hurricanes, sporting events, conventions, power outages, etc. The present invention provides a role-based content assembly process that powers a flexible viewing capability, based on “awareness packages” that have been approved for production use by the commander.",G & H INTERNATIONAL INC,GREENBERG ROBERT;;FISK JONATHAN DAVID;;MOORE SARA L;;SOPEL JEFFREY J,,https://lens.org/186-481-333-210-512,Patent Application,yes,5,8,1,1,0,G06F16/29;;G06F16/9537;;G06F16/9537;;G06F16/29,G06F17/30,715/733,0,0,,,,DISCONTINUED
18,WO,A2,WO 2002/030111 A2,039-173-121-062-752,2002-04-11,2002,US 0129295 W,2001-09-20,US 67059900 A,2000-09-29,METHOD AND SYSTEM FOR CREATING AND PRESENTING A RECOMMENDATION-BASED GUIDE TO TELEVISION VIEWING CHOICES,"A customized and personalized recommendation-based guide is provided. A subset of all available choices are displayed based on what a user is most likely to be interested in, with rankings that put the most highly recommended choices at the top of the displayed recommendation guide. Programming provider information may be received from a user device. Based on the received provider information, available program information for available programs may be retrieved. The available program information may be processed based on user criteria resulting in a customized personal listing. The customized personal program listing may be transmitted to the user device for presentation, the processed program information being a personalized subset of the available program information.",GIST COMMUNICATIONS INC,FINSTER PAUL;;RUDERMAN DAVID B;;ROTH CLIFF;;GREENBERG JONATHAN;;SHINE WILLIAM,,https://lens.org/039-173-121-062-752,Patent Application,yes,0,1,5,5,0,H04N7/17318;;H04N21/252;;H04N21/25883;;H04N21/25891;;H04N21/4524;;H04N21/4532;;H04N21/4622;;H04N21/466;;H04N21/4782;;H04N21/4821;;H04N21/4826;;H04N21/4828;;H04N21/6131;;H04N21/84;;H04N21/44224;;H04N21/44224,H04N5/445;;H04N7/16;;H04N7/173,,0,0,,,,PENDING
19,US,A1,US 2003/0203867 A1,154-664-439-778-991,2003-10-30,2003,US 29046102 A,2002-11-08,US 29046102 A;;US 0121043 W;;US 21564300 P;;US 21955400 P;;US 34813501 P;;US 34419601 P,2000-06-30,NIP3 family of proteins,"
   Methods and compositions for modulating necrosis and for treating neurological and cardiovascular diseases are described. The inventors have shown that BNIP3 is involved in cell necrosis and cell death involved in cardiovascular and neurological diseases. 
",GREENBERG ARNOLD H.;;GEIGER JONATHAN D.;;KIRSHENBAUM LORRIE A.;;HELLNER FAYE,GREENBERG ARNOLD H;;GEIGER JONATHAN D;;KIRSHENBAUM LORRIE A;;HELLNER FAYE,UNIVERSITY OF MANITOBA (2008-10-06),https://lens.org/154-664-439-778-991,Patent Application,yes,2,2,2,7,18,A61K48/00;;A61K48/00;;C07K14/4747;;C07K14/4747,A61K48/00;;C07K14/47,514/44;;424/146.1,0,0,,,,EXPIRED
20,US,B1,US 7848998 B1,061-507-778-568-074,2010-12-07,2010,US 82783107 A,2007-07-13,US 82783107 A,2007-07-13,Convertible hybrid securities,"The present invention is directed to a method comprising the step of issuing one or more convertible hybrid securities by an issuer to one or more investors. The issued hybrid securities may have (1) a legally enforceable covenant (e.g., an RCC) and (2) a mandatory deferral which may require the issuer to withhold certain payments upon an occurrence of specified events. The hybrid securities may be convertible by the investor or callable by the issuer. Upon conversion by an investor, the issuer may make a payment to the investor in an amount of preferred stock up to the par value of the hybrid securities and an amount of common stock for the amount paid over the par value of the hybrid securities. The preferred stock may comprise a dividend rate. The dividend rate may be (1-statutory tax rate) times a coupon for the hybrid securities. The issuer may settle with the investor, or all of the investors, upon the issuer calling the hybrid securities.",MORGAN STANLEY,DHALLA RIZVAN;;SAVASOGLU SERKAN;;GREENBERG SCOTT;;ROSS JONATHAN;;CHOUDHRY JEFFER M,MORGAN STANLEY (2007-07-12);;MORGAN STANLEY SERVICES GROUP INC (2018-09-28),https://lens.org/061-507-778-568-074,Granted Patent,yes,6,8,1,1,0,G06Q40/00;;G06Q40/04;;G06Q40/06;;G06Q40/06;;G06Q40/00;;G06Q40/04,G06Q40/00,705/37;;705/35;;X705 36 R,2,2,010-737-903-168-736;;053-711-624-211-230,10.2307/2328238;;10.2469/faj.v48.n4.74,"A Risk-Reducing Signalling Mechanism Author(s): Edward Henry Robbins and John D. Schatzberg Source: The Journal of Finance, vol. 41, No. 4 (Sep. 1986), pp. 935-949.;;Brooks, Robert, & Attinger, Bill. (1992). Using Duration and Convexity in the Analysis of Callable Convertible Bonds. Financial Analysts Journal, 48(4), 74. Retrieved Aug. 2, 2010, from ABI/INFORM Global. (Document ID: 456886).",ACTIVE
21,WO,A3,WO 2002/030111 A3,139-512-230-341-821,2002-06-27,2002,US 0129295 W,2001-09-20,US 67059900 A,2000-09-29,METHOD AND SYSTEM FOR CREATING AND PRESENTING A RECOMMENDATION-BASED GUIDE TO TELEVISION VIEWING CHOICES,"A customized and personalized recommendation-based guide is provided. A subset of all available choices are displayed based on what a user is most likely to be interested in, with rankings that put the most highly recommended choices at the top of the displayed recommendation guide. Programming provider information may be received from a user device. Based on the received provider information, available program information for available programs may be retrieved. The available program information may be processed based on user criteria resulting in a customized personal listing. The customized personal program listing may be transmitted to the user device for presentation, the processed program information being a personalized subset of the available program information.",GIST COMMUNICATIONS INC,FINSTER PAUL;;RUDERMAN DAVID B;;ROTH CLIFF;;GREENBERG JONATHAN;;SHINE WILLIAM,,https://lens.org/139-512-230-341-821,Search Report,yes,3,0,5,5,0,H04N7/17318;;H04N21/252;;H04N21/25883;;H04N21/25891;;H04N21/4524;;H04N21/4532;;H04N21/4622;;H04N21/466;;H04N21/4782;;H04N21/4821;;H04N21/4826;;H04N21/4828;;H04N21/6131;;H04N21/84;;H04N21/44224;;H04N21/44224,H04N5/445;;H04N7/16;;H04N7/173,,1,1,079-617-652-514-848,10.1007/3-540-48508-2_41,"SMYTH B ET AL: ""SURFING THE DIGITAL WAVE GENERATING PERSONALISED TV LISTINGS USING COLLABORATIVE, CASE-BASEDRECOMMENDATION"", CASE-BASED REASONING RESEARCH AND DEVELOPMENT. INTERNATIONAL CONFERENCE, XX, XX, July 1999 (1999-07-01), pages 561 - 571, XP001030090",PENDING
22,BR,A2,BR 112021023901 A2,093-065-772-865-102,2022-01-18,2022,BR 112021023901 A,2020-05-28,IB 2020055078 W;;US 201962853970 P;;US 201962896478 P,2019-05-29,"Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer","conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, e, uso de um conjugado anticorpofármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer. a presente descrição se refere ao campo das preparações farmacêuticas, regimes de dosagem e administração de um conjugado anticorpo-fármaco (adc). mais especificamente, o adc é composto por um anticorpo antígeno de superfície celular anti-trofoblasto 2 (trop2) conectado por meio de um ligante a um agente anticâncer, como o inibidor de topoisomerase i.",DAIICHI SANKYO CO LTD,OKAJIMA DAISUKE;;GREENBERG JONATHAN;;YASUDA SATORU;;IGUCHI TAKUMA;;YAMASHITA TOMONARI;;NOGUCHI YUTAKA,,https://lens.org/093-065-772-865-102,Patent Application,no,0,0,12,12,0,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61P35/00;;A61K47/68,,0,0,,,,PENDING
23,US,A1,US 2023/0270870 A1,122-673-414-587-957,2023-08-31,2023,US 202017612765 A,2020-05-28,US 202017612765 A;;US 201962853970 P;;US 201962896478 P;;IB 2020055078 W,2019-05-29,DOSAGE OF AN ANTIBODY-DRUG CONJUGATE,"The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.",DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMONARI;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,DAIICHI SANKYO COMPANY LIMITED (2021-11-10);;DAIICHI SANKYO INC (2021-11-11),https://lens.org/122-673-414-587-957,Patent Application,yes,0,0,12,12,46,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68;;A61K47/54;;A61K47/65;;A61P35/00,,0,0,,,,PENDING
24,EP,A1,EP 3976113 A1,079-590-552-574-811,2022-04-06,2022,EP 20732322 A,2020-05-28,US 201962853970 P;;US 201962896478 P;;IB 2020055078 W,2019-05-29,DOSAGE OF AN ANTIBODY-DRUG CONJUGATE,,DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMONARI;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,,https://lens.org/079-590-552-574-811,Patent Application,yes,0,0,12,12,0,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68;;A61P35/00,,0,0,,,,PENDING
25,US,A1,US 2020/0112844 A1,066-177-881-193-322,2020-04-09,2020,US 201916591796 A,2019-10-03,US 201916591796 A;;US 201862740708 P;;US 201862741099 P,2018-10-03,Systems and Methods for Wirelessly Coupling a Wearable Computing Device,"A host computing device receives an advertisement packet via a low-power personal area network and, in response to the advertisement packet, transmits a connection request via the low-power personal area network, pairs via the low-power personal area network and transmits a data message when pairing via the low-power personal area network. The data message instructs a wearable device to pair via a general personal area network.",NORTH INC,GREENBERG SCOTT MICHAEL NICHOLAS;;BRUBACHER JONATHAN;;SLEVINSKY MARK OLIVER;;DIFRANCO MARK P,GOOGLE LLC (2020-09-16);;NORTH INC (2019-06-13),https://lens.org/066-177-881-193-322,Patent Application,yes,3,4,2,2,0,H04W76/14;;H04L67/12;;H04W4/30;;H04W8/005;;H04W4/80;;Y02D30/70;;H04W12/50;;H04W12/33;;H04L67/51;;H04W4/80;;H04W8/005;;H04W12/06;;H04W76/14;;H04W48/16;;H04W84/18;;H04L67/51,H04W4/80;;H04L29/08;;H04W8/00;;H04W12/06;;H04W48/16;;H04W76/14;;H04W84/18,,0,0,,,,ACTIVE
26,CA,A1,CA 3142119 A1,115-188-547-572-019,2020-12-03,2020,CA 3142119 A,2020-05-28,US 201962853970 P;;US 201962896478 P;;IB 2020055078 W,2019-05-29,DOSAGE OF AN ANTIBODY-DRUG CONJUGATE FOR TREATING CANCER,"The present invention relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). Provided is the use of an anti-TR0P2 antibody-drug conjugate for treating or preventing cancer, comprising an anti-TROP2 antibody and an antitumor compound connected by a linker, wherein the linker and the antitumor compound are represented by: -(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX) wherein -(Succinimid-3-yl-N)- is connected to the antibody and (NH-DX) represents: wherein the anti-TROP2 antibody comprises CDRH1 (SEQ ID NO: 23), CDRH2 (SEQ ID NO: 24) and CDRH3 (SEQ ID NO: 25) in its heavy chain variable region and CDRL1 (SEQ ID NO: 26), CDRL2 (SEQ ID NO: 27) and CDRL3 (SEQ ID NO: 28) in its light chain variable region, wherein the antibody-drug conjugate is to be administered to a subject with cancer in a dose in a range of 2 mg/kg to 10 mg/kg.",DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMONARI;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,,https://lens.org/115-188-547-572-019,Patent Application,no,0,0,12,12,46,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68;;A61P35/00,,0,0,,,,PENDING
27,WO,A1,WO 2020/240467 A1,154-549-036-190-807,2020-12-03,2020,IB 2020055078 W,2020-05-28,US 201962853970 P;;US 201962896478 P,2019-05-29,DOSAGE OF AN ANTIBODY-DRUG CONJUGATE,"The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.",DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMONARI;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,,https://lens.org/154-549-036-190-807,Patent Application,yes,35,21,12,12,46,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68;;A61P35/00,,45,31,030-851-356-208-747;;056-939-871-131-764;;047-325-544-933-820;;038-130-035-189-582;;031-994-478-323-000;;044-726-527-887-779;;079-726-622-008-509;;106-753-778-592-300;;041-339-526-074-259;;032-704-388-146-395;;051-940-176-386-905;;106-421-613-215-231;;002-882-009-745-691;;030-607-398-087-475;;006-574-964-805-278;;028-862-168-091-90X;;072-088-626-544-271;;007-890-465-457-476;;047-951-914-695-080;;138-414-695-433-499;;021-387-164-986-656;;050-591-899-484-50X;;057-167-704-218-212;;022-133-574-143-973;;040-759-965-940-758;;030-797-864-869-467;;063-648-077-339-174;;019-451-380-257-732;;103-405-698-907-771;;068-416-071-545-291;;028-101-820-366-93X,10.1002/(sici)1097-0215(19980119)75:2<324::aid-ijc24>3.3.co;2-5;;10.1002/(sici)1097-0215(19980119)75:2<324::aid-ijc24>3.0.co;2-b;;9462726;;10.1073/pnas.78.8.5147;;pmc320350;;7029529;;16707602;;10.1158/1078-0432.ccr-05-1961;;18813308;;10.1038/sj.bjc.6604677;;pmc2570520;;18084248;;10.1038/modpathol.3801001;;10.1007/s10072-013-1326-8;;23397225;;18281513;;10.1158/1535-7163.mct-07-2003;;1172191;;10.1038/256495a0;;18219321;;10.1038/sj.cdd.4402306;;pmc532009;;10.1091/mbc.e04-07-0591;;15385631;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;2448875;;10.1126/science.239.4839.487;;10.1126/science.2448875;;6260373;;10.1016/0092-8674(81)90282-8;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;9171824;;10.1038/ng0697-133;;10.1093/nar/26.14.3447;;pmc147703;;9649633;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;12091431;;15239904;;10.1093/bfgp/1.2.189;;11874742;;10.1016/s0161-6420(01)00997-6;;16151404;;10.1038/nbt1126;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;10.1080/10837450701212610;;17613890;;10.1016/0021-9673(94)01255-d;;7620566;;10.1016/j.ab.2006.10.012;;17113563;;10.1158/1078-0432.ccr-15-2822;;27026201;;pmc2143013;;8563639;;10.1002/pro.5560041120;;26412456;;10.1056/nejmoa1507643;;pmc5705936;;24933332;;10.3410/f.718451079.793497341;;10.1016/s0140-6736(14)60845-x,"DAIICHI SANKYO: ""First-in-human Study of DS-1062a for Advanced Solid Tumors"", 17 January 2018 (2018-01-17), XP055719307, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT03401385> [retrieved on 20200730];;EL SEWEDY T ET AL., INT. J. CANCER, vol. 75, no. 2, 1998, pages 324 - 330;;FAULK WP ET AL., PROC. NATL. ACAD. SCI., vol. 75, no. 4, 1978, pages 1947 - 1951;;LIPINSKI M ET AL., PROC. NATL. ACAD. SCI., vol. 78, no. 8, 1981, pages 5147 - 5150;;""NCBI"", Database accession no. NP_002344;;OHMACHI T ET AL., CLIN. CANCER RES., vol. 12, no. 10, 2006, pages 3057 - 3063;;MUHLMANN G ET AL., J. CLIN. PATHOL., vol. 62, no. 2, 2009, pages 152 - 158;;FONG D ET AL., BR. J. CANCER, vol. 99, no. 8, 2008, pages 1290 - 1295;;FONG D ET AL., MOD. PATHOL., vol. 21, no. 2, 2008, pages 186 - 191;;NING S ET AL., NEUROL. SCI., vol. 34, no. 10, 2013, pages 1745 - 1750;;WANG J ET AL., MOL. CANCER THER., vol. 7, no. 2, 2008, pages 280 - 285;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497;;CELL DEATH AND DIFFERENTIATION, vol. 15, 2008, pages 751 - 761;;MOLECULAR BIOLOGY OF THE CELL, vol. 15, December 2004 (2004-12-01), pages 5268 - 5282;;BIO TECHNIQUES, vol. 28, January 2000 (2000-01-01), pages 162 - 165;;URLAUB, G.CHASIN, L. A., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4126 - 4220;;SAIKI, R. K. ET AL., SCIENCE, vol. 239, 1988, pages 487 - 489;;GLUZMAN, Y., CELL, vol. 23, 1981, pages 175 - 182;;WEIR, D. M.: ""Handbook of Experimental Immunology"", vol. I. II. III., 1978, BLACKWELL SCIENTIFIC PUBLICATIONS;;KABAT, E. A.MAYER, M. M.: ""Experimental Immunochemistry"", 1964, CHARLES C THOMAS PUBLISHER SPRINGFIELD;;KOHLER ET AL., EUR. J. IMMUNOL., vol. 6, 1977, pages 511;;MILSTEIN ET AL., NATURE, vol. 266, 1977, pages 495;;BARBARA, B. M.STANLEY, M. S.: ""Selected Methods in Cellular Immunology"", 1980, W. H. FREEMAN AND COMPANY;;PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;NATURE, vol. 321, 1986, pages 522 - 525;;ALTSCHUL, STEPHEN F.THOMAS L. MADDENALEJANDRO A. SCHAEFFERJINGHUI ZHANGZHENG ZHANGWEBB MILLERDAVID J. LIPMAN: ""Gapped BLAST and PSI-BLAST: a new generation of protein database search programs"", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402, XP002905950, DOI: 10.1093/nar/25.17.3389;;TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143;;KUROIWA, Y. ET AL., NUCL. ACIDS RES., vol. 26, 1998, pages 3447 - 3448;;YOSHIDA, H. ET AL.: ""Animal Cell Technology: Basic and Applied Aspects"", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, pages: 69 - 73;;TOMIZUKA, K. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;WORMSTONE, I. M. ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 43, no. 7, 2002, pages 2301 - 2308;;CARMEN, S. ET AL., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203;;SIRIWARDENA, D. ET AL., OPHTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431;;NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1105 - 1116;;ANNU. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455;;LORI BURTON, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 12, 2007, pages 265 - 273;;JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134;;ANALYTICAL BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83;;HERMANSON, G.T: ""Strategies for Protein Purification and Characterization: A Laboratory Course Manual"", 1996, COLD SPRING HARBOR LABORATORY PRESS, pages: 56 - 136,456493;;""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;OGITANI Y. ET AL., CLINICAL CANCER RESEARCH, vol. 22, no. 20, 15 October 2016 (2016-10-15), pages 5097 - 5108;;PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423;;J. ORG. CHEM., vol. 51, 1986, pages 3196;;BORGHAEI HPAZ-ARES LHORN L ET AL.: ""Nivolumab versus Docetaxe in advanced nonsquamous non-small-cell lung cancer"", N ENGL J MED., vol. 373, no. 17, 2015, pages 1627 - 39, XP055667804, DOI: 10.1056/NEJMoa1507643;;GARON EBCIULEANU TEARRIETA O ET AL.: ""Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial"", LANCET, vol. 384, no. 9944, 2014, pages 665 - 73, XP055184786, DOI: 10.1016/S0140-6736(14)60845-X",PENDING
28,SG,A,SG 11202112429P A,169-044-489-402-092,2021-12-30,2021,SG 11202112429P A,2020-05-28,US 201962853970 P;;US 201962896478 P;;IB 2020055078 W,2019-05-29,DOSAGE OF AN ANTIBODY-DRUG CONJUGATE,,DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMONARI;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,,https://lens.org/169-044-489-402-092,Unknown,no,0,0,12,12,0,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68;;A61P35/00,,0,0,,,,PENDING
29,KR,A,KR 20220015445 A,188-497-394-543-934,2022-02-08,2022,KR 20217042735 A,2020-05-28,US 201962853970 P;;US 201962896478 P;;IB 2020055078 W,2019-05-29,항체-약물 접합체의 투약,"본 발명은 항체-약물 접합체 (ADC) 의 약학 제제, 투여 요법 및 투여 분야에 관한 것이다. 더욱 구체적으로, ADC 는 항암제, 예컨대 토포이소머라제 I 억제제에 링커를 통해 연결된 항-영양막 세포 표면 항원 2 (TROP2) 항체로 구성된다.",DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMONARI;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,,https://lens.org/188-497-394-543-934,Patent Application,no,0,0,12,12,92,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68,,0,0,,,,PENDING
30,AU,A1,AU 2020/285681 A1,116-135-638-230-409,2022-01-27,2022,AU 2020/285681 A,2020-05-28,US 201962853970 P;;US 201962896478 P;;IB 2020055078 W,2019-05-29,Dosage of an antibody-drug conjugate,"The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.",DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMONARI;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,,https://lens.org/116-135-638-230-409,Patent Application,no,0,0,12,12,0,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68;;A61P35/00,,0,0,,,,PENDING
31,US,B2,US 11051154 B2,146-103-167-183-790,2021-06-29,2021,US 201916591796 A,2019-10-03,US 201916591796 A;;US 201862740708 P;;US 201862741099 P,2018-10-03,Systems and methods for wirelessly coupling a wearable computing device,"A host computing device receives an advertisement packet via a low-power personal area network and, in response to the advertisement packet, transmits a connection request via the low-power personal area network, pairs via the low-power personal area network and transmits a data message when pairing via the low-power personal area network. The data message instructs a wearable device to pair via a general personal area network.",GOOGLE LLC,GREENBERG SCOTT MICHAEL NICHOLAS;;BRUBACHER JONATHAN;;SLEVINSKY MARK OLIVER;;DIFRANCO MARK P,GOOGLE LLC (2020-09-16);;NORTH INC (2019-06-13),https://lens.org/146-103-167-183-790,Granted Patent,yes,18,0,2,2,0,H04W76/14;;H04L67/12;;H04W4/30;;H04W8/005;;H04W4/80;;Y02D30/70;;H04W12/50;;H04W12/33;;H04L67/51;;H04W4/80;;H04W8/005;;H04W12/06;;H04W76/14;;H04W48/16;;H04W84/18;;H04L67/51,H04W4/80;;H04L29/08;;H04W8/00;;H04W12/06;;H04W48/16;;H04W76/14;;H04W84/18,,5,0,,,"Toshiba, “Simultaneous Operation of SPP & BLE Mode Application Note”, TC35661-ROM501, Version 1.1, Nov. 22, 2013, 13 pages.;;Non-Final Office Action dated Jan. 6, 2021 for U.S. Appl. No. 16/515,161, 9 pages.;;Non-Final Office Action dated Jul. 23, 2020 for U.S. Appl. No. 16/515,161, 8 pages.;;Final Office Action dated Dec. 21, 2020 for U.S. Appl. No. 16/587,640, 10 pages.;;Non-Final Office Action dated Aug. 6, 2020 for U.S. Appl. No. 16/587,640, 9 pages.",ACTIVE
32,TW,A,TW 202108180 A,025-806-104-364-491,2021-03-01,2021,TW 109117829 A,2020-05-28,US 201962853970 P;;US 201962896478 P,2019-05-29,Dosage of an antibody-drug conjugate,"The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.",DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMONARI;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,,https://lens.org/025-806-104-364-491,Patent of Addition,no,0,0,12,12,0,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68;;A61P35/00,,0,0,,,,PENDING
33,CN,A,CN 113939318 A,145-602-142-740-191,2022-01-14,2022,CN 202080039800 A,2020-05-28,US 201962853970 P;;US 201962896478 P;;IB 2020055078 W,2019-05-29,DOSAGE OF ANTIBODY-DRUG CONJUGATE,"The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.",DAIICHI SANKYO CO LTD,NOGUCHI YUTAKA;;YAMASHITA TOMOYA;;OKAJIMA DAISUKE;;IGUCHI TAKUMA;;YASUDA SATORU;;GREENBERG JONATHAN,,https://lens.org/145-602-142-740-191,Patent Application,no,3,1,12,12,0,A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/6851;;A61K47/6803;;A61P35/00;;A61K47/65;;A61K47/6851;;A61K47/545;;A61K47/6803;;A61P35/00,A61K47/68;;A61P35/00,,0,0,,,,PENDING
34,US,S,US D0787810 S,161-777-320-586-073,2017-05-30,2017,US 201529543258 F,2015-10-22,US 201529543258 F,2015-10-22,Cover for an inhaler,,COHEROHEALTH LLC,WANG CHUN-SHENG;;PITEO TARPY JONATHAN DAVID;;GREENBERG RUSSELL JON;;HONG MINCHUL,COHEROHEALTH LLC (2016-08-08);;APTARGROUP INC (2020-10-16),https://lens.org/161-777-320-586-073,Design Right,no,0,6,2,2,0,,,0301;;D 32031,0,0,,,,ACTIVE
35,US,A1,US 2016/0149786 A1,100-048-127-220-173,2016-05-26,2016,US 201615004113 A,2016-01-22,US 201615004113 A;;US 82533610 A,2010-06-29,Flexible and Safe Monitoring of Computers,"Described is a server monitoring technology that is scalable to large numbers of servers, e.g., in a datacenter. Agents on servers run queries to monitor data sources for that server, such as performance counters and other events. The agents monitor their resource usage and those of monitored events to stay within an administrator-specified resource budget (policy), e.g., by modifying the running queries and/or monitoring parameters. A controller receives results of the monitoring, analyzes the results, and takes action as needed with respect to server operation and monitoring. The controller may dynamically update an agent's queries, monitoring parameters and/or monitored data post-processing operations. The controller may issue alerts and reports, including alerts indicative of inter-server problems between two or more servers.",MICROSOFT TECHNOLOGY LICENSING LLC,MALTZ DAVID A;;GOLDSTEIN JONATHAN DAVID;;GREENBERG ALBERT;;LOBOZ CHARLES;;PATEL PARVEEN K,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2010-09-03),https://lens.org/100-048-127-220-173,Patent Application,yes,12,3,6,6,0,G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;H04L43/0817;;G06F2209/5013;;G06F16/951;;G06F9/5027;;G06F16/951;;G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;G06F2209/5013;;H04L43/0817;;G06F9/5027;;H04L43/0876,H04L12/26;;G06F17/30,,0,0,,,,ACTIVE
36,US,A1,US 2011/0320586 A1,063-749-974-338-107,2011-12-29,2011,US 82533610 A,2010-06-29,US 82533610 A,2010-06-29,Flexible and Safe Monitoring of Computers,"Described is a server monitoring technology that is scalable to large numbers of servers, e.g., in a datacenter. Agents on servers run queries to monitor data sources for that server, such as performance counters and other events. The agents monitor their resource usage and those of monitored events to stay within an administrator-specified resource budget (policy), e.g., by modifying the running queries and/or monitoring parameters. A controller receives results of the monitoring, analyzes the results, and takes action as needed with respect to server operation and monitoring. The controller may dynamically update an agent's queries, monitoring parameters and/or monitored data post-processing operations. The controller may issue alerts and reports, including alerts indicative of inter-server problems between two or more servers.",MALTZ DAVID A;;GOLDSTEIN JONATHAN DAVID;;GREENBERG ALBERT;;LOBOZ CHARLES;;PATEL PARVEEN K;;MICROSOFT CORP,MALTZ DAVID A;;GOLDSTEIN JONATHAN DAVID;;GREENBERG ALBERT;;LOBOZ CHARLES;;PATEL PARVEEN K,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2010-09-03),https://lens.org/063-749-974-338-107,Patent Application,yes,8,63,6,6,0,G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;H04L43/0817;;G06F2209/5013;;G06F16/951;;G06F9/5027;;G06F16/951;;G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;G06F2209/5013;;H04L43/0817;;G06F9/5027;;H04L43/0876,G06F15/16,709/224,0,0,,,,ACTIVE
37,US,B2,US 10298477 B2,037-460-898-649-631,2019-05-21,2019,US 201615004113 A,2016-01-22,US 201615004113 A;;US 82533610 A,2010-06-29,Flexible and safe monitoring of computers,"Described is a server monitoring technology that is scalable to large numbers of servers, e.g., in a datacenter. Agents on servers run queries to monitor data sources for that server, such as performance counters and other events. The agents monitor their resource usage and those of monitored events to stay within an administrator-specified resource budget (policy), e.g., by modifying the running queries and/or monitoring parameters. A controller receives results of the monitoring, analyzes the results, and takes action as needed with respect to server operation and monitoring. The controller may dynamically update an agent's queries, monitoring parameters and/or monitored data post-processing operations. The controller may issue alerts and reports, including alerts indicative of inter-server problems between two or more servers.",MICROSOFT TECHNOLOGY LICENSING LLC,MALTZ DAVID A;;GOLDSTEIN JONATHAN DAVID;;GREENBERG ALBERT;;LOBOZ CHARLES;;PATEL PARVEEN K,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2010-09-03),https://lens.org/037-460-898-649-631,Granted Patent,yes,21,0,6,6,0,G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;H04L43/0817;;G06F2209/5013;;G06F16/951;;G06F9/5027;;G06F16/951;;G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;G06F2209/5013;;H04L43/0817;;G06F9/5027;;H04L43/0876,G06F15/173;;G06F9/50;;G06F11/30;;G06F11/34;;H04L12/26,,12,1,083-647-356-656-982,10.1109/inm.2005.1440772,"“Optimizing Your Data Center”, May 2008, 11 pages Located at: http://download.microsoft.com/download/2/b/8/2b83db38-a749-44e0-9011-2f8bd068483f/SC _Solutions_Optimizing_Optimizing_Data_ Centers_White_Paper.pdf.;;Anerousis, et al., “Health Monitoring and Control for Application Server Environments”, 9th IFIP/IEEE International Symposium on Integrated Network Management, May 15-19, 2005, pp. 75-88 Located at: http://ieeexplore.ieee.org/stamp/stamp.jsp?tp=&arnumber=1440772.;;Moore, et al., “Data Center Workload Monitoring, Analysis, and Emulation”, Proceedings of Workshop on Computer Architecture Evaluation using Commercial Workloads, Feb. 2005, pp. 1-8 Located at: http://citeseerx.ist.psu. edu/viewdoc/download?doi=10.1.1.112.2639&rep=rep1 &type=pdf.;;“Server monitoring software”, Retrieved Date: Apr. 6, 2010, 10 pages Located at: http://windowsmanagement.com/sw-monserver.;;“Integrated Data Center Monitoring”, Retrieved Date: Apr. 6, 2010, 12 pages Located at: http://www.accelops.net/product/data-center-monitoring.php.;;“SiCA for Data Center Monitoring”, Retrieved Date: Apr. 6, 2010, 2 pages Located at: http://www.episensor.com/solutions/data-centers/.;;Office Action Summary, Non-Final Office Action, U.S. Appl. No. 12/825,336, dated Aug. 17, 2012, 24 pages.;;Office Action Summary, Final Office Action, U.S. Appl. No. 12/825,336, dated Dec. 20, 2012, 28 pages.;;Office Action Summary, Non-Final Office Action, U.S. Appl. No. 12/825,336, dated Feb. 13, 2014, 24 pages.;;Office Action Summary, Final Office Action, U.S. Appl. No. 12/825,336, dated Nov. 19, 2014, 32 pages.;;Office Action Summary, Non-Final Office Action, U.S. Appl. No. 12/825,336, dated Apr. 10, 2015, 27 pages.;;Notice of Allowance, U.S. Appl. No. 12/825,336, dated Oct. 23, 2015, 8 pages.",ACTIVE
38,DE,C2,DE 2552098 C2,154-309-183-307-339,1984-08-16,1984,DE 2552098 A,1975-11-20,US 52532774 A,1974-11-20,DE 2552098 C2,,"ETHICON, INC., SOMERVILLE, N.J., US","GREENBERG, JONATHAN FRED, NEW YORK, N.Y., US;;QUADE, ROBERT T., BERNARDSVILLE, N.J., US",,https://lens.org/154-309-183-307-339,Granted Patent,no,0,0,6,6,0,A61B17/06004;;A61B17/06195;;A61B2090/037;;A61B17/06004;;A61B17/06195;;A61B2090/037,A61B17/06;;A61B19/00,,0,0,,,,EXPIRED
39,US,B2,US 9274842 B2,103-627-093-829-524,2016-03-01,2016,US 82533610 A,2010-06-29,US 82533610 A,2010-06-29,Flexible and safe monitoring of computers,"Described is a server monitoring technology that is scalable to large numbers of servers, e.g., in a datacenter. Agents on servers run queries to monitor data sources for that server, such as performance counters and other events. The agents monitor their resource usage and those of monitored events to stay within an administrator-specified resource budget (policy), e.g., by modifying the running queries and/or monitoring parameters. A controller receives results of the monitoring, analyzes the results, and takes action as needed with respect to server operation and monitoring. The controller may dynamically update an agent's queries, monitoring parameters and/or monitored data post-processing operations. The controller may issue alerts and reports, including alerts indicative of inter-server problems between two or more servers.",MALTZ DAVID A;;GOLDSTEIN JONATHAN DAVID;;GREENBERG ALBERT;;LOBOZ CHARLES;;PATEL PARVEEN K;;MICROSOFT TECHNOLOGY LICENSING LLC,MALTZ DAVID A;;GOLDSTEIN JONATHAN DAVID;;GREENBERG ALBERT;;LOBOZ CHARLES;;PATEL PARVEEN K,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2010-09-03),https://lens.org/103-627-093-829-524,Granted Patent,yes,14,4,6,6,0,G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;H04L43/0817;;G06F2209/5013;;G06F16/951;;G06F9/5027;;G06F16/951;;G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;G06F2209/5013;;H04L43/0817;;G06F9/5027;;H04L43/0876,G06F15/173;;G06F9/50;;G06F11/30;;G06F11/34;;H04L12/26,,6,1,083-647-356-656-982,10.1109/inm.2005.1440772,"""Optimizing Your Data Center"", Retrieved at << http://download.microsoft.com/download/2/b/8/2b83db38-a749-44e0-9011-2f8bd068483f/SC-Solutions-Optimizing-Optimizing-Data-Centers-White-Paper.pdf >>, May 2008, pp. 11.;;Anerousis, et al., ""Health Monitoring and Control for Application Server Environments"", Retrieved at >, 9th IFIP/IEEE International Symposium on Integrated Network Management, May 15-19, 2005, pp. 75-88.;;Moore, et al., ""Data Center Workload Monitoring, Analysis, and Emulation"", Retrieved at >, Proceedings of Workshop on Computer Architecture Evaluation using Commercial Workloads, Feb. 2005, pp. 1-8.;;""Server monitoring software"", Retrieved at >, Retrieved Date: Apr. 6, 2010, pp. 10.;;""Integrated Data Center Monitoring"", Retrieved at >, Retrieved Date: Apr. 6, 2010, pp. 12.;;""SiCA for Data Center Monitoring"", Retrieved at >, Retrieved Date: Apr. 6, 2010, pp. 2.",ACTIVE
40,US,A1,US 2019/0238437 A1,036-976-524-703-147,2019-08-01,2019,US 201916375763 A,2019-04-04,US 201916375763 A;;US 201615004113 A;;US 82533610 A,2010-06-29,FLEXIBLE AND SAFE MONITORING OF COMPUTERS,"Described is a server monitoring technology that is scalable to large numbers of servers, e.g., in a datacenter. Agents on servers run queries to monitor data sources for that server, such as performance counters and other events. The agents monitor their resource usage and those of monitored events to stay within an administrator-specified resource budget (policy), e.g., by modifying the running queries and/or monitoring parameters. A controller receives results of the monitoring, analyzes the results, and takes action as needed with respect to server operation and monitoring. The controller may dynamically update an agent's queries, monitoring parameters and/or monitored data post-processing operations. The controller may issue alerts and reports, including alerts indicative of inter-server problems between two or more servers.",MICROSOFT TECHNOLOGY LICENSING LLC,MALTZ DAVID A;;GOLDSTEIN JONATHAN DAVID;;GREENBERG ALBERT;;LOBOZ CHARLES;;PATEL PARVEEN K,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2010-09-03),https://lens.org/036-976-524-703-147,Patent Application,yes,3,1,6,6,0,G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;H04L43/0817;;G06F2209/5013;;G06F16/951;;G06F9/5027;;G06F16/951;;G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;G06F2209/5013;;H04L43/0817;;G06F9/5027;;H04L43/0876,H04L12/26;;G06F9/50;;G06F11/30;;G06F11/34;;G06F16/951,,0,0,,,,ACTIVE
41,BR,S,BR DI7105800 S,086-001-271-874-100,2014-05-13,2014,BR DI7105800 F,2011-11-24,EM 18691730001 F,2011-05-26,CONFIGURAÇÃO APLICADA EM CONJUNTO DE MÁSCARA NASAL,,KONINKL PHILIPS ELECTRONICS NV,GREENBERG JOSHUA;;CLARKE JAIME;;MCCASLIN JONATHAN PAUL;;HARP MAUREEN;;STARTARE ANTHONY;;MICELI JOSEPH,,https://lens.org/086-001-271-874-100,Patent Application,no,0,0,3,3,0,,,,0,0,,,,PENDING
42,US,S,US D0697203 S,057-184-010-209-156,2014-01-07,2014,US 201129406720 F,2011-11-18,EM 18691730001 F,2011-05-26,Nasal mask assembly,,CLARKE JAIME;;GREENBERG JOSHUA;;MCCASLIN JONATHAN PAUL;;HARP MAUREEN;;STARTARE ANTHONY;;MICELI JOSEPH;;KONINKL PHILIPS NV,CLARKE JAIME;;GREENBERG JOSHUA;;MCCASLIN JONATHAN PAUL;;HARP MAUREEN;;STARTARE ANTHONY;;MICELI JOSEPH,KONINKLIJKE PHILIPS ELECTRONICS N.V (2011-12-08),https://lens.org/057-184-010-209-156,Design Right,no,0,10,3,3,0,,,2902;;D24/110.4,0,0,,,,ACTIVE
43,US,B2,US 11140056 B2,155-074-444-265-433,2021-10-05,2021,US 201916375763 A,2019-04-04,US 201916375763 A;;US 201615004113 A;;US 82533610 A,2010-06-29,Flexible and safe monitoring of computers,"Described is a server monitoring technology that is scalable to large numbers of servers, e.g., in a datacenter. Agents on servers run queries to monitor data sources for that server, such as performance counters and other events. The agents monitor their resource usage and those of monitored events to stay within an administrator-specified resource budget (policy), e.g., by modifying the running queries and/or monitoring parameters. A controller receives results of the monitoring, analyzes the results, and takes action as needed with respect to server operation and monitoring. The controller may dynamically update an agent's queries, monitoring parameters and/or monitored data post-processing operations. The controller may issue alerts and reports, including alerts indicative of inter-server problems between two or more servers.",MICROSOFT TECHNOLOGY LICENSING LLC,MALTZ DAVID A;;GOLDSTEIN JONATHAN DAVID;;GREENBERG ALBERT;;LOBOZ CHARLES;;PATEL PARVEEN K,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2010-09-03),https://lens.org/155-074-444-265-433,Granted Patent,yes,4,0,6,6,0,G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;H04L43/0817;;G06F2209/5013;;G06F16/951;;G06F9/5027;;G06F16/951;;G06F11/3006;;G06F11/3072;;G06F11/3093;;G06F11/3409;;G06F11/3495;;G06F2201/88;;G06F2209/5013;;H04L43/0817;;G06F9/5027;;H04L43/0876,G06F15/173;;G06F9/50;;G06F11/30;;G06F11/34;;G06F16/951;;H04L12/26,,0,0,,,,ACTIVE
44,US,A1,US 2015/0254659 A1,071-465-549-819-431,2015-09-10,2015,US 201514642147 A,2015-03-09,US 201514642147 A;;US 201461949689 P,2014-03-07,SECURE VALIDATION OF FINANCIAL TRANSACTIONS,"Methods and apparatuses, including computer program products, are described for secure validation of financial transactions. A server computing device registers a mobile device to receive notification messages from the server computing device. The server computing device transmits a notification message via a first communication channel to a notification agent executing on the registered mobile device, where the message identifies activity associated with a financial account of a user of the registered mobile device. The server computing device receives a response to the notification message via a second communication channel from an application executing on the registered mobile device, if the notification message requires a response. The server computing device stores the response in a database coupled to the server computing device, and determines whether to (i) allow, (ii) deny, or (iii) deny and report as fraud the identified activity based upon the response.",FMR LLC,KULKARNI RAJANDRA LAXMAN;;TRELEAVEN PHILIP PETER;;GREENBERG ADAM;;RAMGOPAL RAM;;STAVIS JONATHAN;;PATEL NAYAN,,https://lens.org/071-465-549-819-431,Patent Application,yes,13,43,3,3,0,A61L31/06;;A61L31/145;;A61L31/18;;A61L2300/44;;A61L2400/06;;A61L2430/20;;C08G65/00;;G06Q20/4016;;G06Q20/4016;;G06Q20/325;;G06Q20/325,G06Q20/40;;G06Q20/32;;G06Q20/38,,0,0,,,,ACTIVE
45,US,B2,US 10032168 B2,055-046-495-565-985,2018-07-24,2018,US 201514642147 A,2015-03-09,US 201514642147 A;;US 201461949689 P,2014-03-07,Secure validation of financial transactions,"Methods and apparatuses, including computer program products, are described for secure validation of financial transactions. A server computing device registers a mobile device to receive notification messages from the server computing device. The server computing device transmits a notification message via a first communication channel to a notification agent executing on the registered mobile device, where the message identifies activity associated with a financial account of a user of the registered mobile device. The server computing device receives a response to the notification message via a second communication channel from an application executing on the registered mobile device, if the notification message requires a response. The server computing device stores the response in a database coupled to the server computing device, and determines whether to (i) allow, (ii) deny, or (iii) deny and report as fraud the identified activity based upon the response.",FMR LLC,KULKARNI RAJANDRA LAXMAN;;TRELEAVEN PHILIP PETER;;GREENBERG ADAM;;RAMGOPAL RAM;;STAVIS JONATHAN;;PATEL NAYAN,FMR LLC (2015-03-06),https://lens.org/055-046-495-565-985,Granted Patent,yes,32,11,3,3,0,A61L31/06;;A61L31/145;;A61L31/18;;A61L2300/44;;A61L2400/06;;A61L2430/20;;C08G65/00;;G06Q20/4016;;G06Q20/4016;;G06Q20/325;;G06Q20/325,G06Q20/40;;A61L31/06;;A61L31/14;;A61L31/18;;C08G65/00;;G06Q20/32,,0,0,,,,ACTIVE
46,US,A9,US 2017/0296710 A9,096-257-692-211-788,2017-10-19,2017,US 201514642147 A,2015-03-09,US 201514642147 A;;US 201461949689 P,2014-03-07,SECURE VALIDATION OF FINANCIAL TRANSACTIONS,"Methods and apparatuses, including computer program products, are described for secure validation of financial transactions. A server computing device registers a mobile device to receive notification messages from the server computing device. The server computing device transmits a notification message via a first communication channel to a notification agent executing on the registered mobile device, where the message identifies activity associated with a financial account of a user of the registered mobile device. The server computing device receives a response to the notification message via a second communication channel from an application executing on the registered mobile device, if the notification message requires a response. The server computing device stores the response in a database coupled to the server computing device, and determines whether to (i) allow, (ii) deny, or (iii) deny and report as fraud the identified activity based upon the response.",FMR LLC,KULKARNI RAJANDRA LAXMAN;;TRELEAVEN PHILIP PETER;;GREENBERG ADAM;;RAMGOPAL RAM;;STAVIS JONATHAN;;PATEL NAYAN,FMR LLC (2015-03-06),https://lens.org/096-257-692-211-788,Amended Application,yes,0,5,3,3,0,A61L31/06;;A61L31/145;;A61L31/18;;A61L2300/44;;A61L2400/06;;A61L2430/20;;C08G65/00;;G06Q20/4016;;G06Q20/4016;;G06Q20/325;;G06Q20/325,A61L31/14;;A61L31/06;;A61L31/18;;C08G65/00;;G06Q20/32;;G06Q20/40,,0,0,,,,ACTIVE
47,WO,A1,WO 2021/243016 A1,050-415-705-040-933,2021-12-02,2021,US 2021/0034510 W,2021-05-27,US 202063032094 P,2020-05-29,"SYSTEMS, DEVICES, AND METHODS FOR DOSING PATTERN MANAGEMENT","Systems, devices, and methods for identifying and managing medication dosage patterns to assist in decisions for administration at, e.g., the time a meal is being consumed, are described. The application can include a new mealtime insulin dose-decisioning feature that is accessible through or in conjunction with an analyte monitoring application. Using retrospective analyte and medication dosing data only, the dosing pattern management application can display patterns in past dose administrations to facilitate easy and better dose decisions for diabetics on a regimen of multiple daily injections.",ABBOTT DIABETES CARE INC,FERN JONATHAN M;;GREENBERG DIANA W;;KUMAR PANGANAMALA ASHWIN;;FLOEH JESSICA ROSE;;CARSON LYNNE LYONS,,https://lens.org/050-415-705-040-933,Patent Application,yes,5,0,7,7,0,G16H20/17;;G16H20/17,G16H20/17,,0,0,,,,PENDING
48,US,A1,US 2023/0207090 A1,183-377-349-427-098,2023-06-29,2023,US 202117925692 A,2021-05-27,US 202117925692 A;;US 202063032094 P;;US 2021/0034510 W,2020-05-29,"SYSTEMS, DEVICES, AND METHODS FOR DOSING PATTERN MANAGEMENT","Systems, devices, and methods for identifying and managing medication dosage patterns to assist in decisions for administration at, e.g., the time a meal is being consumed, are described. The application can include a new mealtime insulin dose-decisioning feature that is accessible through or in conjunction with an analyte monitoring application. Using retrospective analyte and medication dosing data only, the dosing pattern management application can display patterns in past dose administrations to facilitate easy and better dose decisions for diabetics on a regimen of multiple daily injections.",ABBOTT DIABETES CARE INC,FERN JONATHAN M;;GREENBERG DIANA W;;KUMAR PANGANAMALA ASHWIN;;FLOEH JESSICA ROSE;;CARSON LYNNE LYONS,ABBOTT DIABETES CARE INC (2020-07-27),https://lens.org/183-377-349-427-098,Patent Application,yes,0,0,7,7,0,G16H20/17;;G16H20/17,G16H20/17,,0,0,,,,PENDING
49,CN,A,CN 115917661 A,004-013-131-058-80X,2023-04-04,2023,CN 202180039156 A,2021-05-27,US 202063032094 P;;US 2021/0034510 W,2020-05-29,"SYSTEMS, DEVICES AND METHODS FOR DOSE PATTERN MANAGEMENT","Systems, devices, and methods are described for identifying and managing drug dose patterns to assist in deciding to take at, for example, a meal. The present application can include novel meal time insulin dose determination features accessible through or in combination with an analyte monitoring application. Using only retrospective analytes and drug dose data, the dose pattern management application is capable of displaying a pattern of previous dose administration to facilitate a diabetic patient to make a simple and better dose decision for a daily multiple injection regimen.",ABBOTT DIABETES CARE INC,FERN JONATHAN M;;GREENBERG DIANA W;;PANGANAMARA ASHWIN KUMAR;;FLOY JESSICA ROSS;;CASON LYNNE LYONS,,https://lens.org/004-013-131-058-80X,Patent Application,no,0,0,7,7,0,G16H20/17;;G16H20/17,G16H20/17,,0,0,,,,PENDING
50,US,A,US 5029821 A,139-519-207-676-908,1991-07-09,1991,US 44468489 A,1989-12-01,US 44468489 A,1989-12-01,Apparatus for controlling the magnesium content of molten aluminum,"A method for controlling the magnesium content of molten aluminum includes the steps of injecting a halogen gas into the molten aluminum, sampling a portion of the resulting gases evolved from the molten aluminum, detecting the presence of constituents in the sampled gases and/or characteristics of the sampled gases indicative of the imminent evolution of unreacted halogen gas, and adjusting the rate of halogen gas injection to approach the point where unreacted halogen gas is about to be evolved. In the preferred embodiment, the halogen gas is chlorine; the detected constituents are gaseous hydrogen chloride (CHl) and aluminum chlorhydrate compounds (Al.sub.2 Cl.sub.x .multidot.(OH).sub.6-x); and the detected characteristic is the opacity of the sampled gases. The invention includes a technique for adjusting the rate of halogen gas injection so as to approach the optimal rate. The invention also includes (1) a sensor for detecting the content of HCl and Al.sub.2 Cl.sub.x .multidot.(OH).sub.6-x and the opacity of the withdrawn gases, (2) apparatus for controlling the injection of halogen gas in response to detected conditions, and (3) molten aluminum having a desired content of magnesium produced by the method according to the invention.",CARBORUNDUM CO,BAR-ON ARI;;GALLAHER KENNETH L;;GREENBERG JONATHAN S;;NEFF DAVID V;;ROTHENBERG DOUGLAS H,CARBORUNDUM COMPANY THE A CORP. OF DE (1990-01-22);;METAULLICS SYSTEMS CO. L.P (1993-06-09),https://lens.org/139-519-207-676-908,Granted Patent,yes,3,58,1,1,0,F27B3/22;;F27B3/28;;F27D21/00;;F27D2019/0006;;F27B3/22;;F27B3/28;;F27D2019/0006;;F27D21/00,F27B3/22;;F27B3/28;;F27D19/00;;F27D21/00,266/79;;75/385;;75/681,0,0,,,,EXPIRED
51,CA,A1,CA 3175567 A1,149-220-731-212-778,2021-12-02,2021,CA 3175567 A,2021-05-27,US 202063032094 P;;US 2021/0034510 W,2020-05-29,"SYSTEMS, DEVICES, AND METHODS FOR DOSING PATTERN MANAGEMENT","Systems, devices, and methods for identifying and managing medication dosage patterns to assist in decisions for administration at, e.g., the time a meal is being consumed, are described. The application can include a new mealtime insulin dose-decisioning feature that is accessible through or in conjunction with an analyte monitoring application. Using retrospective analyte and medication dosing data only, the dosing pattern management application can display patterns in past dose administrations to facilitate easy and better dose decisions for diabetics on a regimen of multiple daily injections.",ABBOTT DIABETES CARE INC,FERN JONATHAN M;;GREENBERG DIANA W;;KUMAR PANGANAMALA ASHWIN;;FLOEH JESSICA ROSE;;CARSON LYNNE LYONS,,https://lens.org/149-220-731-212-778,Patent Application,no,0,0,7,7,0,G16H20/17;;G16H20/17,G16H20/17,,0,0,,,,PENDING
52,AU,A1,AU 2021/279026 A1,122-898-402-263-709,2022-10-27,2022,AU 2021/279026 A,2021-05-27,US 202063032094 P;;US 2021/0034510 W,2020-05-29,"Systems, devices, and methods for dosing pattern management","Systems, devices, and methods for identifying and managing medication dosage patterns to assist in decisions for administration at, e.g., the time a meal is being consumed, are described. The application can include a new mealtime insulin dose-decisioning feature that is accessible through or in conjunction with an analyte monitoring application. Using retrospective analyte and medication dosing data only, the dosing pattern management application can display patterns in past dose administrations to facilitate easy and better dose decisions for diabetics on a regimen of multiple daily injections.",ABBOTT DIABETES CARE INC,FERN JONATHAN M;;GREENBERG DIANA W;;KUMAR PANGANAMALA ASHWIN;;FLOEH JESSICA ROSE;;CARSON LYNNE LYONS,,https://lens.org/122-898-402-263-709,Patent Application,no,0,0,7,7,0,G16H20/17;;G16H20/17,G16H20/17,,0,0,,,,PENDING
53,US,S,US D0974382 S,192-429-069-427-200,2023-01-03,2023,US 202129785858 F,2021-05-27,US 202129785858 F,2021-05-27,Display screen or portion thereof with graphical user interface,,ABBOTT DIABETES CARE INC,FERN JONATHAN M;;GREENBERG DIANA W;;KUMAR PANGANAMALA ASHWIN;;FLOEH JESSICA ROSE;;CARSON LYNNE LYONS,ABBOTT DIABETES CARE INC (2021-06-04),https://lens.org/192-429-069-427-200,Design Right,no,27,4,1,1,0,,,1404;;D14/485,0,0,,,,ACTIVE
54,EP,A1,EP 4158643 A1,017-164-643-619-607,2023-04-05,2023,EP 21742206 A,2021-05-27,US 202063032094 P;;US 2021/0034510 W,2020-05-29,"SYSTEMS, DEVICES, AND METHODS FOR DOSING PATTERN MANAGEMENT",,ABBOTT DIABETES CARE INC,FERN JONATHAN M;;GREENBERG DIANA W;;KUMAR PANGANAMALA ASHWIN;;FLOEH JESSICA ROSE;;CARSON LYNNE LYONS,,https://lens.org/017-164-643-619-607,Patent Application,yes,0,0,7,7,0,G16H20/17;;G16H20/17,G16H20/17,,0,0,,,,PENDING
55,US,A1,US 2015/0135045 A1,016-125-766-339-447,2015-05-14,2015,US 201414539458 A,2014-11-12,US 201414539458 A;;US 201361903720 P,2013-11-13,METHOD AND SYSTEM FOR CREATION AND/OR PUBLICATION OF COLLABORATIVE MULTI-SOURCE MEDIA PRESENTATIONS,"A method implemented in a computer infrastructure having computer executable code tangibly embodied on a computer readable medium, including recording at least one of audio, video, still image, text and other data representations; and creating a multi-source media presentation, including the one or more of the audio, video, still image, text and other data representations",TUTTI DYNAMICS INC,HOFFMAN DARREN;;SULLIVAN KRISTEN;;BELLARD ADAM;;BIGUENET JONATHAN;;GREENBERG MIKE;;READE CHRIS;;JONES RYLAND;;WREN DEMETRIUS,TUTTI DYNAMICS INC (2014-11-09),https://lens.org/016-125-766-339-447,Patent Application,yes,18,1,1,1,0,H04L51/10;;H04L51/10;;H04L12/1831;;H04L12/1831,H04L12/18,715/202,0,0,,,,DISCONTINUED
56,US,A1,US 2009/0024530 A1,059-884-056-084-475,2009-01-22,2009,US 17518308 A,2008-07-17,US 17518308 A;;US 95071507 P,2007-07-19,AUTOMATIC GIFT MESSAGING SYSTEM,"Electronic and automatic gifting techniques are provided for messages, such as short message service (SMS) or multimedia messaging service (MMS) messages, wherein a gifter designates a recipient for one or more gift(s) offered in a set of gifts. Based on a selection of gift(s), message(s) are automatically generated for the gift(s) having unique identifier(s) that correspond to products or services of an enabling entity that enables the products or services. The message(s) including the unique identifier(s) are then automatically transmitted to the recipient. The unique identifier(s) can be encrypted/hashed with a secret provided by the recipient for an additional layer of security. Any of gifter information, giftee information, context of the service, or external information, such as global positioning service (GPS) location, can be used to make recommendations for gifts in the set of gifts.",MOZES INC,PORTER DORRIAN GRANT;;GREENBERG DAN ACKERMAN;;TOKOPH JASON CARL;;HOOVER ROGER PHYLOS;;QIN HUAJUN;;CHIU JONATHAN,MOZES INCORPORATED (2008-09-01),https://lens.org/059-884-056-084-475,Patent Application,yes,5,36,1,1,0,G06Q30/00;;G06Q30/0601;;G06Q30/00;;G06Q30/0601,G06Q30/00;;H04L9/00,705/50;;705/26,0,0,,,,DISCONTINUED
57,EP,B1,EP 1506286 B1,053-617-608-590-209,2014-03-19,2014,EP 03731338 A,2003-05-22,US 0316283 W;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,,MERCK SHARP & DOHME,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP. (2012-08-15),https://lens.org/053-617-608-590-209,Granted Patent,yes,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N5/12;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07H21/04;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/08,,3,1,031-534-268-204-129,10.1016/j.canlet.2004.09.036;;15723715,"CAINE G J ET AL: ""Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer"", CANCER LETTERS, NEW YORK, NY, US, vol. 219, no. 2, 10 March 2005 (2005-03-10), pages 163 - 167, XP004758823, ISSN: 0304-3835;;NATIONAL CANCER INSTITUTE (NCI): ""Therapeutic Modulation of Angiogenesis in Disease"", Retrieved from the Internet <URL:http://grants.nih.gov/grants/guide/pa-files/PAR-98-096.html> [retrieved on 20090505];;ZUBAR, R.V.: ""TRENDS IN ANGIOGENESIS RESEARCH"", 2005, NOVA SCIENCE PUBLISHERS, INC,., article CORADINI DANILA ET AL: ""Vascular endothelial growth factor and breast cancer"", pages: 187",EXPIRED
58,US,B2,US 7847068 B2,171-791-230-290-520,2010-12-07,2010,US 59852006 A,2006-11-13,US 59852006 A;;US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MEDAREX INCORPORATED (2008-01-17);;MERCK SHARP & DOHME CORP (2008-01-23),https://lens.org/171-791-230-290-520,Granted Patent,yes,102,7,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N15/09;;A61K39/00;;C12P21/08;;A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/00;;C07K16/28;;C07K17/00;;C07K17/14;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10,530/387.3;;530/387.1;;530/388.1;;530/388.22;;530/391.1;;424/130.1;;424/133.1;;424/143.1;;424/178.1,99,94,002-536-676-460-583;;071-117-827-714-488;;003-262-280-086-282;;115-800-617-650-990;;097-174-906-919-515;;067-620-509-667-771;;066-912-513-219-523;;025-114-183-199-748;;040-675-726-528-59X;;004-423-858-779-175;;070-311-797-413-117;;037-149-535-070-661;;040-239-601-782-040;;012-934-571-932-122;;081-280-969-081-05X;;078-794-986-614-92X;;020-893-750-321-724;;064-327-493-747-459;;056-637-250-652-512;;031-616-493-083-780;;034-109-833-747-866;;095-131-315-238-82X;;075-104-279-361-070;;044-809-864-554-776;;031-592-893-929-34X;;091-670-589-840-911;;057-564-019-868-507;;117-418-085-943-623;;079-861-467-759-75X;;113-073-836-369-700;;013-323-148-570-367;;042-187-547-330-545;;064-912-888-572-443;;061-985-327-786-642;;003-428-892-358-143;;064-327-493-747-459;;016-762-945-842-234;;088-902-136-362-226;;001-826-939-592-182;;020-258-715-333-487;;004-078-078-793-270;;035-247-137-448-696;;054-244-084-470-27X;;108-328-157-315-242;;129-849-404-301-477;;022-648-069-840-113;;027-713-460-602-505;;096-654-301-744-608;;046-056-125-843-776;;163-935-833-431-492;;000-009-798-094-596;;023-918-308-836-52X;;103-810-451-890-743;;044-434-064-672-362;;026-791-779-077-922;;003-353-895-173-837;;005-458-479-554-482;;063-796-750-967-643;;109-037-058-380-133;;027-380-338-864-138;;013-090-598-011-461;;056-136-313-668-621;;020-794-430-809-364;;015-075-033-461-569;;034-109-833-747-866;;071-117-827-714-488;;009-668-625-696-536;;046-166-624-867-77X;;001-745-412-733-159;;035-321-998-935-819;;063-876-757-064-973;;015-746-376-377-558;;012-139-204-135-647;;028-677-787-189-119;;130-978-743-660-825;;021-725-851-294-394;;013-100-324-346-340;;117-350-069-614-784;;060-555-750-112-761;;012-739-783-887-198;;027-477-313-726-928;;003-849-961-384-35X;;007-822-064-014-928;;027-885-659-586-865;;030-273-961-635-104;;132-118-555-562-745;;026-744-100-669-883;;087-659-066-526-147;;072-423-112-724-457;;005-289-784-916-65X;;077-986-778-120-36X;;096-683-076-478-544;;002-225-579-589-336;;028-383-058-454-759,10648924;;10.1016/s0022-1759(99)00137-4;;11410521;;1313689;;10.1038/bjc.1992.65;;pmc1977607;;9850076;;9515800;;2963690;;10.1016/0006-291x(87)91635-4;;2961338;;10.1172/jci114315;;2553774;;pmc304004;;2556929;;pmc1880481;;9829727;;2553250;;9699666;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;10.1073/pnas.91.6.2181;;8134369;;pmc43334;;12566306;;10.1016/s0046-8177(99)90027-8;;10534157;;10.1023/a:1005955017615;;9516079;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4;;pmc49290;;1319060;;10.1073/pnas.89.12.5356;;8216340;;10.1006/bbrc.1993.2220;;10.1016/s0021-9258(18)32449-9;;6304046;;9972281;;10.1016/s0305-0491(98)10106-2;;9438850;;10.1126/science.279.5350.563;;10446966;;8620490;;10430101;;8665514;;10.1016/s0889-8529(05)70202-4;;11571931;;10.1007/s002620000115;;10941907;;14695208;;14573361;;10.1016/j.tibtech.2003.08.007;;12941837;;14576153;;10.1074/jbc.m310132200;;10.1074/jbc.274.39.27371;;10488067;;9553667;;10.1023/a:1008241804078;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4;;10.1038/bjc.1997.41;;9010034;;pmc2063278;;8595162;;pmc2074471;;10.1038/bjc.1996.84;;3011795;;10.1016/s0021-9258(19)57454-3;;8910616;;10.1074/jbc.271.46.29483;;10487687;;10.1210/jc.84.9.3197;;10.1210/jcem.84.9.5965;;10.1210/en.140.12.5579;;10579321;;10.1210/endo.140.12.7213;;1349849;;2451200;;15805282;;10.1158/0008-5472.can-04-2898;;10.1074/jbc.m500815200;;15757893;;10.1158/1078-0432.ccr-04-1070;;15756033;;10.1158/1078-0432.ccr-04-1586;;15837762;;15386423;;10.1002/ijc.20543;;10.1006/cbir.2001.0756;;11482908;;1316907;;10.1016/s0021-9258(19)50066-7;;2831241;;10.1002/jcb.240350406;;14612496;;9404729;;10.1016/s0167-0115(97)01026-4;;10.4049/jimmunol.173.5.3564;;15322222;;14710368;;10.1055/s-2004-814144;;10.1158/0008-5472.can-04-4602;;15867374;;10766192;;10.1002/ijc.2910580325;;8050827;;10.1016/0006-291x(90)90819-9;;2171510;;15913990;;10.1016/j.ejca.2005.03.015;;10519379;;10096569;;10211534;;10.1016/s0149-2918(00)88288-0;;10.1016/s0021-9258(18)32449-9;;6304046;;11410521;;pmc115841;;10.1186/1471-2407-2-15;;12057025;;10.1016/s0021-9258(18)42367-8;;1377676;;7923191;;7812953;;10438568;;10.1006/excr.1999.4562;;12516969;;10.1158/1535-7163.mct-05-0048;;16093437;;10.1038/nbt0595-475;;9634788;;8862554;;10.1093/protein/9.6.531;;10.2174/1386207053258532;;15777175;;164891;;10.1021/bi00679a002;;2406607;;10.1038/343662a0;;10.1016/0006-291x(85)91905-9;;3000370;;8205537;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;10.1128/mcb.8.3.1247-1252.1988;;10.1128/mcb.8.3.1247;;pmc363269;;3285178;;3306677;;pmc299085;;10.1073/pnas.84.18.6408;;1974323;;10.1016/0076-6879(90)85044-o;;6256079;;10.1016/0092-8674(80)90348-7;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;1575710;;10.1002/bies.950140208;;9202712;;10.1016/s0022-1759(97)00034-3;;11733228;;10.1677/erc.0.0080315;;10.1016/0168-1656(95)00072-x;;7576533;;10.1016/s1046-2023(05)80214-2;;11259845;;10.1016/s0169-409x(00)00144-7;;10.1016/s0378-5173(99)00152-0;;10460913,"Green, Larry L.; ""Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies""; Journal of Immunological Methods; 231:11-23 (1999).;;Stefania Benini et al., Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine Against Ewing's Sarcoma Cells, Clinical Cancer Research, vol. 7, 1790-1797, Jun. 2001.;;V.M. Macaulay, Insulin-like Growth Factors and Cancer, Br. J. Cancer, 65, 311-320, 1992.;;Xiangdang Liu et al., Inhibition of Insulin-like Growth Factor I Receptor Expression in Neuroblastoma Cells Induces the Regression of Established Tumors in Mice, Cancer Research 58, 5432-5438, Dec. 1, 1998.;;Jamie L. Resnik et al., Elevated Insulin-like Growth Factor I Receptor Autophosphorylation and Kinase Activity in Human Breast Cancer, Cancer Research 58, 1159-1164, Mar. 15, 1998.;;Fredrika Pekonen et al., Receptors for Epidermal Growth Factor and Insulin-like Growth Factor I and Their Relation to Steroid Receptors in Human Breast Cancer, Cancer Research 48, 1343-1347, Mar. 1, 1988.;;Quynh T. Rohlik et al., An Antibody to the Receptor for Insulin-like Growth Factor I Inhibits the Growth of MCF-7 Cells in Tissue Culture, Biochemical and Biophysical Research Communications, vol. 149, No. 1, 276-281, 1987.;;Carlos L. Arteaga et al., Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice, J. Clin. Invest., vol. 84, 1418-1423, Nov. 1989.;;Ted Gansler et al., Rapid Communication Antibody to Type I Insulinlike Growth Factor Receptor Inhibits Growth of Wilms' Tumor in Culture and in Athymic Mice, American Journal of Pathology, vol. 135, No. 6, 961-966, Dec. 1989.;;Krzysztof Reiss et al., Inhibition of Tumor Growth by a Dominant Negative Mutant of the Insulin-like Growth Factor I Receptor with a Bystander Effect, Clinical Cancer Research, vol. 4, 2647-2655, Nov. 1998.;;Carlos L. Arteaga et al., Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antobody Against the Type I Somatomedin Receptor, Cancer Research, 49, 6237-6241, Nov. 15, 1989.;;Sandra E. Dunn et al., A Dominant Negative Mutant of the Insulin-like Growth Factor-I Receptor Inhibits the Adhesion, Invasion, and Metastasis of Breast Cancer, Cancer Research, 58, 3353-3361, Aug. 1, 1998.;;Peter Burfeind, Antisense RNA to the Type I Insulin-like Growth Factor Receptor Suppresses Tumor Growth and Prevents Invasion by Rate Prostate Cancer Cells in Vivo, Proc. Natl. Acad. Sci. USA, vol. 93 7263-7268, Jul. 1996.;;Diane Prager et al., Dominant Negative Inhibition of Tumorigenesis in Vivo by Human Insulin-like Growth Factor I Receptor Mutant, Proc. Natl. Acad. Sci. USA, vol. 91, 2181-2185, Mar. 1994.;;Deepali Sachdev, A Chimeric Humanized Single-Chain Antibody Against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-1, Cancer Research 63: 627-635, 2003.;;Hakam et al., Human Pathology (1999) 30(10): 1128-1133.;;Sepp-Lorenzino, Breast Cancer Research and Treatment (1998) 47: 235-253.;;Happerfield, et al., ""The localization of insulin-like growth factor receptor 1 (IGFR1) in benign and malignant breast tissue"" Journal of Pathology 183:412-417 (1997).;;Xiong et al., ""Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor"" Proc. Nat. Acad. Sci. 89: 5356-5360 (1992).;;Li et al., ""Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor"" Biochem. Biophys. Res. Comm. 196(1):92-98 (1993).;;Kull et al., ""Monoclonal antibodies to receptors for insulin and somatomedin-C"" J. Biol. Chem. 258(10):6561-6566 (1983).;;Butler et al., ""Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology"" Comp. Biochem. Physiol. (B) 121(1):19-26 (1998).;;Chan et al., ""Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study"" Science. 279(5350):563-566 (1998).;;Xie et al., ""Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype"" Cancer Res. 59(15):3588-3591 (1999).;;Steller et al., ""Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells"" Cancer Res. 56(8):1761-1765 (1996).;;Pandini et al., ""Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling"" Clin. Cancer Res. 5(7):1935-1944 (1999).;;Webster et al., ""Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer"" Cancer Res. 56(12):2781-2788 (1996).;;Ben-Schlomo et al., ""Acromegaly"" Endocrin. Metab. Clin. N. America 30(3):565-583 (2001).;;Li et al., ""Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth"", Cancer Immunol. Immunother. 49: 243-252 (2000).;;Burtrum et al., ""A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo."" Cancer Res. Dec. 15, 2003;63(24):8912-21.;;Business Wire, ""Imclone systems incorporated reports advancements in several pipeline programs"" (Jul. 14, 2003).;;Zhenping Zhu, ""Monoclonal Antibodies in Cancer-Fourth International Congress (Part II), Colorado Springs, CO, USA"" Investigational Drug Database Meeting Report (Sep. 3-6, 2004).;;Laura Williams, ""American Association for Cancer Research-94th Annual Meeting (Part III)-Overnight Report, Washington, D.C., USA"" Investigational Drug Database Meeting Report (Jul. 11-14, 2003).;;Imclone Systems, Inc. Form 10-K (filed Mar. 15, 2004).;;Holt et al., Domain antibodies: proteins for therapy, Trends in Biotechnology 21(11): 484-490 (2003).;;Maloney et al., An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation, Cancer Research 63, 5073-5083 (2003).;;Lu et al., Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth . . . J. Bio. Chem.279(4): 2856-65 (2004).;;Tang et al., Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody. J Biol Chem. Sep. 24, 1999;274(39):27371-8.;;Boylan et al., The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann Oncol. Feb. 1998;9(2):205-11.;;Happerfield et al., The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol. Dec. 1997;183(4):412-7.;;Clarke et al., Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997;75(2):251-7.;;Van den berg et al., Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br J Cancer. Feb. 1996;73(4):477-81.;;Lebon et al., Purification of insulin-like growth factor I receptor from human placental membranes. J Biol Chem. Jun. 15, 1986;261(17):7685-9.;;Warren et al., Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. Nov. 15, 1996;271(46):29483-8.;;Auclair et al., Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I. J Clin Endocrinol Metab. Sep. 1999;84(9):3197-3206.;;Gori et al., Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology Dec. 1999;140(12):5579-86.;;Kasprzyk et al., Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. May 15, 1992;52(10):2771-6.;;Drebin et al., Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. Mar. 1988;2(3):273-7.;;Shin et al., Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res. Apr. 1, 2005;65(7):2815-24.;;Lu et al., A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. May 20, 2005;280(20):19665-72.;;Cohen et al., Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. Mar. 1, 2005;11(5):2063-73.;;Wu et al., In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. Apr. 15, 2005;11(8):3065-74.;;Goetsch et al., A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. Jan. 10, 2005;113(2):316-28.;;Granerus et al., Effects of insulin-like growth factor-binding protein 2 and an IGF-type I receptor-blocking antibody on apoptosis in human teratocarcinoma cells in vitro. Cell Biol Int. 2001;25(8):825-8.;;Kaliman et al., Antipeptide antibody to the insulin-like growth factor-I receptor sequence 1232-1246 inhibits the receptor kinase activity. J Biol Chem. May 25, 1992;267(15):10645-51.;;Rodeck et al., Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem. Dec. 1987;35(4):315-20.;;lwakiri et al., Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res. Nov. 1, 2003;63(21):7062-7.;;Kiess et al., Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept. Sep. 26, 1997;72(1):19-29.;;Pritchard et al., Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol. Sep. 1, 2004;173(5):3564-9.;;Jackson-Booth et al., Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res. Nov.-Dec. 2003;35(11-12):850-6.;;Carboni et al., Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. May. 1, 2005;65(9):3781-7.;;Remacle-Bonnet et al., Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res. Apr. 1, 2000;60(7):2007-17.;;Lahm et al., Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer. Aug. 1, 1994;58(3):452-9.;;Steele-Perkins et al., Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding. Biochem Biophys Res Commun. Sep. 28, 1990;171(3):1244-51.;;Scotlandi et al., Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. Jun. 2005;41(9):1349-61.;;Agus et al., Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. Oct. 1, 1999;59(19):4761-4.;;Pietras et al., Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. Mar. 15, 1999;59(6):1347-55.;;Goldenberg, Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. Feb. 1999;21(2):309-18. Review.;;Kull et al., Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem. May 25, 1983;258(10):6561-6.;;Benini et al., Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. Jun. 2001;7(6):1790-7.;;Seely et al., Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer. May 31, 2002;2:15.;;Soos et al., A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem. Jun. 25, 1992;267(18):12955-63.;;Kalebic et al., In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. Nov. 1, 1994;54(21):5531-4.;;Baserga, The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. Jan. 15, 1995;55(2):249-52.;;Rubini et al., Characterization of an antibody that can detect an activated IGF-I receptor in human cancers. Exp Cell Res. Aug. 25, 1999;251(1):22-32.;;Hailey et al., Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells, Mol. Cancer Ther. Dec. 2002;1(14):1349-53.;;Wang et al., Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody, Mol Cancer Ther. Aug. 2005;4(8):1214-21.;;Davies et al., Antibody VH domains as small recognition units, Biotechnology (N Y). May 1995;13(5):475-9.;;Davies et al., Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. Jun. 1996;9(6):531-7.;;Immunobiology, the immune system in health and disease, 6th edition, Garland Science (NY), 2005, pp. 104-107.;;Conrad et al., Considerations on antibody-phage display methodology, Comb. Chem. High Throughput Screen. Mar. 2005;8(2):117-26.;;Lin et al.Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon. biochemistry 14: 1559-1563 (1975).;;Acland et al., Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon.Nature 343:662-665 (1990).;;Cordera et al.Inhibition of insulin and epidermal growth factor (EGF) receptor autophosphorylation by a human polyclonal IgG. BBRC 132(3): 991-1000 (1985).;;Freund et al.Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res. 54(12):3179-3185 (1994).;;Rudikoff et al.Single amino acid substitution altering antigen-binding specificity PNAS 79:1979 (1982).;;Burgess et al., Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue.J. Cell. Bio. 111:2129-2138 (1990).;;Lazar et al.Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Mol. Cell. Bio. 8(3):1247-1252 (1988).;;Schwartz et al.A superactive insulin: [B10-aspartic acid]insulin(human). PNAS 84:6408-6411 (1987).;;Kaufman., R.J., Selection and coamplification of heterogeneous genes in mammalian cells, Methods in Enzymology 185: 537-566 (1990).;;Ju et al., Nucleotide sequence analysis of the long terminal repeat (LTR) of avian retroviruses: structural similarities with transposable elements.Cell. 22(2 Pt 2):379-86 (1980).;;Takebe et al., SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.Mol Cell Biol. 8(1):466-72 (1988).;;Wahle, The end of the message: 3'-end processing leading to polyadenylated messenger RNA. Bioessays. 14(2):113-8 (1992).;;Nordenhaug et al., Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells, J. Immunol. Methods. May 12, 1997;204(1):77-87.;;Zhang et al., An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma, Endocr. Relat. Cancer Dec. 2001;8(4):315-25.;;Flamez et al., Production in Escherichia coli of a functional murine and murine::human chimeric F(ab')2 fragment and mature antibody directed against human placental alkaline phosphatase, J. Biotechnol. Sep. 29, 1995;42(2):133-43.;;Bebbington CR: ""Expression of antibody genes in nonlymphoid mammalian cells"" Methods: A companion to methods in Enzymology, Academic Press Inc., New York, NY, US, vol. 2, No. 2, Apr. 1991, pp. 136-145.;;Arakawa et al., Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev. Mar. 1, 2001;46(1-3):307-26.;;Wang, Instability, stabilization, and formulation of liquid protein pharmaceuticals.Int J Pharm. Aug. 20, 1999;185(2):129-88.",INACTIVE
59,EP,A1,EP 2316921 A1,046-060-570-866-257,2011-05-04,2011,EP 11150589 A,2003-05-22,EP 03731338 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP. (2012-08-15),https://lens.org/046-060-570-866-257,Patent Application,yes,70,0,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N5/12;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07H21/04;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/08,,141,108,070-311-797-413-117;;046-166-624-867-77X;;079-861-467-759-75X;;002-536-676-460-583;;001-473-019-693-166;;029-886-563-941-284;;003-262-280-086-282;;020-893-750-321-724;;095-131-315-238-82X;;075-104-279-361-070;;057-564-019-868-507;;044-809-864-554-776;;117-418-085-943-623;;034-109-833-747-866;;031-616-493-083-780;;056-637-250-652-512;;106-421-613-215-231;;020-533-566-973-694;;024-841-374-797-219;;061-444-349-075-997;;102-808-907-197-009;;110-859-707-485-225;;020-120-613-015-267;;065-114-602-989-551;;101-171-874-734-776;;078-076-853-526-487;;024-306-721-277-054;;115-802-414-738-000;;034-513-906-158-646;;027-802-945-966-731;;056-201-471-905-934;;113-749-629-542-678;;010-808-659-558-50X;;028-862-168-091-90X;;022-806-324-000-826;;104-038-311-148-69X;;093-620-729-161-804;;005-277-749-572-427;;175-236-946-121-717;;023-907-179-348-058;;080-856-085-597-555;;013-181-635-285-001;;019-779-601-634-917;;052-355-281-820-493;;036-427-544-795-059;;018-715-973-972-571;;061-175-802-642-804;;049-134-753-209-354;;024-995-475-936-443;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;032-820-729-763-323;;020-753-772-581-741;;038-613-711-274-229;;050-836-464-727-069;;106-753-778-592-300;;063-686-499-145-852;;020-026-345-586-213;;027-079-724-921-441;;106-753-778-592-300;;040-577-067-037-463;;104-212-297-137-759;;066-749-017-721-197;;031-063-853-127-197;;035-318-090-591-262;;110-088-048-889-302;;059-034-937-597-632;;152-520-430-306-466;;052-962-624-690-411;;114-414-257-216-602;;007-763-570-350-177;;022-856-092-371-964;;054-481-398-737-44X;;020-134-111-407-516;;052-176-596-515-633;;135-114-522-815-727;;008-587-496-850-953;;000-830-926-739-574;;094-857-606-776-915;;001-431-119-334-376;;021-423-005-445-292;;002-933-844-837-060;;116-641-153-355-395;;069-594-400-665-496;;130-571-338-281-966;;017-055-428-100-332;;069-594-400-665-496;;044-203-857-201-407;;017-648-305-325-092;;014-430-992-456-906;;003-690-096-860-216;;071-216-234-219-08X;;031-770-374-929-195;;058-429-436-163-000;;040-562-576-592-711;;019-878-579-549-559;;025-744-440-758-624;;054-961-802-466-059;;040-677-853-269-884;;050-836-464-727-069,2553250;;10.1016/s0021-9258(18)42367-8;;1377676;;10.1007/s002620000115;;10941907;;10648924;;10.1016/s0022-1759(99)00137-4;;6343062;;10.1210/endo-112-6-2215;;10.1016/0014-5793(78)80237-3;;658418;;1313689;;10.1038/bjc.1992.65;;pmc1977607;;10.1023/a:1005955017615;;9516079;;9972281;;10.1016/s0305-0491(98)10106-2;;9438850;;10.1126/science.279.5350.563;;8665514;;10446966;;10.1016/s0889-8529(05)70202-4;;11571931;;10.1016/s0021-9258(18)32449-9;;6304046;;8216340;;10.1006/bbrc.1993.2220;;pmc49290;;1319060;;10.1073/pnas.89.12.5356;;2448875;;10.1126/science.239.4839.487;;10.1126/science.2448875;;10.1073/pnas.74.2.560;;265521;;pmc392330;;10.1073/pnas.74.12.5463;;271968;;pmc431765;;10.1038/290304a0;;6259538;;6257399;;10.1016/0092-8674(80)90555-3;;10.1073/pnas.78.3.1441;;pmc319146;;6262799;;10.1038/296039a0;;6278311;;358198;;pmc392859;;10.1073/pnas.75.8.3727;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;6154310;;10.1038/scientificamerican0480-74;;10.1073/pnas.81.7.2035;;6371808;;pmc345431;;10.1016/0022-2836(86)90385-2;;3537305;;3315856;;10.1016/0378-1119(87)90165-x;;3065146;;10.1016/0378-1119(88)90028-5;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1038/ng0393-266;;8485583;;10.1016/s0076-6879(96)66011-x;;8743682;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1101/gr.7.6.649;;9199938;;pmc310664;;10.1016/0097-8485(93)85006-x;;10.1093/bioinformatics/10.1.67;;7514951;;pmc7130686;;2051488;;10.1016/0022-2836(91)90193-a;;10.1016/s1046-2023(05)80165-3;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1007/bf00160485;;8483166;;10.1073/pnas.87.6.2264;;2315319;;pmc53667;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1214/aop/1176988493;;10.1007/978-1-4615-5903-0_1;;10.1016/s0065-3233(08)60574-4;;362869;;408353;;10.1016/s0021-9258(17)39891-5;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;8159246;;10.1038/368856a0;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1172191;;10.1038/256495a0;;3178787;;25291284;;10.1016/0167-5699(83)90123-8;;10.1073/pnas.80.7.2026;;6572959;;pmc393745;;1172191;;10.1038/256495a0;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;1428404;;10.1007/978-3-642-78432-3_11;;11459459;;10.1021/bc0001443;;4360349;;10.1021/bi00702a028;;10.1177/30.5.7042815;;7042815;;10955787;;10.1038/sj.cgt.7700008;;10195881;;9125381;;10.1016/s0165-0270(96)00132-x;;10.1007/bf01306455;;7964989;;1644927;;pmc443142;;10.1172/jci115902;;10.1016/0378-1119(91)90411-4;;1829048;;6098454;;10.1002/j.1460-2075.1984.tb02232.x;;pmc557789;;886304;;10.1099/0022-1317-36-1-59;;11554590;;10.1007/978-1-4615-1277-6_4;;10.1016/0092-8674(83)90344-6;;6678608;;2831375;;10.1128/jvi.62.4.1120-1124.1988;;pmc253118;;pmc110499;;9811723;;10.1128/jvi.72.12.9873-9880.1998;;11525555;;10.1128/jvi.73.1.576-584.1999;;pmc103863;;9847362;;10.1128/mr.58.3.491-562.1994;;10.1128/mmbr.58.3.491-562.1994;;pmc372977;;7968923;;10.1128/jvi.67.11.6439-6446.1993;;pmc238079;;8411346;;9675133;;10.1006/bbrc.1998.8922;;10.1128/mr.58.3.491-562.1994;;10.1128/mmbr.58.3.491-562.1994;;pmc372977;;7968923;;10757020;;10.1038/sj.gt.3301122;;10071792;;10.3109/10799899909036679;;pmc299306;;10.1073/pnas.84.21.7413;;2823261;;2446313;;pmc299420;;10.1073/pnas.84.22.7851;;10.1016/s0021-9258(18)48379-2;;1370472;;10.1073/pnas.88.7.2726;;2011582;;pmc51311;;3049582;;10.1016/s0021-9258(18)68081-0;;11526457;;10.1038/sj.gt.3301484;;11274756;;10.1016/s0301-472x(00)00679-2;;11206915;;10.1016/s0302-4598(00)00112-4;;10482195;;11595543;;10.1016/s1043-2760(01)00461-1;;10.1111/j.1749-6632.1995.tb55879.x;;7486582,"ARTEAGA C L ET AL: ""Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor."", CANCER RESEARCH 15 NOV 1989, vol. 49, no. 22, 15 November 1989 (1989-11-15), pages 6237 - 6241, XP002477382, ISSN: 0008-5472;;SOOS M A ET AL: ""A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity."", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 JUN 1992, vol. 267, no. 18, 25 June 1992 (1992-06-25), pages 12955 - 12963, XP002477383, ISSN: 0021-9258;;LI S-L ET AL: ""SINGLE-CHAIN ANTIBODIES AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR: EXPRESSION, PURIFICATION AND EFFECT ON TUMOR GROWTH"", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 49, no. 4/5, July 2000 (2000-07-01), pages 243 - 252, XP001113064, ISSN: 0340-7004;;GREEN L L: ""Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies."", JOURNAL OF IMMUNOLOGICAL METHODS 10 DEC 1999, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 11 - 23, XP004186071, ISSN: 0022-1759;;KLAPPER ET AL., ENDOCRINOL., vol. 112, 1983, pages 2215;;RINDERKNECHT, FEBS.LETT., vol. 89, 1978, pages 283;;MACAULAY, BR. J. CANCER, vol. 65, 1992, pages 311;;SEPP-LORENZINO, BREAST CANCER RESEARCH AND TREATMENT, vol. 47, 1998, pages 235;;BUTLER ET AL., COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY, vol. 121, 1998, pages 19;;CHAN, SCIENCE, vol. 279, 1998, pages 563;;PANDINI ET AL., CANCER RES., vol. 5, 1999, pages 1935;;WEBSTER, CANCER RES., vol. 56, 1996, pages 2781;;PEKONEN ET AL., CANCER RES., vol. 48, 1998, pages 1343;;STELLER ET AL., CANCER RES., vol. 56, 1996, pages 1762;;XIE ET AL., CANCER RES., vol. 59, 1999, pages 3588;;BEN-SCHLOMO ET AL., ENDOCRIN. METAB.CLIN. NORTH. AM., vol. 30, 2001, pages 565 - 583;;KULL ET AL., J. BIOL. CHEM., vol. 258, 1983, pages 6561;;LI ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 196, 1993, pages 92 - 98;;XIONG ET AL., PROC. NATL. ACAD. SCI., U.S.A., vol. 89, 1992, pages 5356 - 5360;;SAMBROOK; FRITSCH; MANIATIS: ""Molecular Cloninq: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;""DNA Cloning: A Practical Approach"", vol. I, II, 1985;;""Oligonucleotide Synthesis"", 1984;;""Nucleic Acid Hybridization"", 1985;;""Transcription And Translation"", 1984;;""Animal Cell Culture"", 1986;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;B. PERBAL: ""A Practical Guide To Molecular Cloning"", 1984;;""Current Protocols in Molecular Biology"", 1994, JOHN WILEY & SONS, INC.;;SAIKI ET AL., SCIENCE, vol. 239, 1988, pages 487;;MAXAM; GILBERT, PROC. NATL. ACAD. SCI. USA, vol. 74, 1977, pages 560;;SANGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 74, 1977, pages 5463;;BENOIST ET AL., NATURE, vol. 290, 1981, pages 304 - 310;;YAMAMOTO ET AL., CELL, vol. 22, 1980, pages 787 - 797;;WAGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 1441 - 1445;;BRINSTER ET AL., NATURE, vol. 296, 1982, pages 39 - 42;;VILLA-KOMAROFF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 3727 - 3731;;DEBOER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 21 - 25;;""Useful proteins from recombinant bacteria"", SCIENTIFIC AMERICAN, vol. 242, 1980, pages 74 - 94;;DAVANLOO, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 2035 - 2039;;STUDIER, F. W ET AL., J. MOL. BIOL., vol. 189, 1986, pages 113 - 130;;ROSENBERG, A. H. ET AL., GENE, vol. 56, 1987, pages 125 - 135;;DUNN, J. J. ET AL., GENE, vol. 68, 1988, pages 259;;ALTSCHUL, S.F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;GISH, W. ET AL., NATURE GENET, vol. 3, 1993, pages 266 - 272;;MADDEN, T.L. ET AL., METH. ENZYMOL., vol. 266, 1996, pages 131 - 141;;ALTSCHUL, S.F. ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;ZHANG, J. ET AL., GENOME RES., vol. 7, 1997, pages 649 - 656;;WOOTTON, J.C. ET AL., COMPUT. CHEM., vol. 17, 1993, pages 149 - 163;;HANCOCK, J.M. ET AL., COMPUT. APPL. BIOSCI., vol. 10, 1994, pages 67 - 70;;DAYHOFF, M.O. ET AL.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1978, NATL. BIOMED. RES. FOUND., article ""A model of evolutionary change in proteins"", pages: 345 - 352;;SCHWARTZ, R.M. ET AL.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1978, NATL. BIOMED. RES. FOUND., article ""Matrices for detecting distant relationships"", pages: 353 - 358;;ALTSCHUL, S.F., J. MOL. BIOL., vol. 219, 1991, pages 555 - 565;;STATES, D.J. ET AL., METHODS, vol. 3, 1991, pages 66 - 70;;HENIKOFF, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 10919;;ALTSCHUL, S.F. ET AL., J. MOL. EVOL., vol. 36, 1993, pages 290 - 300;;KARLIN, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268;;KARLIN, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877;;DEMBO, A. ET AL., ANN. PROB., vol. 22, 1994, pages 2022 - 2039;;ALTSCHUL, S.F.: ""Theoretical and Computational Methods in Genome Research"", 1997, PLENUM, article ""Evaluating the statistical significance of multiple distinct local alignments"", pages: 1 - 14;;""Fundamental Immunology"", 1989, RAVEN PRESS;;KABAT ET AL.: ""Sequences of Proteins of lmmunoloqical Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;KABAT: ""Adv. Prot. Chem."", vol. 32, 1978, pages: 1 - 75;;KABAT ET AL., J. BIOL. CHEM., vol. 252, 1977, pages 6609 - 6616;;CHOTHIA ET AL., J MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;LONBERG, N. ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook of Experimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N. ET AL., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F. ET AL., ANN. N. Y ACAD. SCI, vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J LMMUNOL., vol. 152, 1994, pages 2912 - 2920;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;HARDING, F. ET AL., ANN. N.Y ACAD. SCI, vol. 764, 1995, pages 536 - 546;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;HARDING ET AL., ANNALS NY ACAD. SCI, vol. 764, 1995, pages 536 - 546;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497;;HERING ET AL., BIOMED. BIOCHIM. ACTA., vol. 47, 1988, pages 211 - 216;;HAGIWAR ET AL., HUM. ANTIBOD. HYBRIDOMAS, vol. 4, 1993, pages 15;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72;;COTE ET AL., PROC. NATL. ACAD. SCI. U.S.A, vol. 80, 1983, pages 2026 - 2030;;COLE ET AL.: ""Monoclonal Antibodies and Cancer Therapy"", 1985, ALAN R. LISS, INC., pages: 77 - 96;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;SONGSIVILAI ET AL., CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;HOLLIGER ET AL., PNAS USA, vol. 90, 1993, pages 6444 - 6448;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659;;TRAUNECKER ET AL., INT. J. CANCER, vol. 7, 1992, pages 51 - 52;;PLUCKTHUN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;LEE ET AL., BIOCONJ. CHEM., vol. 10, 1999, pages 973 - 981;;WEN ET AL., BIOCONJ. CHEM., vol. 12, 2001, pages 545 - 553;;HUNTER ET AL., NATURE, vol. 144, 1962, pages 945;;DAVID ET AL., BIOCHEMISTRY, vol. 13, 1974, pages 1014;;PAIN ET AL., J. IMMUNOL. METH., vol. 40, 1981, pages 219;;NYGREN, J., HISTOCHEM. AND CYTOCHEM., vol. 30, 1982, pages 407;;ALVAREZ ET AL., CLINICAL CANCER RESEARCH, vol. 6, 2000, pages 3081 - 3087;;MILLER ET AL., BIOTECHNIQUES, vol. 7, 1992, pages 980 - 990;;KANNO ET AL., CANCER GEN. THER., vol. 6, 1999, pages 147 - 154;;KAPLITT ET AL., J. NEUROSCI. METH., vol. 71, 1997, pages 125 - 132;;KAPLITT ET AL., J. NEURO ONC., vol. 19, 1994, pages 137 - 147;;STRATFORD-PERRICAUDET ET AL., J. CLIN. INVEST., vol. 90, 1992, pages 626 - 630;;LEVRERO ET AL., GENE, vol. 101, 1991, pages 195;;GRAHAM, EMBO J., vol. 3, 1984, pages 2917;;GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59;;DALY ET AL., GENE THER., vol. 8, 2001, pages 1343 - 1346,1245-1315;;LARSON ET AL., ADV. EXP. MED. BIO., vol. 489, 2001, pages 45 - 57;;MANN ET AL., CELL, vol. 33, 1983, pages 153;;MARKOWITZ ET AL., J. VIROL., vol. 62, 1988, pages 1120;;ZUFFEREY ET AL., J. VIROL., vol. 72, 1998, pages 9873 - 80;;KAFRI ET AL., CURR. OPIN. MOL. THER., vol. 3, 2001, pages 316 - 326;;KAFRI ET AL., J. VIROL., vol. 73, 1999, pages 576 - 584;;STRAUS ET AL., MICROBIOL. REV., vol. 58, 1994, pages 491 - 562;;BREDENBEEK ET AL., J. VIROL., vol. 67, 1993, pages 6439 - 6446;;LIJIMA ET AL., INT. J. CANCER, vol. 80, 1999, pages 110 - 118;;SAWAI ET AL., BIOCHIM. BIOPHYR. RES. COMM, vol. 248, 1998, pages 315 - 323;;STRAUSS ET AL., MICROBIOL. REV., vol. 58, 1994, pages 491 - 562;;WAHLFORS ET AL., GENE. THER., vol. 7, 2000, pages 472 - 480;;LUNDSTROM, J. RECEP. SIG. TRANSDUCT. RES., vol. 19, no. 1-4, 1999, pages 673 - 686;;FELGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7417;;WANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7851 - 7855;;WILSON ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 963 - 967;;WILLIAMS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 2726 - 2730;;WU ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 14621 - 14624;;VILQUIN ET AL., GENE THER., vol. 8, 2001, pages 1097;;PAYEN ET AL., EXP. HEMATOL., vol. 29, 2001, pages 295 - 300;;MIR, BIOELECTROCHEMISTRY, vol. 53, no. 1-10, 2001;;""The Pharmacoloqical Bases of Therapeutics"", 1990, PERGAMON PRESS;;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING CO.;;""Pharmaceutical Dosage Forms: Parenteral Medications"", 1993, DEKKER;;""Pharmaceutical Dosage Forms: Tablets"", 1990, DEKKER;;""Pharmaceutical Dosage Forms: Disperse Systems"", 1990, DEKKER;;""Druqs and the Pharmaceutical Sciences"", vol. 119, 2002, MARCEL DEKKER, article ""Dermatoloqical and Transdermal Formulations"";;FOSTER ET AL., COCHRANE DATABASE SYSTEM REV., vol. 3, 2001, pages CD001816;;SLIWKOWSKI ET AL., SEMIN. ONCOL., vol. 26, no. 4, 1999, pages 60 - 70;;DRAKE ET AL., TRENDS ENDOCRIN. METAB., vol. 12, 2001, pages 408 - 413;;ZOLA: ""Monoclonal Antibodies: A Manual of Techniques"", 1987, CRC PRESS, INC., pages: 147 - 158;;HARDING ET AL., ANN. NY ACAD. SCI., vol. 764, 1995, pages 536 - 546",EXPIRED
60,AU,A1,AU 2007/200876 A1,060-106-615-225-831,2007-03-22,2007,AU 2007/200876 A,2007-02-28,AU 2003/241590 A;;AU 2007/200876 A;;US 38345902 P;;US 43625402 P;;US 39321402 P,2002-05-24,Neutralizing human anti-IGFR antibody,,SCHERING CORP,PACHTER JONATHAN A;;PRESTA LEONARD;;SRINIVASAN MOHAN;;FEINGERSH DIANE;;GREENBERG ROBERT;;WANG YAN;;HAILEY JUDITH;;WILLIAMS DENISE;;BRAMS PETER,,https://lens.org/060-106-615-225-831,Patent Application,no,0,0,2,48,0,,C12N15/09;;A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,EXPIRED
61,PE,A1,PE 20040519 A1,031-102-094-358-363,2004-08-24,2004,PE 2003000505 A,2003-05-23,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,ANTICUERPO NEUTRALIZANTE HUMANO ANTI-IGFR,"SE REFIERE A UNA COMPOSICION FARMACEUTICA DE ANTICUERPOS MONOCLONALES INTEGRADA POR: A) DOS SECUENCIAS DE AMINOACIDOS DE CADENA LIVIANA: CDR-L1, CDR-L2, CDR-L3; B) DOS SECUENCIAS DE AMINOACIDOS DE CADENA PESADA: CDR-H1, CDR-H2, CDR-H3; C) UN VEHICULO ACEPTABLE DE USO FARMACEUTICO PARA ADMINISTRACION PARENTERAL. SE REFIERE TAMBIEN A LA PRODUCCION DE DICHOS ANTICUERPOS. DICHA COMPOSICION ES INHIBIDORA DEL IGFR1 Y ES UTIL EN EL TRATAMIENTO O PREVENCION DE CONDICIONES MEDICAS RELACIONADAS CON EL CRECIMIENTO Y SUPERVIVENCIA DE CELULAS TUMORALES TALES COMO ACROMEGALIA, CANCER DE VEJIGA, CANCER DE OVARIO, GIGANTISMO, CANCER DE PULMON, ENTRE OTROS",SCHERING CORP,FEINGERSH DIANE;;WANG YAN;;GREENBERG ROBERT;;PACHTER JONATHAN A;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;HAILEY JUDITH;;PRESTA LEONARD;;BRAMS PETER,,https://lens.org/031-102-094-358-363,Patent Application,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/00;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,EXPIRED
62,JP,A,JP 2006265262 A,110-923-763-184-64X,2006-10-05,2006,JP 2006138156 A,2006-05-17,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,"<P>PROBLEM TO BE SOLVED: To provide a fully human monoclonal antibody against human Insulin-like Growth Factor Receptor-I (IGFR1), useful for treating or preventing the disease (e.g. malignant disorder) mediated by the IGFR1. <P>SOLUTION: The binding composition contains a member selected from the group consisting of a light chain amino acid sequence containing CDR-L1, CDR-L2 and CDR-L3, and a heavy chain amino acid sequence containing CDR-H1, CDR-H2 and CDR-H3, and specifically binds to the IGFR1. The fully human, neutralizing, monoclonal antibody against human Insulin-like growth factor receptor-I (IGFR1) is also provided. The antibody is useful for treatment or prevention of cancer in a test object. The methods for using and producing the antibody are also provided. <P>COPYRIGHT: (C)2007,JPO&INPIT",SCHERING PLOUGH CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,,https://lens.org/110-923-763-184-64X,Patent Application,no,1,1,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C07K16/28;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,PENDING
63,PL,A1,PL 373886 A1,083-498-424-380-185,2005-09-19,2005,PL 37388603 A,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,,SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,,https://lens.org/083-498-424-380-185,Patent Application,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;C12N15/09;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,EXPIRED
64,WO,A3,WO 2003/100008 A3,106-367-534-336-428,2004-04-08,2004,US 0316283 W,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP;;WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,,https://lens.org/106-367-534-336-428,Search Report,yes,1,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;C12N15/09;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,1,1,064-327-493-747-459,9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4,"HAPPERFIELD ET AL.: ""The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue"", JOURNAL OF PATHOLOGY, vol. 183, 1997, pages 412 - 417, XP002970794",PATENTED
65,CA,A1,CA 2484000 A1,140-970-167-160-983,2003-12-04,2003,CA 2484000 A,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 P;;US 0316283 W,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WILLIAMS DENISE;;HAILEY JUDITH;;WANG YAN;;GREENBERG ROBERT;;FEINGERSH DIANE;;BRAMS PETER;;SRINIVASAN MOHAN;;PRESTA LEONARD;;PACHTER JONATHAN A,,https://lens.org/140-970-167-160-983,Patent Application,no,0,0,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;C12N15/09;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,DISCONTINUED
66,US,B2,US 7667021 B2,174-688-826-745-50X,2010-02-23,2010,US 59861806 A,2006-11-13,US 59861806 A;;US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes isolated nucleic acids encoding fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MEDAREX INCORPORATED (2008-01-17);;MERCK SHARP & DOHME CORP (2008-01-23),https://lens.org/174-688-826-745-50X,Granted Patent,yes,99,6,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C07H21/04;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/04;;C12P21/08,536/23.53;;424/133.1;;424/141.1;;424/143.1;;424/155.1;;435/69.6;;435/70.21;;435/320.1;;435/328;;530/387.3;;530/388.1;;530/388.22;;530/388.8,105,97,027-477-313-726-928;;029-611-134-469-353;;095-334-545-560-259;;045-942-104-775-903;;071-117-827-714-488;;003-262-280-086-282;;108-945-813-243-798;;115-800-617-650-990;;097-174-906-919-515;;067-620-509-667-771;;066-912-513-219-523;;025-114-183-199-748;;040-675-726-528-59X;;004-423-858-779-175;;070-311-797-413-117;;037-149-535-070-661;;040-239-601-782-040;;012-934-571-932-122;;081-280-969-081-05X;;078-794-986-614-92X;;020-893-750-321-724;;064-327-493-747-459;;056-637-250-652-512;;031-616-493-083-780;;034-109-833-747-866;;095-131-315-238-82X;;075-104-279-361-070;;044-809-864-554-776;;031-592-893-929-34X;;091-670-589-840-911;;057-564-019-868-507;;117-418-085-943-623;;079-861-467-759-75X;;113-073-836-369-700;;013-323-148-570-367;;042-187-547-330-545;;064-912-888-572-443;;061-985-327-786-642;;003-428-892-358-143;;064-327-493-747-459;;016-762-945-842-234;;088-902-136-362-226;;001-826-939-592-182;;020-258-715-333-487;;004-078-078-793-270;;035-247-137-448-696;;054-244-084-470-27X;;108-328-157-315-242;;129-849-404-301-477;;022-648-069-840-113;;027-713-460-602-505;;096-654-301-744-608;;046-056-125-843-776;;163-935-833-431-492;;000-009-798-094-596;;023-918-308-836-52X;;103-810-451-890-743;;044-434-064-672-362;;026-791-779-077-922;;003-353-895-173-837;;005-458-479-554-482;;063-796-750-967-643;;109-037-058-380-133;;027-380-338-864-138;;013-090-598-011-461;;056-136-313-668-621;;020-794-430-809-364;;015-075-033-461-569;;034-109-833-747-866;;071-117-827-714-488;;009-668-625-696-536;;046-166-624-867-77X;;001-745-412-733-159;;035-321-998-935-819;;063-876-757-064-973;;015-746-376-377-558;;012-139-204-135-647;;028-677-787-189-119;;130-978-743-660-825;;021-725-851-294-394;;002-536-676-460-583;;117-350-069-614-784;;002-225-579-589-336;;057-681-466-050-339;;096-683-076-478-544;;001-956-738-655-04X;;067-427-650-920-583;;000-033-459-409-063;;003-849-961-384-35X;;060-555-750-112-761;;028-677-787-189-119;;130-978-743-660-825;;029-578-036-571-424;;012-606-099-583-412;;077-986-778-120-36X;;012-739-783-887-198;;151-353-100-487-530,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1006/jmbi.1996.0548;;8876650;;12850000;;10.1016/s0006-291x(03)01131-8;;11410521;;1313689;;10.1038/bjc.1992.65;;pmc1977607;;9599296;;10.1111/j.1749-6632.1998.tb09634.x;;9850076;;9515800;;2963690;;10.1016/0006-291x(87)91635-4;;2961338;;10.1172/jci114315;;2553774;;pmc304004;;2556929;;pmc1880481;;9829727;;2553250;;9699666;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;10.1073/pnas.91.6.2181;;8134369;;pmc43334;;12566306;;10.1016/s0046-8177(99)90027-8;;10534157;;10.1023/a:1005955017615;;9516079;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4;;pmc49290;;1319060;;10.1073/pnas.89.12.5356;;8216340;;10.1006/bbrc.1993.2220;;10.1016/s0021-9258(18)32449-9;;6304046;;9972281;;10.1016/s0305-0491(98)10106-2;;9438850;;10.1126/science.279.5350.563;;10446966;;8620490;;10430101;;8665514;;10.1016/s0889-8529(05)70202-4;;11571931;;10.1007/s002620000115;;10941907;;14695208;;14573361;;10.1016/j.tibtech.2003.08.007;;12941837;;14576153;;10.1074/jbc.m310132200;;10.1074/jbc.274.39.27371;;10488067;;9553667;;10.1023/a:1008241804078;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4;;10.1038/bjc.1997.41;;9010034;;pmc2063278;;8595162;;pmc2074471;;10.1038/bjc.1996.84;;3011795;;10.1016/s0021-9258(19)57454-3;;8910616;;10.1074/jbc.271.46.29483;;10487687;;10.1210/jc.84.9.3197;;10.1210/jcem.84.9.5965;;10.1210/en.140.12.5579;;10579321;;10.1210/endo.140.12.7213;;1349849;;2451200;;15805282;;10.1158/0008-5472.can-04-2898;;10.1074/jbc.m500815200;;15757893;;10.1158/1078-0432.ccr-04-1070;;15756033;;10.1158/1078-0432.ccr-04-1586;;15837762;;15386423;;10.1002/ijc.20543;;10.1006/cbir.2001.0756;;11482908;;1316907;;10.1016/s0021-9258(19)50066-7;;2831241;;10.1002/jcb.240350406;;14612496;;9404729;;10.1016/s0167-0115(97)01026-4;;10.4049/jimmunol.173.5.3564;;15322222;;14710368;;10.1055/s-2004-814144;;10.1158/0008-5472.can-04-4602;;15867374;;10766192;;10.1002/ijc.2910580325;;8050827;;10.1016/0006-291x(90)90819-9;;2171510;;15913990;;10.1016/j.ejca.2005.03.015;;10519379;;10096569;;10211534;;10.1016/s0149-2918(00)88288-0;;10.1016/s0021-9258(18)32449-9;;6304046;;11410521;;pmc115841;;10.1186/1471-2407-2-15;;12057025;;10.1016/s0021-9258(18)42367-8;;1377676;;7923191;;7812953;;10438568;;10.1006/excr.1999.4562;;12516969;;10.1158/1535-7163.mct-05-0048;;16093437;;10.1038/nbt0595-475;;9634788;;8862554;;10.1093/protein/9.6.531;;10.2174/1386207053258532;;15777175;;10648924;;10.1016/s0022-1759(99)00137-4;;2406607;;10.1038/343662a0;;11259845;;10.1016/s0169-409x(00)00144-7;;10.1021/bi00590a025;;497177;;10.1016/s1046-2023(05)80214-2;;10.3892/or.8.2.325;;11182049;;10.1093/oxfordjournals.annonc.a058252;;1498071;;11743213;;10.1634/theoncologist.6-6-506;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;10.1016/0006-291x(85)91905-9;;3000370;;10.1038/nbt0595-475;;9634788;;8862554;;10.1093/protein/9.6.531;;10.1053/ejso.2000.0955;;11034814;;9053512;;10.1200/jco.1997.15.2.840;;10.1016/0168-1656(95)00072-x;;7576533;;8205537;;11595711,"Fundamental Immunology, 3rd Edition, William E. Paul, MD ed., pp. 292-295, 1993.;;Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.;;Colman P. M. Research in Immunology, 145:33-36, 1994.;;Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.;;MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.;;Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.;;Stefania Benini et al., Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine Against Ewing's Sarcoma Cells, Clinical Cancer Research, vol. 7, 1790-1797, Jun. 2001.;;V.M. Macaulay, Insulin-like Growth Factors and Cancer, Br. J. Cancer, 65, 311-320, 1992.;;Mariana Resnicoff et al., The Role of the Insulin-like Growth Factor I Receptor in Transformation and Apoptosis, Kimmel Cancer Institute, Thomas Jefferson University pp. 76-81.;;Xiangdang Liu et al., Inhibition of Insulin-like Growth Factor I Receptor Expression in Neuroblastoma Cells Induces the Regression of Established Tumors in Mice, Cancer Research 58, 5432-5438, Dec. 1, 1998.;;Jamie L. Resnik et al., Elevated Insulin-like Growth Factor I Receptor Autophosphorylation and Kinase Activity in Human Breast Cancer, Cancer Research 58, 1159-1164, Mar. 15, 1998.;;Fredrika Pekonen et al., Receptors for Epidermal Growth Factor and Insulin-like Growth Factor I and Their Relation to Steroid Receptors in Human Breast Cancer, Cancer Research 48, 1343-1347, Mar. 1, 1988.;;Quynh T. Rohlik et al., An Antibody to the Receptor for Insulin-like Growth Factor I Inhibits the Growth of MCF-7 Cells in Tissue Culture, Biochemical and Biophysical Research Communications, vol. 149, No. 1, 276-281, 1987.;;Carlos L. Arteaga et al., Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice, J. Clin. Invest., vol. 84, 1418-1423, Nov. 1989.;;Ted Gansler et al., Rapid Communication Antibody to Type I Insulinlike Growth Factor Receptor Inhibits Growth of Wilms' Tumor in Culture and in Athymic Mice, American Journal of Pathology, vol. 135, No. 6, 961-966, Dec. 1989.;;Krzysztof Reiss et al., Inhibition of Tumor Growth by a Dominant Negative Mutant of the Insulin-like Growth Factor I Receptor with a Bystander Effect, Clinical Cancer Research, vol. 4, 2647-2655, Nov. 1998.;;Carlos L. Arteaga et al., Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antobody Against the Type I Somatomedin Receptor, Cancer Research, 49, 6237-6241, Nov. 15, 1989.;;Sandra E. Dunn et al., A Dominant Negative Mutant of the Insulin-like Growth Factor-I Receptor Inhibits the Adhesion, Invasion, and Metastasis of Breast Cancer, Cancer Research, 58, 3353-3361, Aug. 1, 1998.;;Peter Burfeind, Antisense RNA to the Type I Insulin-like Growth Factor Receptor Suppresses Tumor Growth and Prevents Invasion by Rate Prostate Cancer Cells In Vivo, Proc. Natl. Acad. Sci. USA, vol. 93 7263-7268, Jul. 1996.;;Diane Prager et al., Dominant Negative Inhibition of Tumorigenesis In Vivo by Human Insulin-like Growth Factor I Receptor Mutant, Proc. Natl. Acad. Sci. USA, vol. 91, 2181-2185, Mar. 1994.;;Deepali Sachdev, A Chimeric Humanized Single-Chain Antibody Against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-1, Cancer Research 63: 627-635, 2003.;;Hakam et al., Human Pathology (1999) 30(10): 1128-1133.;;Sepp-Lorenzino, Breast Cancer Research and Treatment (1998) 47: 235-253.;;Happerfield, et al., ""The localization of insulin-like growth factor receptor 1 (IGFR1) in benign and malignant breast tissue"" Journal of Pathology 183:412-417 (1997).;;Xiong et al., ""Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor"" Proc. Nat. Acad. Sci. 89: 5356-5360 (1992).;;Li et al., ""Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor"" Biochem. Biophys. Res. Comm. 196(1):92-98 (1993).;;Kull et al., ""Monoclonal antibodies to receptors for insulin and somatomedin-C"" J. Biol. Chem. 258(10):6561-6566 (1983).;;Butler et al., ""Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology"" Comp. Biochem. Physiol. (B) 121(1):19-26 (1998).;;Chan et al., ""Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study"" Science. 279(5350):563-566 (1998).;;Xie et al., ""Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype"" Cancer Res. 59(15):3588-3591 (1999).;;Steller et al., ""Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells"" Cancer Res. 56(8):1761-1765 (1996).;;Pandini et al., ""Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling"" Clin. Cancer Res. 5(7):1935-1944 (1999).;;Webster et al., ""Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer"" Cancer Res. 56(12):2781-2788 (1996).;;Ben-Schlomo et al., ""Acromegaly"" Endocrin. Metab. Clin. N. America 30(3):565-583 (2001).;;Li et al., ""Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth"", Cancer Immunol. Immunother. 49: 243-252 (2000).;;Burtrum et al., ""A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo."" Cancer Res. Dec. 15, 2003;63(24):8912-21.;;Business Wire, ""Imclone systems incorporated reports advancements in several pipeline programs"" (Jul. 14, 2003).;;Zhenping Zhu, ""Monoclonal Antibodies in Cancer-Fourth International Congress (Part II), Colorado Springs, CO, USA"" Investigational Drug Database Meeting Report (Sep. 3-6, 2004).;;Laura Williams, ""American Association for Cancer Research-94th Annual Meeting (Part III)-Overnight Report, Washington, D.C., USA"" Investigational Drug Database Meeting Report (Jul. 11-14, 2003).;;Imclone Systems, Inc. Form 10-K (filed Mar. 15, 2004).;;Holt et al., Domain antibodies: proteins for therapy, Trends in Biotechnology 21(11): 484-490 (2003).;;Maloney et al., An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation, Cancer Research 63, 5073-5083 (2003).;;Lu et al., Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth . . . J. Bio. Chem.279(4): 2856-65 (2004).;;Tang et al., Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody. J Biol Chem. Sep. 24, 1999;274(39):27371-8.;;Boylan et al., The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann Oncol. Feb. 1998;9(2):205-11.;;Happerfield et al., The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol. Dec. 1997;183(4):412-7.;;Clarke et al., Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997;75(2):251-7.;;Van den berg et al., Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br J Cancer. Feb. 1996;73(4):477-81.;;Lebon et al., Purification of insulin-like growth factor I receptor from human placental membranes. J Biol Chem. Jun. 15, 1986;261(17):7685-9.;;Warren et al., Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. Nov. 15, 1996;271(46):29483-8.;;Auclair et al., Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I. J Clin Endocrinol Metab. Sep. 1999;84(9):3197-3206.;;Gori et al., Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology. Dec. 1999;140(12):5579-86.;;Kasprzyk et al., Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. May 15, 1992;52(10):2771-6.;;Drebin et al., Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. Mar. 1988;2(3):273-7.;;Shin et al., Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res. Apr. 1, 2005;65(7):2815-24.;;Lu et al., A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. May 20, 2005;280(20):19665-72.;;Cohen et al., Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. Mar. 1, 2005;11(5):2063-73.;;Wu et al., In vivo effects of the human type I insulin-like growth factor receptor antibody A 12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. Apr. 15, 2005;11(8):3065-74.;;Goetsch et al., A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. Jan. 10, 2005;113(2):316-28.;;Granerus et al., Effects of insulin-like growth factor-binding protein 2 and an IGF-type I receptor-blocking antibody on apoptosis in human teratocarcinoma cells in vitro. Cell Biol Int. 2001;25(8):825-8.;;Kaliman et al., Antipeptide antibody to the insulin-like growth factor-I receptor sequence 1232-1246 inhibits the receptor kinase activity. J Biol Chem. May 25, 1992;267(15):10645-51.;;Rodeck et al., Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem. Dec. 1987;35(4):315-20.;;Iwakiri et al., Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res. Nov. 1, 2003;63(21):7062-7.;;Kiess et al., Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept. Sep. 26, 1997;72(1):19-29.;;Pritchard et al., Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol. Sep. 1, 2004;173(5):3564-9.;;Jackson-Booth et al., Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res. Nov.-Dec. 2003:35(11-12):850-6.;;Carboni et al., Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. May 1, 2005;65(9):3781-7.;;Remacle-Bonnet et al., Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res. Apr. 1, 2000;60(7):2007-17.;;Lahm et al., Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer. Aug. 1, 1994;58(3):452-9.;;Steele-Perkins et al., Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding. Biochem Biophys Res Commun. Sep. 28, 1990;171(3):1244-51.;;Scotlandi et al., Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. Jun. 2005;41(9):1349-61.;;Agus et al., Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. Oct. 1, 1999;59(19):4761-4.;;Pietras et al., Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. Mar. 15, 1999;59(6):1347-55.;;Goldenberg, Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. Feb. 1999;21(2):309-18. Review.;;Kull et al., Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem. May 25, 1983;258(10):6561-6.;;Benini et al., Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. Jun. 2001;7(6):1790-7.;;Seely et al., Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer. May 31, 2002;2:15.;;Soos et al., A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem. Jun. 25, 1992;267(18):12955-63.;;Kalebic et al., In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. Nov. 1, 1994;54(21):5531-4.;;Baserga, The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. Jan. 15, 1995;55(2):249-52.;;Rubini et al., Characterization of an antibody that can detect an activated IGF-I receptor in human cancers. Exp Cell Res. Aug. 25, 1999;251(1):22-32.;;Hailey et al., Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells, Mol. Cancer Ther. Dec. 2002;1(14):1349-53.;;Wang et al., Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody, Mol Cancer Ther. Aug. 2005;4(8):1214-21.;;Davies et al., Antibody VH domains as small recognition units, Biotechnology (N Y). May 1995;13(5):475-9.;;Davies et al., Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. Jun. 1996;9(6):531-7.;;Immunobiology, the immune system in health and disease, 6th edition, Garland Science (NY), 2005, pp. 104-107.;;Conrad et al., Considerations on antibody-phage display methodology, Comb. Chem. High Throughput Screen. Mar. 2005;8(2):117-26.;;Green, Larry L.; ""Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies""; Journal of Immunological Methods; 231:11-23 (1999).;;Acland, Piers, et al., ""Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon""; Nature 343:662-665 (1990).;;Arakawa, Tsutomu, et al., ""Factors affecting short-term and long-term stabilities of proteins""; Adv Drug Deliv Rev.; 46(1-3):307-326 (2001).;;Back, Joan F., et al., ""Increased thermal stability of proteins in the presence of sugars and polyols""; Biochemistry. 18(23):5191-5196 (1997).;;Bebbington, Christopher R.; ""Expression of antibody genes in nonlymphoid mammalian cells""; Methods: A companion to methods in Enzymology, Academic Press Inc., New York, NY, US, 2(2):136-145 (1991).;;Beech, Derrick J., et al., ""Insulin-like growth factor-1 receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol""; Oncology Reports; 8:325-329 (2001).;;Bollag, W., et al., ""Retinoids in cancer prevention and therapy""; Ann Oncol. 3(7):513-526 (1992).;;Bomgaards, Lisa, et al.; ""The development of camptothecin analogs in childhood cancers""; Oncologist; 6(6):506-516 (2001).;;Burgess, Wilson H., et al.; ""Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue""; J. Cell. Bio.; 111:2129-2138 (1990).;;Cordera, Renzo, et al.; ""Inhibition of insulin and epidermal growth factor (EGF) receptor autophosphorylation by a human polyclonal IgG""; Biochemical and Biophysical Research Communications; 132(3):991-1000 (1985).;;Davies, Julian, et al.; Antibody VH domains as small recognition units. Biotechnology (N Y). May 1995;13(5):475-9.;;Davies, Julian, et al.; ""Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability""; Protein Eng.; 9(6):531-537 (1996).;;Physicians' Desk Reference, 54th edition, Medical Economics Co., New Jersey (2000): Doxil.;;Napier & Ledermann, ""Novel chemotherapeutic agents in colorectal cancer"", Eur J Surg Oncol. Sep. 2000;26(6):605-10.;;Gradishar & Jordan, ""Clinical potential of new antiestrogens"", J Clin Oncol. Feb. 1997;15(2):840-52.;;Flamez, Daisy, et al.; ""Production in Escherichia coli of a functional murine and murine::human chimeric F(ab')2 fragment and mature antibody directed against human placental alkaline phosphatase""; J. Biotechnol. 42(2):133-143 (1995).;;Freund, Gregory G., et al.; ""Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines""; Cancer Res.; 54(12):3179-3185 (1994).;;Greenberger, Lee M., et al.; ""A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats""; Clin Cancer Res.; 7(10):3166-3177 (2001).",EXPIRED
67,EP,A2,EP 1506286 A2,197-071-065-503-585,2005-02-16,2005,EP 03731338 A,2003-05-22,US 0316283 W;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,,SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP. (2012-08-15),https://lens.org/197-071-065-503-585,Patent Application,yes,0,0,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;C12N5/12;;A61P21/00;;C12N15/09;;A61P35/00;;C07H21/04;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/08,,0,0,,,,EXPIRED
68,US,B2,US 7851181 B2,044-993-101-667-089,2010-12-14,2010,US 83579107 A,2007-08-08,US 83579107 A;;US 59852006 A;;US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MEDAREX INCORPORATED (2008-01-15);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/044-993-101-667-089,Granted Patent,yes,99,6,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N15/09;;A61K39/395;;C12P21/02;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,435/69.1;;435/320.1;;435/325;;435/254.1;;530/324;;530/350;;536/23.5,83,77,002-536-676-460-583;;071-117-827-714-488;;003-262-280-086-282;;115-800-617-650-990;;097-174-906-919-515;;067-620-509-667-771;;066-912-513-219-523;;025-114-183-199-748;;040-675-726-528-59X;;004-423-858-779-175;;070-311-797-413-117;;037-149-535-070-661;;040-239-601-782-040;;012-934-571-932-122;;081-280-969-081-05X;;078-794-986-614-92X;;020-893-750-321-724;;064-327-493-747-459;;056-637-250-652-512;;031-616-493-083-780;;034-109-833-747-866;;095-131-315-238-82X;;075-104-279-361-070;;044-809-864-554-776;;031-592-893-929-34X;;091-670-589-840-911;;057-564-019-868-507;;117-418-085-943-623;;079-861-467-759-75X;;113-073-836-369-700;;013-323-148-570-367;;042-187-547-330-545;;064-912-888-572-443;;061-985-327-786-642;;003-428-892-358-143;;064-327-493-747-459;;016-762-945-842-234;;088-902-136-362-226;;001-826-939-592-182;;020-258-715-333-487;;004-078-078-793-270;;035-247-137-448-696;;054-244-084-470-27X;;108-328-157-315-242;;129-849-404-301-477;;022-648-069-840-113;;027-713-460-602-505;;096-654-301-744-608;;046-056-125-843-776;;163-935-833-431-492;;000-009-798-094-596;;023-918-308-836-52X;;103-810-451-890-743;;044-434-064-672-362;;026-791-779-077-922;;003-353-895-173-837;;005-458-479-554-482;;063-796-750-967-643;;109-037-058-380-133;;027-380-338-864-138;;013-090-598-011-461;;056-136-313-668-621;;020-794-430-809-364;;015-075-033-461-569;;034-109-833-747-866;;071-117-827-714-488;;009-668-625-696-536;;046-166-624-867-77X;;001-745-412-733-159;;035-321-998-935-819;;063-876-757-064-973;;015-746-376-377-558;;012-139-204-135-647;;028-677-787-189-119;;130-978-743-660-825;;021-725-851-294-394;;108-945-813-243-798,10648924;;10.1016/s0022-1759(99)00137-4;;11410521;;1313689;;10.1038/bjc.1992.65;;pmc1977607;;9850076;;9515800;;2963690;;10.1016/0006-291x(87)91635-4;;2961338;;10.1172/jci114315;;2553774;;pmc304004;;2556929;;pmc1880481;;9829727;;2553250;;9699666;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;10.1073/pnas.91.6.2181;;8134369;;pmc43334;;12566306;;10.1016/s0046-8177(99)90027-8;;10534157;;10.1023/a:1005955017615;;9516079;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4;;pmc49290;;1319060;;10.1073/pnas.89.12.5356;;8216340;;10.1006/bbrc.1993.2220;;10.1016/s0021-9258(18)32449-9;;6304046;;9972281;;10.1016/s0305-0491(98)10106-2;;9438850;;10.1126/science.279.5350.563;;10446966;;8620490;;10430101;;8665514;;10.1016/s0889-8529(05)70202-4;;11571931;;10.1007/s002620000115;;10941907;;14695208;;14573361;;10.1016/j.tibtech.2003.08.007;;12941837;;14576153;;10.1074/jbc.m310132200;;10.1074/jbc.274.39.27371;;10488067;;9553667;;10.1023/a:1008241804078;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4;;10.1038/bjc.1997.41;;9010034;;pmc2063278;;8595162;;pmc2074471;;10.1038/bjc.1996.84;;3011795;;10.1016/s0021-9258(19)57454-3;;8910616;;10.1074/jbc.271.46.29483;;10487687;;10.1210/jc.84.9.3197;;10.1210/jcem.84.9.5965;;10.1210/en.140.12.5579;;10579321;;10.1210/endo.140.12.7213;;1349849;;2451200;;15805282;;10.1158/0008-5472.can-04-2898;;10.1074/jbc.m500815200;;15757893;;10.1158/1078-0432.ccr-04-1070;;15756033;;10.1158/1078-0432.ccr-04-1586;;15837762;;15386423;;10.1002/ijc.20543;;10.1006/cbir.2001.0756;;11482908;;1316907;;10.1016/s0021-9258(19)50066-7;;2831241;;10.1002/jcb.240350406;;14612496;;9404729;;10.1016/s0167-0115(97)01026-4;;10.4049/jimmunol.173.5.3564;;15322222;;14710368;;10.1055/s-2004-814144;;10.1158/0008-5472.can-04-4602;;15867374;;10766192;;10.1002/ijc.2910580325;;8050827;;10.1016/0006-291x(90)90819-9;;2171510;;15913990;;10.1016/j.ejca.2005.03.015;;10519379;;10096569;;10211534;;10.1016/s0149-2918(00)88288-0;;10.1016/s0021-9258(18)32449-9;;6304046;;11410521;;pmc115841;;10.1186/1471-2407-2-15;;12057025;;10.1016/s0021-9258(18)42367-8;;1377676;;7923191;;7812953;;10438568;;10.1006/excr.1999.4562;;12516969;;10.1158/1535-7163.mct-05-0048;;16093437;;10.1038/nbt0595-475;;9634788;;8862554;;10.1093/protein/9.6.531;;10.2174/1386207053258532;;15777175;;9599296;;10.1111/j.1749-6632.1998.tb09634.x,"Green, Larry L.; ""Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies""; Journal of Immunological Methods; 231:11-23 (1999).;;Stefania Benini et al., Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine Against Ewing's Sarcoma Cells, Clinical Cancer Research, vol. 7, '1790-1797, Jun. 2001.;;V.M. Macaulay, Insulin-like Growth Factors and Cancer, Br. J. Cancer, 65, 311-320, 1992.;;Xiangdang Liu et al., Inhibition of Insulin-like Growth Factor I Receptor Expression in Neuroblastoma Cells Induces the Regression of Established Tumors in Mice, Cancer Research 58, 5432-5438, Dec. 1, 1998.;;Jamie L. Resnik et al., Elevated Insulin-like Growth Factor I Receptor Autophosphorylation and Kinase Activity in Human Breast Cancer, Cancer Research 58, 1159-1164, Mar. 15, 1998.;;Fredrika Pekonen et al., Receptors for Epidermal Growth Factor and Insulin-like Growth Factor I and Their Relation to Steroid Receptors in Human Breast Cancer, Cancer Research 48, 1343-1347, Mar. 1, 1988.;;Quynh T. Rohlik et al., An Antibody to the Receptor for Insulin-like Growth Factor I Inhibits the Growth of MCF-7 Cells in Tissue Culture, Biochemical and Biophysical Research Communications, vol. 149, No. 1, 276-281, 1987.;;Carlos L. Arteaga et al., Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice, J. Clin. Invest., vol. 84, 1418-1423, Nov. 1989.;;Ted Gansler et al., Rapid Communication Antibody to Type I Insulinlike Growth Factor Receptor Inhibits Growth of Wilms' Tumor in Culture and in Athymic Mice, American Journal of Pathology, vol. 135, No. 6, 961-966, Dec. 1989.;;Krzysztof Reiss et al., Inhibition of Tumor Growth by a Dominant Negative Mutant of the Insulin-like Growth Factor I Receptor with a Bystander Effect, Clinical Cancer Research, vol. 4, 2647-2655, Nov. 1998.;;Carlos L. Arteaga et al., Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antobody Against the Type I Somatomedin Receptor, Cancer Research, 49, 6237-6241, Nov. 15, 1989.;;Sandra E. Dunn et al., A Dominant Negative Mutant of the Insulin-like Growth Factor-I Receptor Inhibits the Adhesion, Invasion, and Metastasis of Breast Cancer, Cancer Research, 58, 3353-3361, Aug. 1, 1998.;;Peter Burfeind, Antisense RNA to the Type I Insulin-like Growth Factor Receptor Suppresses Tumor Growth and Prevents Invasion by Rate Prostate Cancer Cells In Vivo, Proc. Natl. Acad. Sci. USA, vol. 93 7263-7268, Jul. 1996.;;Diane Prager et al., Dominant Negative Inhibition of Tumorigenesis In Vivo by Human Insulin-like Growth Factor I Receptor Mutant, Proc. Natl. Acad. Sci. USA, vol. 91, 2181-2185, Mar. 1994.;;Deepali Sachdev, A Chimeric Humanized Single-Chain Antibody Against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-1, Cancer Research 63: 627-635, 2003.;;Hakam et al., Human Pathology (1999) 30(10): 1128-1133.;;Sepp-Lorenzino, Breast Cancer Research and Treatment (1998) 47: 235-253.;;Hepperfield, et al., ""The localization of insulin-like growth factor receptor 1 (IGFR1) in benign and malignant breast tissue"" Journal of Pathology 183:412-417 (1997).;;Xiong et al., ""Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor"" Proc. Nat. Acad. Sci. 89: 5356-5360 (1992).;;Li et al., ""Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor"" Biochem. Biophys. Res. Comm. 196(1):92-98 (1993).;;Kull et al., ""Monoclonal antibodies to receptors for insulin and somatomedin-C"" J. Biol. Chem. 258(10):6561-6566 (1983).;;Butler et al., ""Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology"" Comp. Biochem. Physiol. (B) 121(1):19-26 (1998).;;Chan et al.,""Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study"" Science. 279(5350):563-566 (1998).;;Xie et al., ""Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype"" Cancer Res. 59(15):3588-3591 (1999).;;Steller et al., ""Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells"" Cancer Res. 56(8):1761-1765 (1996).;;Pandini et al., ""Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling"" Clin. Cancer Res. 5(7):1935-1944 (1999).;;Webster et al., ""Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer"" Cancer Res. 56(12):2781-2788 (1996).;;Ben-Schlomo et al., ""Acromegaly"" Endocrin. Metab. Clin. N. America 30(3):565-583 (2001).;;Li et al., ""Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth"", Cancer Immunol. Immunother. 49: 243-252 (2000).;;Burtrum et al., ""A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo."" Cancer Res. Dec. 15, 2003;63(24):8912-21.;;Holt et al., Domain antibodies: proteins for therapy, Trends in Biotechnology 21(11): 484-490 (2003).;;Maloney et al., An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation, Cancer Research 63, 5073-5083 (2003).;;Lu et al., Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth . . . J. Bio. Chem.279(4): 2856-65 (2004).;;Tang et al., Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody. J Biol Chem. Sep. 24, 1999;274(39):27371-8.;;Boylan et al., The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann Oncol. Feb. 1998;9(2):205-11.;;Happerfield et al., The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol. Dec. 1997;183(4):412-7.;;Clarke et al., Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997;75(2):251-7.;;Van den berg et al., Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br J Cancer. Feb. 1996;73(4):477-81.;;Lebon et al., Purification of insulin-like growth factor I receptor from human placental membranes. J Biol Chem. Jun. 15, 1986;261(17):7685-9.;;Warren et al., Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. Nov. 15, 1996;271(46):29483-8.;;Auclair et al., Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I. J Clin Endocrinol Metab. Sep. 1999;84(9):3197-3206.;;Gori et al., Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology. Dec. 1999;140(12):5579-86.;;Kasprzyk et al., Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. May 15, 1992;52(10):2771-6.;;Drebin et al., Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. Mar. 1988;2(3):273-7.;;Shin et al., Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res. Apr. 1, 2005;65(7)2815-24.;;Lu et al., A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. May 20, 2005;280(20):19665-72.;;Cohen et al., Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. Mar. 1, 2005;11(5):2063-73.;;Wu et al., In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. Apr. 15, 2005;11(8):3065-74.;;Goetsch et al., A recombinant humanized anti-insulin-like growth factor receptor type 1 antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. Jan. 10, 2005;113(2):316-28.;;Granerus et al., Effects of insulin-like growth factor-binding protein 2 and an IGF-type I receptor-blocking antibody on apoptosis in human teratocarcinoma cells in vitro. Cell Biol. Int. 2001;25(8):825-8.;;Kaliman et al., Antipeptide antibody to the insulin-like growth factor-I receptor sequence 1232-1246 inhibits the receptor kinase activity. J Biol Chem. May 25, 1992;267(15):10645-51.;;Rodeck et al., Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem. Dec. 1987;35(4):315-20.;;Iwakiri et al., Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res. Nov. 1, 2003;63(21):7062-7.;;Kiess et al., Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept. Sep. 26, 1997;72(1):19-29.;;Pritchard et al., Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol. Sep. 1, 2004;173(5):3564-9.;;Jackson-Booth et al., Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res. Nov.-Dec. 2003;35(11-12):850-6.;;Carboni et al., Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. May 1, 2005;65(9):3781-7.;;Remacle-Bonnet et al., Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res. Apr. 1, 2000;60(7):2007-17.;;Lahm et al., Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer. Aug. 1, 1994;58(3):452-9.;;Steele-Perkins et al., Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding. Biochem Biophys Res Commun. Sep. 28, 1990;171(3):1244-51.;;Scotlandi et al., Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. Jun. 2005;41(9):1349-61.;;Agus et al., Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. Oct. 1, 1999;59(19):4761-4.;;Pietras et al., Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. Mar. 15, 1999;59(6)1347-55.;;Goldenberg, Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. Feb. 1999;21(2):309-18. Review.;;Kull et al., Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem. May 25, 1983;258(10):6561-6.;;Benini et al., Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. Jun. 2001;7(6):1790-7.;;Seely et al., Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer. May 31, 2002;2:15.;;Soos et al., A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem. Jun. 25, 1992;267(18):12955-63.;;Kalebic et al., In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. Nov. 1, 1994;54(21):5531-4.;;Baserga, The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. Jan. 15, 1995:55(2):249-52.;;Rubini et al., Characterization of an antibody that can detect an activated IGF-I receptor in human cancers. Exp Cell Res. Aug. 25, 1999;251(1):22-32.;;Halley et al., Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells, Mol. Cancer Ther. Dec. 2002;1(14):1349-53.;;Wang et al., Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody, Mol Cancer Ther. Aug. 2005;4(8):1214-21.;;Davies et al., Antibody VH domains as small recognition units, Biotechnology (N Y). May 1995;13(5):475-9.;;Davies et al., Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. Jun. 1996;9(6):531-7.;;Immunobiology, the immune system in health and disease, 6th edition, Garland Science (NY), 2005, pp. 104-107.;;Conrad et al., Considerations on antibody-phage display methodology, Comb. Chem. High Throughput Screen. Mar. 2005;8(2):117-26.;;Mariana Resnicoff et al., The Role of the Insulin-like Growth Factor I Receptor in Transformation and Apoptosis, Kimmel Cancer Institute, Thomas Jefferson University Ann. NY Acad. Sci. 842: 76-81 (1998).;;Press Release; Publisher: Business Wire; ""Imclone systems incorporated reports advancements in several pipeline programs"" (Published: Jul. 14, 2003).;;Zhenping Zhu, Investigational Drug Database Meeting Report. ""Monoclonal Antibodies in Cancer-Fourth International Congress (Part II), Colorado Springs, CO, USA"" (meeting date: Sep. 3-6, 2004) (accessed online Dec. 22, 2004 at www. Iddb3.com).;;Laura Williams, Investigational Drug Database Meeting Report , ""American Association for Cancer Research-94th Annual Meeting (Part III)-Overnight Report, Washington, D.C., USA"" (meeting date: Jul. 11-14, 2003) (accessed online Dec. 22, 2004 at www. Iddb3.com).;;lmclone Systems, Inc. S.E.C. Form 10-K (filed with S.E.C.: Mar. 15, 2004).;;R&D Systems Catalogue: monoclonal anti-IGF1R antibody MAB391 (Sep. 23, 2003).",EXPIRED
69,CN,A,CN 1671837 A,091-330-093-078-264,2005-09-21,2005,CN 03817686 A,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,,SCHERING CORP,YAN WANG;;ROBERT GREENBERG;;LEONARD PRESTA;;PACHTER JONATHAN A;;JUDITH HAILEY;;PETER BRAMS;;DENISE WILLIAMS;;MOHAN SRINIVASAN;;DIANE FEINGERSH,MSD CORP. (2012-12-26),https://lens.org/091-330-093-078-264,Patent Application,no,0,1,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;C12N15/09;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,EXPIRED
70,US,A1,US 2007/0059241 A1,158-956-092-272-851,2007-03-15,2007,US 59852006 A,2006-11-13,US 59852006 A;;US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MEDAREX INCORPORATED (2008-01-17);;MERCK SHARP & DOHME CORP (2008-01-23),https://lens.org/158-956-092-272-851,Patent Application,yes,65,9,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K51/00;;A61K31/704;;C12N15/09;;A61K31/7048;;A61K31/7072;;A61K38/16;;A61K38/21;;A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,424/1.49;;530/388.22;;530/391.1;;424/155.1;;424/178.1;;514/8;;514/34;;514/49;;424/85.7;;424/649;;514/263.31;;514/283;;514/492;;514/27;;514/254.07;;514/410,0,0,,,,EXPIRED
71,EP,B1,EP 2316921 B1,025-651-682-040-049,2014-05-14,2014,EP 11150589 A,2003-05-22,EP 03731338 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,,MERCK SHARP & DOHME,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP. (2012-08-15),https://lens.org/025-651-682-040-049,Granted Patent,yes,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N5/12;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07H21/04;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/08,,4,0,,,"ARTEAGA C L ET AL: ""Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor."", CANCER RESEARCH 15 NOV 1989, vol. 49, no. 22, 15 November 1989 (1989-11-15), pages 6237-6241, XP002477382, ISSN: 0008-5472;;SOOS M A ET AL: ""A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity."", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 JUN 1992, vol. 267, no. 18, 25 June 1992 (1992-06-25), pages 12955-12963, XP002477383, ISSN: 0021-9258;;LI S-L ET AL: ""SINGLE-CHAIN ANTIBODIES AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR: EXPRESSION, PURIFICATION AND EFFECT ON TUMOR GROWTH"", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 49, no. 4/5, July 2000 (2000-07), pages 243-252, XP001113064, ISSN: 0340-7004;;GREEN L L: ""Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies."", JOURNAL OF IMMUNOLOGICAL METHODS 10 DEC 1999, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 11-23, XP004186071, ISSN: 0022-1759",EXPIRED
72,EP,A1,EP 2316922 A1,155-959-514-140-176,2011-05-04,2011,EP 11150594 A,2003-05-22,EP 03731338 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1) . The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP. (2012-08-15),https://lens.org/155-959-514-140-176,Patent Application,yes,70,0,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N5/12;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07H21/04;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/08,,140,108,070-311-797-413-117;;046-166-624-867-77X;;002-536-676-460-583;;079-861-467-759-75X;;001-473-019-693-166;;029-886-563-941-284;;003-262-280-086-282;;020-893-750-321-724;;095-131-315-238-82X;;075-104-279-361-070;;057-564-019-868-507;;044-809-864-554-776;;117-418-085-943-623;;034-109-833-747-866;;031-616-493-083-780;;056-637-250-652-512;;106-421-613-215-231;;020-533-566-973-694;;024-841-374-797-219;;061-444-349-075-997;;102-808-907-197-009;;110-859-707-485-225;;020-120-613-015-267;;065-114-602-989-551;;101-171-874-734-776;;078-076-853-526-487;;024-306-721-277-054;;115-802-414-738-000;;034-513-906-158-646;;027-802-945-966-731;;056-201-471-905-934;;113-749-629-542-678;;010-808-659-558-50X;;028-862-168-091-90X;;022-806-324-000-826;;104-038-311-148-69X;;093-620-729-161-804;;005-277-749-572-427;;175-236-946-121-717;;023-907-179-348-058;;080-856-085-597-555;;013-181-635-285-001;;019-779-601-634-917;;052-355-281-820-493;;036-427-544-795-059;;018-715-973-972-571;;061-175-802-642-804;;049-134-753-209-354;;024-995-475-936-443;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;032-820-729-763-323;;020-753-772-581-741;;038-613-711-274-229;;050-836-464-727-069;;106-753-778-592-300;;063-686-499-145-852;;020-026-345-586-213;;027-079-724-921-441;;106-753-778-592-300;;040-577-067-037-463;;104-212-297-137-759;;066-749-017-721-197;;031-063-853-127-197;;035-318-090-591-262;;110-088-048-889-302;;059-034-937-597-632;;152-520-430-306-466;;052-962-624-690-411;;114-414-257-216-602;;007-763-570-350-177;;022-856-092-371-964;;054-481-398-737-44X;;020-134-111-407-516;;052-176-596-515-633;;135-114-522-815-727;;008-587-496-850-953;;000-830-926-739-574;;094-857-606-776-915;;001-431-119-334-376;;021-423-005-445-292;;002-933-844-837-060;;116-641-153-355-395;;069-594-400-665-496;;130-571-338-281-966;;017-055-428-100-332;;069-594-400-665-496;;044-203-857-201-407;;017-648-305-325-092;;014-430-992-456-906;;003-690-096-860-216;;071-216-234-219-08X;;031-770-374-929-195;;058-429-436-163-000;;040-562-576-592-711;;019-878-579-549-559;;025-744-440-758-624;;054-961-802-466-059;;040-677-853-269-884;;050-836-464-727-069,2553250;;10.1016/s0021-9258(18)42367-8;;1377676;;10648924;;10.1016/s0022-1759(99)00137-4;;10.1007/s002620000115;;10941907;;6343062;;10.1210/endo-112-6-2215;;10.1016/0014-5793(78)80237-3;;658418;;1313689;;10.1038/bjc.1992.65;;pmc1977607;;10.1023/a:1005955017615;;9516079;;9972281;;10.1016/s0305-0491(98)10106-2;;9438850;;10.1126/science.279.5350.563;;8665514;;10446966;;10.1016/s0889-8529(05)70202-4;;11571931;;10.1016/s0021-9258(18)32449-9;;6304046;;8216340;;10.1006/bbrc.1993.2220;;pmc49290;;1319060;;10.1073/pnas.89.12.5356;;2448875;;10.1126/science.239.4839.487;;10.1126/science.2448875;;10.1073/pnas.74.2.560;;265521;;pmc392330;;10.1073/pnas.74.12.5463;;271968;;pmc431765;;10.1038/290304a0;;6259538;;6257399;;10.1016/0092-8674(80)90555-3;;10.1073/pnas.78.3.1441;;pmc319146;;6262799;;10.1038/296039a0;;6278311;;358198;;pmc392859;;10.1073/pnas.75.8.3727;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;6154310;;10.1038/scientificamerican0480-74;;10.1073/pnas.81.7.2035;;6371808;;pmc345431;;10.1016/0022-2836(86)90385-2;;3537305;;3315856;;10.1016/0378-1119(87)90165-x;;3065146;;10.1016/0378-1119(88)90028-5;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1038/ng0393-266;;8485583;;10.1016/s0076-6879(96)66011-x;;8743682;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1101/gr.7.6.649;;9199938;;pmc310664;;10.1016/0097-8485(93)85006-x;;10.1093/bioinformatics/10.1.67;;7514951;;pmc7130686;;2051488;;10.1016/0022-2836(91)90193-a;;10.1016/s1046-2023(05)80165-3;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1007/bf00160485;;8483166;;10.1073/pnas.87.6.2264;;2315319;;pmc53667;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1214/aop/1176988493;;10.1007/978-1-4615-5903-0_1;;10.1016/s0065-3233(08)60574-4;;362869;;408353;;10.1016/s0021-9258(17)39891-5;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;8159246;;10.1038/368856a0;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1172191;;10.1038/256495a0;;3178787;;25291284;;10.1016/0167-5699(83)90123-8;;10.1073/pnas.80.7.2026;;6572959;;pmc393745;;1172191;;10.1038/256495a0;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;1428404;;10.1007/978-3-642-78432-3_11;;11459459;;10.1021/bc0001443;;4360349;;10.1021/bi00702a028;;10.1177/30.5.7042815;;7042815;;10955787;;10.1038/sj.cgt.7700008;;10195881;;9125381;;10.1016/s0165-0270(96)00132-x;;10.1007/bf01306455;;7964989;;1644927;;pmc443142;;10.1172/jci115902;;10.1016/0378-1119(91)90411-4;;1829048;;6098454;;10.1002/j.1460-2075.1984.tb02232.x;;pmc557789;;886304;;10.1099/0022-1317-36-1-59;;11554590;;10.1007/978-1-4615-1277-6_4;;10.1016/0092-8674(83)90344-6;;6678608;;2831375;;10.1128/jvi.62.4.1120-1124.1988;;pmc253118;;pmc110499;;9811723;;10.1128/jvi.72.12.9873-9880.1998;;11525555;;10.1128/jvi.73.1.576-584.1999;;pmc103863;;9847362;;10.1128/mr.58.3.491-562.1994;;10.1128/mmbr.58.3.491-562.1994;;pmc372977;;7968923;;10.1128/jvi.67.11.6439-6446.1993;;pmc238079;;8411346;;9675133;;10.1006/bbrc.1998.8922;;10.1128/mr.58.3.491-562.1994;;10.1128/mmbr.58.3.491-562.1994;;pmc372977;;7968923;;10757020;;10.1038/sj.gt.3301122;;10071792;;10.3109/10799899909036679;;pmc299306;;10.1073/pnas.84.21.7413;;2823261;;2446313;;pmc299420;;10.1073/pnas.84.22.7851;;10.1016/s0021-9258(18)48379-2;;1370472;;10.1073/pnas.88.7.2726;;2011582;;pmc51311;;3049582;;10.1016/s0021-9258(18)68081-0;;11526457;;10.1038/sj.gt.3301484;;11274756;;10.1016/s0301-472x(00)00679-2;;11206915;;10.1016/s0302-4598(00)00112-4;;10482195;;11595543;;10.1016/s1043-2760(01)00461-1;;10.1111/j.1749-6632.1995.tb55879.x;;7486582,"ARTEAGA C L ET AL: ""Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor."", CANCER RESEARCH 15 NOV 1989, vol. 49, no. 22, 15 November 1989 (1989-11-15), pages 6237 - 6241, XP002477382, ISSN: 0008-5472;;SOOS M A ET AL: ""A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity."", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 JUN 1992, vol. 267, no. 18, 25 June 1992 (1992-06-25), pages 12955 - 12963, XP002477383, ISSN: 0021-9258;;GREEN L L: ""Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies."", JOURNAL OF IMMUNOLOGICAL METHODS 10 DEC 1999, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 11 - 23, XP004186071, ISSN: 0022-1759;;LI S-L ET AL: ""SINGLE-CHAIN ANTIBODIES AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR: EXPRESSION, PURIFICATION AND EFFECT ON TUMOR GROWTH"", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 49, no. 4/5, July 2000 (2000-07-01), pages 243 - 252, XP001113064, ISSN: 0340-7004;;KLAPPER ET AL., ENDOCRINOL., vol. 112, 1983, pages 2215;;RINDERKNECHT, FEBS.LETT., vol. 89, 1978, pages 283;;MACAULAY, BR. J. CANCER, vol. 65, 1992, pages 311;;SEPP-LORENZINO, BREAST CANCER RESEARCH AND TREATMENT, vol. 47, 1998, pages 235;;BUTLER ET AL., COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY, vol. 121, 1998, pages 19;;CHAN, SCIENCE, vol. 279, 1998, pages 563;;PANDINI ET AL., CANCER RES., vol. 5, 1999, pages 1935;;WEBSTER, CANCER RES., vol. 56, 1996, pages 2781;;PEKONEN ET AL., CANCER RES., vol. 48, 1998, pages 1343;;STELLER ET AL., CANCER RES., vol. 56, 1996, pages 1762;;XIE ET AL., CANCER RES., vol. 59, 1999, pages 3588;;BEN-SCHLOMO ET AL., ENDOCRIN. METAB.CLIN. NORTH. AM., vol. 30, 2001, pages 565 - 583;;KULL ET AL., J. BIOL. CHEM., vol. 258, 1983, pages 6561;;LI ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 196, 1993, pages 92 - 98;;XIONG ET AL., PROC. NATL. ACAD. SCI., U.S.A., vol. 89, 1992, pages 5356 - 5360;;SAMBROOK; FRITSCH; MANIATIS: ""Molecular Cloninq: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;""DNA Cloning: A Practical Approach"", vol. I, II, 1985;;""Oligonucleotide Synthesis"", 1984;;""Nucleic Acid Hybridization"", 1985;;""Transcription And Translation"", 1984;;""Animal Cell Culture"", 1986;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;B. PERBAL: ""A Practical Guide To Molecular Cloning"", 1984;;""Current Protocols in Molecular Biology"", 1994, JOHN WILEY & SONS, INC.;;SAIKI ET AL., SCIENCE, vol. 239, 1988, pages 487;;MAXAM; GILBERT, PROC. NATL. ACAD. SCI. USA, vol. 74, 1977, pages 560;;SANGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 74, 1977, pages 5463;;BENOIST ET AL., NATURE, vol. 290, 1981, pages 304 - 310;;YAMAMOTO ET AL., CELL, vol. 22, 1980, pages 787 - 797;;WAGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 1441 - 1445;;BRINSTER ET AL., NATURE, vol. 296, 1982, pages 39 - 42;;VILLA-KOMAROFF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 3727 - 3731;;DEBOER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 21 - 25;;""Useful proteins from recombinant bacteria"", SCIENTIFIC AMERICAN, vol. 242, 1980, pages 74 - 94;;DAVANLOO, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 2035 - 2039;;STUDIER, F. W. ET AL., J. MOL. BIOL., vol. 189, 1986, pages 113 - 130;;ROSENBERG, A. H. ET AL., GENE, vol. 56, 1987, pages 125 - 135;;DUNN, J. J. ET AL., GENE, vol. 68, 1988, pages 259;;ALTSCHUL, S.F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;GISH, W. ET AL., NATURE GENET, vol. 3, 1993, pages 266 - 272;;MADDEN, T.L. ET AL., METH. ENZYMOL., vol. 266, 1996, pages 131 - 141;;ALTSCHUL, S.F. ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;ZHANG, J. ET AL., GENOME RES., vol. 7, 1997, pages 649 - 656;;WOOTTON, J.C. ET AL., COMPUT. CHEM., vol. 17, 1993, pages 149 - 163;;HANCOCK, J.M. ET AL., COMPUT. APPL. BIOSCI., vol. 10, 1994, pages 67 - 70;;DAYHOFF, M.O. ET AL.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1978, NATL. BIOMED. RES. FOUND., article ""A model of evolutionary change in proteins"", pages: 345 - 352;;SCHWARTZ, R.M. ET AL.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1978, NATL. BIOMED. RES. FOUND., article ""Matrices for detecting distant relationships"", pages: 353 - 358;;ALTSCHUL, S.F., J. MOL. BIOL., vol. 219, 1991, pages 555 - 565;;STATES, D.J. ET AL., METHODS, vol. 3, 1991, pages 66 - 70;;HENIKOFF, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 10919;;ALTSCHUL, S.F. ET AL., J. MOL. EVOL., vol. 36, 1993, pages 290 - 300;;KARLIN, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268;;KARLIN, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877;;DEMBO, A. ET AL., ANN. PROB., vol. 22, 1994, pages 2022 - 2039;;ALTSCHUL, S.F.: ""Theoretical and Computational Methods in Genome Research"", 1997, PLENUM, article ""Evaluating the statistical significance of multiple distinct local alignments"", pages: 1 - 14;;""Fundamental Immunology"", 1989, RAVEN PRESS;;KABAT ET AL.: ""Sequences of Proteins of lmmunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;KABAT, ADV. PROT. CHEM., vol. 32, 1978, pages 1 - 75;;KABAT ET AL., J. BIOL. CHEM., vol. 252, 1977, pages 6609 - 6616;;CHOTHIA ET AL., J MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;LONBERG, N. ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook of Experimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N. ET AL., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F. ET AL., ANN. N. Y ACAD. SCI, vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J LMMUNOL., vol. 152, 1994, pages 2912 - 2920;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;HARDING, F. ET AL., ANN. N.Y ACAD. SCI, vol. 764, 1995, pages 536 - 546;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;HARDING ET AL., ANNALS NY ACAD. SCI., vol. 764, 1995, pages 536 - 546;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497;;HERING ET AL., BIOMED. BIOCHIM. ACTA., vol. 47, 1988, pages 211 - 216;;HAGIWARA ET AL., HUM. ANTIBOD. HYBRIDOMAS, vol. 4, 1993, pages 15;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72;;COTE ET AL., PROC. NATL. ACAD. SCI. U.S.A, vol. 80, 1983, pages 2026 - 2030;;COLE ET AL.: ""Monoclonal Antibodies and Cancer Therapy"", 1985, ALAN R. LISS, INC., pages: 77 - 96;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;SONGSIVILAI ET AL., CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;HOLLIGER ET AL., PNAS USA, vol. 90, 1993, pages 6444 - 6448;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659;;TRAUNECKER ET AL., INT. J. CANCER, 1992, pages 51 - 52;;PLUCKTHUN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;LEE ET AL., BIOCONJ. CHEM., vol. 10, 1999, pages 973 - 981;;WEN ET AL., BIOCONJ. CHEM., vol. 12, 2001, pages 545 - 553;;HUNTER ET AL., NATURE, vol. 144, 1962, pages 945;;DAVID ET AL., BIOCHEMISTRY, vol. 13, 1974, pages 1014;;PAIN ET AL., J. IMMUNOL. METH., vol. 40, 1981, pages 219;;NYGREN, J., HISTOCHEM. AND CYTOCHEM., vol. 30, 1982, pages 407;;ALVAREZ ET AL., CLINICAL CANCER RESEARCH, vol. 6, 2000, pages 3081 - 3087;;MILLER ET AL., BIOTECHNIQUES, vol. 7, 1992, pages 980 - 990;;KANNO ET AL., CANCER GEN. THER., vol. 6, 1999, pages 147 - 154;;KAPLITT ET AL., J. NEUROSCI. METH., vol. 71, 1997, pages 125 - 132;;KAPLITT ET AL., J. NEURO ONC., vol. 19, 1994, pages 137 - 147;;STRATFORD-PERRICAUDET ET AL., J. CLIN. INVEST., vol. 90, 1992, pages 626 - 630;;LEVRERO ET AL., GENE, vol. 101, 1991, pages 195;;GRAHAM, EMBO J., vol. 3, 1984, pages 2917;;GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59;;DALY ET AL., GENE THER., vol. 8, 2001, pages 1343 - 1346,1245-1315;;LARSON ET AL., ADV. EXP. MED. BIO., vol. 489, 2001, pages 45 - 57;;MANN ET AL., CELL, vol. 33, 1983, pages 153;;MARKOWITZ ET AL., J. VIROL., vol. 62, 1988, pages 1120;;ZUFFEREY ET AL., J. VIROL., vol. 72, 1998, pages 9873 - 80;;KAFRI ET AL., CURR. OPIN. MOL. THER., vol. 3, 2001, pages 316 - 326;;KAFRI ET AL., J. VIROL., vol. 73, 1999, pages 576 - 584;;STRAUS ET AL., MICROBIOL. REV., vol. 58, 1994, pages 491 - 562;;BREDENBEEK ET AL., J. VIROL., vol. 67, 1993, pages 6439 - 6446;;LIJIMA ET AL., INT. J. CANCER, vol. 80, 1999, pages 110 - 118;;SAWAI ET AL., BIOCHIM. BIOPHYR. RES. COMM., vol. 248, 1998, pages 315 - 323;;STRAUSS ET AL., MICROBIOL. REV., vol. 58, 1994, pages 491 - 562;;WAHLFORS ET AL., GENE. THER., vol. 7, 2000, pages 472 - 480;;LUNDSTROM, J. RECEP. SIG. TRANSDUCT. RES., vol. 19, no. 1-4, 1999, pages 673 - 686;;FELGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7417;;WANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7851 - 7855;;WILSON ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 963 - 967;;WILLIAMS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 2726 - 2730;;WU ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 14621 - 14624;;VILQUIN ET AL., GENE THER., vol. 8, 2001, pages 1097;;PAYEN ET AL., EXP. HEMATOL., vol. 29, 2001, pages 295 - 300;;MIR, BIOELECTROCHEMISTRY, vol. 53, 2001, pages 1 - 10;;""The Pharmacoloqical Bases of Therapeutics"", 1990, PERGAMON PRESS;;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING CO.;;""Pharmaceutical Dosage Forms: Parenteral Medications"", 1993, DEKKER;;""Pharmaceutical Dosage Forms: Tablets"", 1990, DEKKER;;""Pharmaceutical Dosage Forms: Disperse Systems"", vol. 119, 1990, DEKKER, article ""Dermatoloqical and Transdermal Formulations"";;""Drugs and the Pharmaceutical Sciences"", vol. 119, 2002, MARCEL DEKKER, article ""Dermatoloqical and Transdermal Formulations"";;SLIWKOWSKI ET AL., SEMIN. ONCOL., vol. 26, no. 4, 1999, pages 60 - 70;;DRAKE ET AL., TRENDS ENDOCRIN. METAB., vol. 12, 2001, pages 408 - 413;;ZOLA: ""Monoclonal Antibodies: A Manual of Techniques"", 1987, CRC PRESS, INC., pages: 147 - 158;;HARDING ET AL., ANN. NY ACAD. SCI., vol. 764, 1995, pages 536 - 546",EXPIRED
73,NZ,A,NZ 554740 A,057-295-076-026-792,2009-01-31,2009,NZ 55474003 A,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"Disclosed is a pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that binds to IGFR1 comprising a CDR-L1, CDR-L2 and CDR-L3 found in a light chain variable region which comprises the amino acid sequence set forth in SEQ ID NO: 78 ; or a CDR-H1, CDR-H2 and CDR-H3 found in a heavy chain variable region which comprises the amino acid sequence set forth in SEQ ID NO: 45; or both; and a pharmaceutically acceptable carrier which comprises water, buffer and sugar. Also disclosed are uses of the said composition.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,"SCHERING CORPORATION, US (2010-08-27)",https://lens.org/057-295-076-026-792,Patent Application,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;C12N15/09;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,DISCONTINUED
74,US,A1,US 2004/0018191 A1,084-941-130-158-140,2004-01-29,2004,US 44346603 A,2003-05-22,US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"
   The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention. 
",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MEDAREX INCORPORATED (2008-01-17);;MERCK SHARP & DOHME CORP (2003-07-10),https://lens.org/084-941-130-158-140,Patent Application,yes,49,251,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;A61P9/10;;C12N15/09;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,424/143.1;;530/388.22,0,0,,,,EXPIRED
75,US,A1,US 2011/0060130 A1,094-529-294-281-370,2011-03-10,2011,US 94161710 A,2010-11-08,US 94161710 A;;US 83579107 A;;US 59852006 A;;US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/094-529-294-281-370,Patent Application,yes,6,2,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;C07K16/00;;A61P1/04;;C12N15/09;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,530/387.1,0,0,,,,EXPIRED
76,EP,B1,EP 2316922 B1,114-575-719-314-168,2013-05-22,2013,EP 11150594 A,2003-05-22,EP 03731338 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,,MERCK SHARP & DOHME,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP. (2012-08-15),https://lens.org/114-575-719-314-168,Granted Patent,yes,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N5/12;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07H21/04;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/08,,4,0,,,"ARTEAGA C L ET AL: ""Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor."", CANCER RESEARCH 15 NOV 1989, vol. 49, no. 22, 15 November 1989 (1989-11-15), pages 6237-6241, XP002477382, ISSN: 0008-5472;;SOOS M A ET AL: ""A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity."", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 JUN 1992, vol. 267, no. 18, 25 June 1992 (1992-06-25), pages 12955-12963, XP002477383, ISSN: 0021-9258;;GREEN L L: ""Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies."", JOURNAL OF IMMUNOLOGICAL METHODS 10 DEC 1999, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 11-23, XP004186071, ISSN: 0022-1759;;LI S-L ET AL: ""SINGLE-CHAIN ANTIBODIES AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR: EXPRESSION, PURIFICATION AND EFFECT ON TUMOR GROWTH"", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 49, no. 4/5, July 2000 (2000-07), pages 243-252, XP001113064, ISSN: 0340-7004",EXPIRED
77,US,A1,US 2008/0014197 A1,024-616-305-904-753,2008-01-17,2008,US 83579107 A,2007-08-08,US 83579107 A;;US 59852006 A;;US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MEDAREX INCORPORATED (2008-01-15);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/024-616-305-904-753,Patent Application,yes,76,9,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;C12N15/09;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/22;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,424/139.1;;530/387.3;;530/387.9,0,0,,,,EXPIRED
78,WO,A2,WO 2003/100008 A2,043-694-736-910-867,2003-12-04,2003,US 0316283 W,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP;;WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,,https://lens.org/043-694-736-910-867,Patent Application,yes,10,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,8,7,001-473-019-693-166;;029-886-563-941-284;;003-262-280-086-282;;020-893-750-321-724;;095-131-315-238-82X;;075-104-279-361-070;;050-836-464-727-069,6343062;;10.1210/endo-112-6-2215;;10.1016/0014-5793(78)80237-3;;658418;;1313689;;10.1038/bjc.1992.65;;pmc1977607;;10.1023/a:1005955017615;;9516079;;9972281;;10.1016/s0305-0491(98)10106-2;;9438850;;10.1126/science.279.5350.563;;10.1111/j.1749-6632.1995.tb55879.x;;7486582,"KLAPPER ET AL., ENDOCRINOL., vol. 112, 1983, pages 2215;;RINDERKNECHT ET AL., FEBS.LETT., vol. 89, 1978, pages 283;;MACAULAY, BR. J. CANCER, vol. 65, 1992, pages 311;;SEPP-LORENZINO, BREAST CANCER RESEARCH AND TREATMENT, vol. 47, 1998, pages 235;;BUTLER ET AL., COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY, vol. 121, 1998, pages 19;;CHAN ET AL., SCIENCE, vol. 279, 1998, pages 563;;HARDING ET AL., ANN. NY ACAD. SCI., vol. 764, 1995, pages 536 - 546;;See also references of EP 1506286A4",PATENTED
79,EP,A4,EP 1506286 A4,167-359-297-481-420,2008-05-28,2008,EP 03731338 A,2003-05-22,US 0316283 W;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,,SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP. (2012-08-15),https://lens.org/167-359-297-481-420,Search Report,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N5/12;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07H21/04;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/08,,5,4,079-861-467-759-75X;;070-311-797-413-117;;046-166-624-867-77X;;002-536-676-460-583,10.1007/s002620000115;;10941907;;2553250;;10.1016/s0021-9258(18)42367-8;;1377676;;10648924;;10.1016/s0022-1759(99)00137-4,"LI S-L ET AL: ""SINGLE-CHAIN ANTIBODIES AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR: EXPRESSION, PURIFICATION AND EFFECT ON TUMOR GROWTH"", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 49, no. 4/5, July 2000 (2000-07-01), pages 243 - 252, XP001113064, ISSN: 0340-7004;;ARTEAGA C L ET AL: ""Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor."", CANCER RESEARCH 15 NOV 1989, vol. 49, no. 22, 15 November 1989 (1989-11-15), pages 6237 - 6241, XP002477382, ISSN: 0008-5472;;SOOS M A ET AL: ""A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity."", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 JUN 1992, vol. 267, no. 18, 25 June 1992 (1992-06-25), pages 12955 - 12963, XP002477383, ISSN: 0021-9258;;GREEN L L: ""Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies."", JOURNAL OF IMMUNOLOGICAL METHODS 10 DEC 1999, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 11 - 23, XP004186071, ISSN: 0022-1759;;See also references of WO 03100008A2",EXPIRED
80,US,B2,US 8173779 B2,153-788-944-230-378,2012-05-08,2012,US 94161710 A,2010-11-08,US 94161710 A;;US 83579107 A;;US 59852006 A;;US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE;;SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/153-788-944-230-378,Granted Patent,yes,6,2,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N15/09;;A61K39/395;;C12P21/08;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10,530/387.3;;530/350;;530/388.22;;536/23.1;;536/23.5;;435/69.1;;435/254.1;;435/320.1;;435/325;;435/358,0,0,,,,EXPIRED
81,US,A1,US 2007/0059305 A1,002-632-593-750-550,2007-03-15,2007,US 59861806 A,2006-11-13,US 59861806 A;;US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MEDAREX INCORPORATED (2008-01-17);;MERCK SHARP & DOHME CORP (2008-01-23),https://lens.org/002-632-593-750-550,Patent Application,yes,93,15,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;C12N15/09;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07H21/04;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/06;;C12N5/10;;C12P21/06;;C12P21/08,424/143.1;;530/388.22;;435/69.1;;435/320.1;;435/334;;536/23.5;;536/23.53,0,0,,,,EXPIRED
82,US,B2,US 7217796 B2,072-822-095-320-968,2007-05-15,2007,US 44346603 A,2003-05-22,US 44346603 A;;US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,Neutralizing human anti-IGFR antibody,"The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,MEDAREX INCORPORATED (2008-01-17);;MERCK SHARP & DOHME CORP (2003-07-10),https://lens.org/072-822-095-320-968,Granted Patent,yes,100,84,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;C12N15/09;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,530/387.3;;530/350;;530/380;;530/385;;530/387.1;;530/387.7;;530/388.1;;530/388.15;;530/388.24;;424/134.1;;424/135.1;;424/141.1;;424/142.1;;424/155.1;;424/174.1;;435/7.9;;435/188;;435/320.1,88,82,027-477-313-726-928;;003-849-961-384-35X;;007-822-064-014-928;;027-885-659-586-865;;013-100-324-346-340;;117-350-069-614-784;;060-555-750-112-761;;012-739-783-887-198;;081-280-969-081-05X;;027-713-460-602-505;;015-746-376-377-558;;079-861-467-759-75X;;113-073-836-369-700;;064-327-493-747-459;;056-637-250-652-512;;031-616-493-083-780;;034-109-833-747-866;;095-131-315-238-82X;;075-104-279-361-070;;044-809-864-554-776;;031-592-893-929-34X;;091-670-589-840-911;;057-564-019-868-507;;117-418-085-943-623;;078-794-986-614-92X;;020-893-750-321-724;;071-117-827-714-488;;003-262-280-086-282;;108-945-813-243-798;;115-800-617-650-990;;097-174-906-919-515;;067-620-509-667-771;;066-912-513-219-523;;025-114-183-199-748;;040-675-726-528-59X;;004-423-858-779-175;;070-311-797-413-117;;037-149-535-070-661;;040-239-601-782-040;;012-934-571-932-122;;081-280-969-081-05X;;013-323-148-570-367;;042-187-547-330-545;;064-912-888-572-443;;061-985-327-786-642;;003-428-892-358-143;;064-327-493-747-459;;016-762-945-842-234;;088-902-136-362-226;;001-826-939-592-182;;020-258-715-333-487;;004-078-078-793-270;;035-247-137-448-696;;054-244-084-470-27X;;108-328-157-315-242;;129-849-404-301-477;;022-648-069-840-113;;027-713-460-602-505;;096-654-301-744-608;;046-056-125-843-776;;163-935-833-431-492;;000-009-798-094-596;;023-918-308-836-52X;;103-810-451-890-743;;044-434-064-672-362;;026-791-779-077-922;;003-353-895-173-837;;005-458-479-554-482;;063-796-750-967-643;;109-037-058-380-133;;027-380-338-864-138;;013-090-598-011-461;;056-136-313-668-621;;020-794-430-809-364;;015-075-033-461-569;;034-109-833-747-866;;071-117-827-714-488;;009-668-625-696-536;;046-166-624-867-77X;;001-745-412-733-159;;035-321-998-935-819;;063-876-757-064-973,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;10.1128/mcb.8.3.1247-1252.1988;;10.1128/mcb.8.3.1247;;pmc363269;;3285178;;3306677;;pmc299085;;10.1073/pnas.84.18.6408;;164891;;10.1021/bi00679a002;;2406607;;10.1038/343662a0;;10.1016/0006-291x(85)91905-9;;3000370;;8205537;;12566306;;10.1158/1078-0432.ccr-04-1070;;15756033;;12516969;;10.1007/s002620000115;;10941907;;14695208;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4;;pmc49290;;1319060;;10.1073/pnas.89.12.5356;;8216340;;10.1006/bbrc.1993.2220;;10.1016/s0021-9258(18)32449-9;;6304046;;9972281;;10.1016/s0305-0491(98)10106-2;;9438850;;10.1126/science.279.5350.563;;10446966;;8620490;;10430101;;8665514;;10.1016/s0889-8529(05)70202-4;;11571931;;10.1016/s0046-8177(99)90027-8;;10534157;;10.1023/a:1005955017615;;9516079;;11410521;;1313689;;10.1038/bjc.1992.65;;pmc1977607;;9599296;;10.1111/j.1749-6632.1998.tb09634.x;;9850076;;9515800;;2963690;;10.1016/0006-291x(87)91635-4;;2961338;;10.1172/jci114315;;2553774;;pmc304004;;2556929;;pmc1880481;;9829727;;2553250;;9699666;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;10.1073/pnas.91.6.2181;;8134369;;pmc43334;;12566306;;14573361;;10.1016/j.tibtech.2003.08.007;;12941837;;14576153;;10.1074/jbc.m310132200;;10.1074/jbc.274.39.27371;;10488067;;9553667;;10.1023/a:1008241804078;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4;;10.1038/bjc.1997.41;;9010034;;pmc2063278;;8595162;;pmc2074471;;10.1038/bjc.1996.84;;3011795;;10.1016/s0021-9258(19)57454-3;;8910616;;10.1074/jbc.271.46.29483;;10487687;;10.1210/jc.84.9.3197;;10.1210/jcem.84.9.5965;;10.1210/en.140.12.5579;;10579321;;10.1210/endo.140.12.7213;;1349849;;2451200;;15805282;;10.1158/0008-5472.can-04-2898;;10.1074/jbc.m500815200;;15757893;;10.1158/1078-0432.ccr-04-1070;;15756033;;10.1158/1078-0432.ccr-04-1586;;15837762;;15386423;;10.1002/ijc.20543;;10.1006/cbir.2001.0756;;11482908;;1316907;;10.1016/s0021-9258(19)50066-7;;2831241;;10.1002/jcb.240350406;;14612496;;9404729;;10.1016/s0167-0115(97)01026-4;;10.4049/jimmunol.173.5.3564;;15322222;;14710368;;10.1055/s-2004-814144;;10.1158/0008-5472.can-04-4602;;15867374;;10766192;;10.1002/ijc.2910580325;;8050827;;10.1016/0006-291x(90)90819-9;;2171510;;15913990;;10.1016/j.ejca.2005.03.015;;10519379;;10096569;;10211534;;10.1016/s0149-2918(00)88288-0;;10.1016/s0021-9258(18)32449-9;;6304046;;11410521;;pmc115841;;10.1186/1471-2407-2-15;;12057025;;10.1016/s0021-9258(18)42367-8;;1377676;;7923191;;7812953;;10438568;;10.1006/excr.1999.4562,"Rudikoff et al (Proc Natl Acad USA 1982 vol. 79 p. 1979).;;Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.;;Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.;;Schwartz et al, Proc Natl Acad Sci USA vol. 1987 84:6408-6411.;;Lin et al Biochemistry USA vol. 14:1559-1563 (1975).;;Acland et al., Nature vol. 343:662-665 (1990).;;Cordera et al (Biochem Biophys Res Commun. Nov. 15, 1985;132(3):991-1000).;;Freund et al (Cancer Research 1994, 54(12):3179-3185).;;Sachdev et al (Cancer Research. 2003. 63:627-635).;;Cohen et al (Clinical Cancer Research. 2005. 11:2063-2073).;;Hailey et al (Molecular Cancer Therapeutics. 2002. 1:1349-1353).;;Li et al., ""Single-chain antibodies against human insulin-like growth factor 1 receptor: expression, purification, and effect on tumor growth"", Cancer Immunol. Immunother. 49: 243-252 (2000).;;Burtrum et al., ""A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo."" Cancer Res. Dec. 15, 2003;63(24):8912-21.;;Business Wire, ""Imclone systems incorporated reports advancements in several pipeline programs"" (Jul. 14, 2003).;;Zhenping Zhu, ""Monoclonal Antibodies in Cancer-Fourth International Congress (Part II), Colorado Springs, CO, USA"" Investigational Drug Database Meeting Report (Sep. 3-6, 2004).;;Laura Williams, ""American Association for Cancer Research-94<SUP>th </SUP>Annual Meeting (Part III)- Overnight Report, Washington, D.C., USA"" Investigational Drug Database Meeting Report (Jul. 11-14, 2003).;;Imclone Systems, Inc. Form 10-K (filed Mar. 15, 2004).;;Happerfield, et al., ""The localization of insulin-like growth factor receptor 1 (IGFR1) in benign and malignant breast tissue"" Journal of Pathology 183:412-417 (1997).;;Search Report for International Application No. PCT/US03/16283.;;R&D Systems catalogue pages-monoclonal anti-IGF-IR antibody MAB391.;;Xiong et al., ""Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor"" Proc. Nat. Acad. Sci. 89: 5356-5360 (1992).;;Li et al., ""Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor"" Biochem. Biophys. Res. Comm. 196(1):92-98 (1993).;;Kull et al., ""Monoclonal antibodies to receptors for insulin and somatomedin-C"" J. Biol. Chem. 258(10):6561-6566 (1983).;;Butler et al., ""Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology"" Comp. Biochem. Physiol. (B) 121(1):19-26 (1998).;;Chan et al., ""Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study"" Science. 279(5350):563-566 (1998).;;Xie et al., ""Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype"" Cancer Res. 59(15):3588-3591 (1999).;;Steller et al., ""Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells"" Cancer Res. 56(8):1761-1765 (1996).;;Pandini et al., ""Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling"" Clin. Cancer Res. 5(7):1935-1944 (1999).;;Webster et al., ""Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer"" Cancer Res. 56(12):2781-2788 (1996).;;Ben-Schlomo et al., ""Acromegaly"" Endocrin. Metab. Clin. N. America 30(3):565-583 (2001).;;Hakam et al., Human Pathology (1999) 30(10): 1128-1133.;;Sepp-Lorenzino, Breast Cancer Research and Treatment (1998) 47: 235-253.;;Stefania Benini et al., Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine Against Ewing's Sarcoma Cells, Clinical Cancer Research, vol. 7, 1790-1797, Jun. 2001.;;V.M. Macaulay, Insulin-like Growth Factors and Cancer, Br. J. Cancer, 65, 311-320, 1992.;;Mariana Resnicoff et al., The Role of the Insulin-like Growth Factor I Receptor in Transformation and Apoptosis, Kimmel Cancer Institute, Thomas Jefferson University pp. 76-81.;;Xiangdang Liu et al., Inhibition of Insulim-like Growth Factor I Receptor Expression in Neuroblastoma Cells Induces the Regression of Established Tumors in Mice, Cancer Research 58, 5432-5438, Dec. 1, 1998.;;Jamie L. Resnik et al., Elevated Insulin-like Growth Factor I Receptor Autophosphorylation and Kinase Activity in Human Breast Cancer, Cancer Research 58, 1159-1164, Mar. 15, 1998.;;Fredrika Pekonen et al., Receptors for Epidermal Growth Factor and Insulin-like Growth Factor I and Their Relation to Steroid Receptors in Human Breast Cancer, Cancer Research 48, 1343-1347, Mar. 1, 1988.;;Quynh T. Rohlik et al., An Antibody to the Receptor for Insulin-like Growth Factor-I Inhibits the Growth of MCF-7 Cells in Tissue Culture, Biochemical and Biophysical Research Communications, vol. 149, No. 1, 276-281, 1987.;;Carlos L. Arteaga et al., Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice, J. Clin. Invest., vol. 84, 1418-1423, Nov. 1989.;;Tert Gansler et al., Rapid Communication Antibody to Type I Insulinlike Growth Factor Receptor Inhibits Growth of Wilms' Tumor in Culture and in Athymic Mice, American Journal of Pathology, vol. 135, No. 6, 961-966, Dec. 1989.;;Krzysztof Reiss et al., Inhibition of Tumor Growth by a Dominant Negative Mutant of the Insulin-like Growth Factor I Receptor with a Bystander Effect, Clinical Cancer Research, vol. 4, 2647-2655, Nov. 1998.;;Carlos L. Arteaga et al., Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody Against the Type I Somatomedin Receptor, Cancer Research, 49, 6237-6241, Nov. 15, 1989.;;Sandra E. Dunn et al., A Dominant Negative Mutant of the Insulin-like Growth Factor-I Receptor Inhibits the Adhesion, Invasion, and Metastasis of Breast Cancer, Cancer Research, 58, 3353-3361, Aug. 1, 1998.;;Peter Burfeind, Antisense RNA to the Type I Insulin-like Growth Factor Receptor Suppresses Tumor Growth and Prevents Invasion by Rat Prostate Cancer Cells In Vivo, Proc. Natl. Acad. Sci. USA, vol. 93 7263-7268, Jul. 1996.;;Diane Prager et al., Dominant Negative Inhibition of Tumorigenesis In Vivo by Human Insulin-like Growth Factor I Receptor Mutant, Proc. Natl. Acad. Sci. USA, vol. 91, 2181-2185, Mar. 1994.;;Deepali Sachdev, A Chimeric Humanized Single-Chain Antibody Against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-1, Cancer Research 63, 627-635, 2003.;;Holt et al., Domain antibodies: proteins for therapy, Trends in Biotechnology 21(11): 484-490 (2003).;;Maloney et al., An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation, Cancer Research 63, 5073-5083 (2003).;;Lu et al., Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth . . . J. Bio. Chem.279(4): 2856-65 (2004).;;Tang et al., Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody. J Biol Chem. Sep. 24, 1999;274(39):27371-8.;;Boylan et al., The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann Oncol. Feb. 1999;9(2):205-11.;;Happerfield et al., The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol. Dec. 1997;183(4):412-7.;;Clarke et al., Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997;75(2):251-7.;;Van den berg et al., Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br J Cancer. Feb. 1996;73(4):477-81.;;Lebon et al., Purification of insulin-like growth factor I recptor from human placental membranes. J Biol Chem. Jun. 15, 1986;261(17):7685-9.;;Warren et al., Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. Nov. 15, 1996;271(46):29483-8.;;Auclair et al., Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I. J Clin Endocrinol Metab. Sep. 1999;84(9):3197-3206.;;Gori et al., Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology. Dec. 1999;140(12):5579-86.;;Kasprzyk et al., Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. May 15, 1992;52(10):2771-6.;;Drebin et al., Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. Mar. 1988;2(3):273-7.;;Shin et al., Proapoptotic activity cell-permeable anti-Akt single-chain antibodies. Cancer Res. Apr. 1, 2005;65(7):2815-24.;;Lu et al., A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. May 20, 2005;280(20):19665-72.;;Cohen et al., Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. Mar. 1, 2005;11(5):2063-73.;;Wu et al., In vivo effects of the human type I Insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. Apr. 15, 2005;11(8):3065-74.;;Goetsch et al., A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. Jan. 10, 2005;113(2):316-28.;;Granerus et al., Effects of insulin-like growth factor-binding protein 2 and an IGF-type I receptor-blocking antibody on apoptosis in human teratocarcinoma cells in vitro. Cell Biol Int. 2001;25(8):825-8.;;Kaliman et al., Antipeptide antibody to the insulin-like growth factor-I receptor sequence 1232-1246 inhibits the receptor kinase activity. J Biol Chem. May 25, 1992;267(15):10645-51.;;Rodeck et al., Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem. Dec. 1987;35(4):315-20.;;Iwakiri et al., Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein Barr virus-encoded small RNA. Cancer Res. Nov. 1, 2003;63(21):7062-7.;;Kiess et al., Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept. Sep. 26, 1997;72(1):19-29.;;Pritchard et al., Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol. Sep. 1, 2004;173(5):3564-9.;;Jackson-Booth et al., Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res. Nov-Dec. 2003;35(11-12):850-6.;;Carboni et al., Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. May 1, 2005;65(9):3781-7.;;Rernacle-Bonnet et al., Insulin-like growth factor-1 protects colon cancer cells from death factor-induced apoptsis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res. Apr. 1, 2000;60(7):2007-17.;;Lahm et al., Blockade of the Insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer. Aug. 1, 1994;58(3):452-9.;;Steele-Perkins et al., Monoclonal antibody alpha IR-3 inihibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding. Biochem Biophys Res Commun. Sep. 28, 1990;171(3):1244-51.;;Scotlandi et al., Prognastic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. Jun. 2005;41(9):1349-61.;;Agus et al., Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. Oct. 1, 1999;59(19):4761-4.;;Pietras et al., Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. Mar. 15, 1999;59(6):1347-55.;;Goldenberg, Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. Feb. 1999;21(2):309-18. Review.;;Kull et al., Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem. May 25, 1983;258(10):6561-6.;;Benini et al., Inhibition of Insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. Jun. 2001;7(6):1790-7.;;Seely et al., Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer. May 31, 2002;2:15.;;Soos et al., A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem. Jun. 25, 1992;267(18):12955-63.;;Kalebic et al., In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. Nov. 1, 1994;54(21):5531-4.;;Baserga, The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. Jan. 15, 1995;55(2):249-52.;;Rubini et al., Characterization of an antibody that can detect an activated IGF-I receptor in human cancers. Exp Cell Res. Aug. 25, 1999;251(1):22-32.",EXPIRED
83,ZA,B,ZA 200409440 B,109-436-805-330-366,2006-07-26,2006,ZA 200409440 A,2004-11-23,US 38345902 P,2002-05-24,Neutralizing human anti-IGFR antibody,,SCHERING CORP,WANG YAN;;PRESTA LEONARD;;HAILEY JUDITH;;WILLIAMS DENISE;;FEINGERSH DIANE;;GREENBERG ROBERT;;PACHTER JONATHAN A;;BRAMS PETER;;SRINIVASAN MOHAN,,https://lens.org/109-436-805-330-366,Granted Patent,no,0,0,4,48,0,,A61K/;;C07H/;;C07K/;;C12N/,,0,0,,,,ACTIVE
84,NZ,A,NZ 536475 A,161-471-553-722-580,2008-06-30,2008,NZ 53647503 A,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 P;;US 0316283 W,2002-05-24,Neutralizing human anti-igfr antibody,"Disclosed are fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-1 (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Further disclosed are methods of using and producing the antibodies.",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,"SCHERING CORPORATION, US (2010-08-27)",https://lens.org/161-471-553-722-580,Patent Application,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N15/09;;C12N5/10;;C12P21/08,,0,0,,,,DISCONTINUED
85,AU,A1,AU 2003/241590 A1,182-283-600-520-820,2003-12-12,2003,AU 2003/241590 A,2003-05-22,US 39321402 P;;US 43625402 P;;US 38345902 P;;US 0316283 W,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,,MERCK SHARP & DOHME,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,,https://lens.org/182-283-600-520-820,Patent Application,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N15/09;;A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,EXPIRED
86,AU,B2,AU 2007/200876 B2,150-356-791-295-235,2010-11-04,2010,AU 2007/200876 A,2007-02-28,AU 2003/241590 A;;AU 2007/200876 A;;US 38345902 P;;US 43625402 P;;US 39321402 P,2002-05-24,Neutralizing human anti-IGFR antibody,,MERCK SHARP & DOHME,PACHTER JONATHAN A;;PRESTA LEONARD;;SRINIVASAN MOHAN;;FEINGERSH MARY DIANE;;GREENBERG ROBERT;;WANG YAN;;HAILEY JUDITH;;WILLIAMS DENISE;;BRAMS PETER,,https://lens.org/150-356-791-295-235,Granted Patent,no,0,0,2,48,0,,C12N15/09;;A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,2,2,079-861-467-759-75X;;064-327-493-747-459,10.1007/s002620000115;;10941907;;9496257;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.3.co;2-w;;10.1002/(sici)1096-9896(199712)183:4<412::aid-path944>3.0.co;2-4,"Li et al., Cancer Immunol. Immunother., 2000, vol. 49(4-5), pages 243-252;;Happerfield et al., J Pathol., 1997, vol. 183(4), pp. 412-417",EXPIRED
87,NO,L,NO 20045645 L,174-484-662-710-858,2004-12-23,2004,NO 20045645 A,2004-12-23,US 38345902 P;;US 39321402 P;;US 43625402 P;;US 0316283 W,2002-05-24,Noytraliserende humant anti-IGFR-antistoff,"Foreliggende oppfinnelse inkluderer fiillt humane, nøyttaliserende, monoklonale antistoffer mot human insulinliknende vekstfaktorreseptor-I (IGFRl). Antistoffene er nyttige ved behandling eller forebygging av kreft hos et individ. Også inkludert er fremgangsmåter for anvendelse av og fremstilling av antistoffene ifølge oppfirmelsen.",SCHERING CORP,PRESTA LEONARD G;;PACHTER JONATHAN A;;WANG YAN;;GREENBERG ROBERT;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH DIANE,,https://lens.org/174-484-662-710-858,Abstract,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,A61K39/395;;A61P1/04;;C12N15/09;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,PENDING
88,JP,A,JP 2010246567 A,191-805-080-130-459,2010-11-04,2010,JP 2010174047 A,2010-08-02,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,"<P>PROBLEM TO BE SOLVED: To provide fully human anti-human IGFR1 monoclonal antibodies which are useful for treating or preventing diseases which are mediated by IGFR1 (e.g., malignancy). <P>SOLUTION: There is provided a binding composition specifically binding to IGFR1, which includes a member selected from the group consisting of a light chain amino acid sequence comprising CDR-L1, CDR-L2, and CDR-L3; and a heavy chain amino acid sequence comprising CDR-H1, CDR-H2, and CDR-H3. A neutralizing human anti-IGFR antibody includes fully human, neutralizing monoclonal antibodies against the human IGFR1. The antibody is useful for treating or preventing cancer in a subject. There also are included methods of using and producing the antibody. <P>COPYRIGHT: (C)2011,JPO&INPIT",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH MARY DIANE,,https://lens.org/191-805-080-130-459,Patent Application,no,0,0,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N15/09;;A61K39/395;;C12P21/08;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10,,0,0,,,,DISCONTINUED
89,JP,A,JP 2011092202 A,029-814-100-023-898,2011-05-12,2011,JP 2010288975 A,2010-12-24,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,"<P>PROBLEM TO BE SOLVED: To provide fully human anti-human IGFR1 monoclonal antibodies which are useful for treating or preventing diseases which are mediated by IGFR1 (e.g., malignancy). <P>SOLUTION: A binding composition is provided which specifically binds to human IGFR1 comprising a member selected from the group consisting of a light chain amino acid sequence including CDR-L1, CDR-L2, and CDR-L3 and a heavy chain amino acid sequence including CDR-H1, CDR-H2, and CDR-H3. The invention includes fully human monoclonal antibodies specific for human insulin-like growth factor receptor 1 (IGFR1). The antibodies are useful for treating or preventing cancers in a subject's body. The invention also includes methods of using the antibodies and methods of producing the antibodies. <P>COPYRIGHT: (C)2011,JPO&INPIT",SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH MARY DIANE,,https://lens.org/029-814-100-023-898,Patent Application,no,0,0,42,48,120,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N15/09;;A61K39/395;;A61P1/04;;A61P1/12;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/02;;C12P21/08,,0,0,,,,DISCONTINUED
90,PL,B1,PL 210412 B1,046-886-005-342-291,2012-01-31,2012,PL 37388603 A,2003-05-22,US 38345902 P;;US 39321402 P;;US 43625402 P,2002-05-24,NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY,,SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PRESTA LEONARD;;PACHTER JONATHAN A;;HAILEY JUDITH;;BRAMS PETER;;WILLIAMS DENISE;;SRINIVASAN MOHAN;;FEINGERSH MARY DIANE,,https://lens.org/046-886-005-342-291,Granted Patent,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N5/12;;A61K39/395;;C12N15/09;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07H21/04;;C07K16/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,EXPIRED
91,AU,A1,AU 2010/227116 A1,158-735-431-169-738,2010-11-04,2010,AU 2010/227116 A,2010-10-08,AU 2007/200876 A;;AU 2010/227116 A;;US 38345902 P;;US 43625402 P;;US 39321402 P,2002-05-24,Neutralizing human anti-IGFR antibody,,SCHERING CORP,WANG YAN;;GREENBERG ROBERT;;PACHTER JONATHAN A;;PRESTA LEONARD;;HAILEY JUDITH;;BRAMS PETER;;SRINIVASAN MOHAN;;WILLIAMS DENISE;;FEINGERSH MARY DIANE,,https://lens.org/158-735-431-169-738,Patent Application,no,0,0,42,48,0,A61K2039/505;;C07K16/2863;;C07K16/2869;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/73;;C07K2317/76;;A61P1/04;;A61P1/12;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;A61P9/10;;C07K16/28;;A61K39/395;;C12N5/12;;C07K16/2863;;C07K2317/565;;C07K2317/21;;C07K2317/73;;C07K2317/24;;C07K2317/56;;A61K2039/505;;C07K16/2869;;C07K2317/76,C12N15/09;;A61K39/395;;A61P1/04;;A61P9/10;;A61P13/08;;A61P17/06;;A61P21/00;;A61P35/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,DISCONTINUED
92,US,A1,US 2017/0017831 A1,107-141-793-895-878,2017-01-19,2017,US 201615206453 A,2016-07-11,US 201615206453 A;;US 201662308204 P;;US 201562191780 P,2015-07-13,"FACE DETECTION, AUGMENTATION, SPATIAL CUEING AND CLUTTER REDUCTION FOR THE VISUALLY IMPAIRED","An apparatus for improving performance of a retinal implant may include processing circuitry. The processing circuitry may be configured to receive image data corresponding to a camera field of view, determine whether a particular object is detected within the camera field of view, perform image data processing to enable a representation of a portion of the image data corresponding to an implant field of view to be provided on a retinal implant where the implant field of view is smaller than the camera field of view, and, responsive to the particular object being located outside the implant field of view, provide a directional indicator in the implant field of view to indicate a location of the particular object relative to the implant field of view.",UNIV JOHNS HOPKINS,ROLLEND DEREK M;;KATYAL KAPIL D;;WOLFE KEVIN C;;KLEISSAS DEAN M;;PARA MATTHEW P;;ROSENDALL PAUL E;;HELDER JOHN B;;BURLINA PHILIPPE M;;CORNISH DUANE C;;MURPHY RYAN J;;JOHANNES MATTHEW S;;ROY ARUP;;BILLINGS SETH D;;OBEN JONATHAN M;;GREENBERG ROBERT J,THE JOHNS HOPKINS UNIVERSITY (2016-08-17),https://lens.org/107-141-793-895-878,Patent Application,yes,5,21,2,2,0,G06F3/011;;G06F3/013;;G06F3/0304;;A61N1/36046;;G06F1/163;;G06V40/161;;G06T5/40;;G06F1/163;;G06T2207/10004;;G06T2207/30201;;G06F3/011;;G06F3/013;;G06F3/0304;;A61N1/36046;;G06V40/161;;G06T7/11,G06K9/00;;G06F1/16;;G06T5/40;;G06T7/00,,2,2,115-038-203-045-852;;052-104-972-727-451,25307496;;10.1088/1741-2560/11/6/066002;;10.1088/1741-2560/10/2/026017;;23449023,"Kiral-Kornek et al. ""Improved visual performance in letter perception through edge orientation encoding in a retinal prosthesis simulation"", Journal of Neural Engineering, Volume 11, Number 6, Published 13 October 2014, Available online at: http://iopscience.iop.org/article/10.1088/1741-2560/11/6/066002/meta;;Parih et al., ""Performance of visually guided tasks using simulated prosthetic vision and saliency-based cues"", Journal of Neural Engineering, Volume 10, Number 2, Published 28 February 2013, Available online at: http://iopscience.iop.org/article/10.1088/1741-2560/10/2/026017/meta",ACTIVE
93,US,B2,US 10013599 B2,118-631-943-326-293,2018-07-03,2018,US 201615206453 A,2016-07-11,US 201615206453 A;;US 201662308204 P;;US 201562191780 P,2015-07-13,"Face detection, augmentation, spatial cueing and clutter reduction for the visually impaired","An apparatus for improving performance of a retinal implant may include processing circuitry. The processing circuitry may be configured to receive image data corresponding to a camera field of view, determine whether a particular object is detected within the camera field of view, perform image data processing to enable a representation of a portion of the image data corresponding to an implant field of view to be provided on a retinal implant where the implant field of view is smaller than the camera field of view, and, responsive to the particular object being located outside the implant field of view, provide a directional indicator in the implant field of view to indicate a location of the particular object relative to the implant field of view.",UNIV JOHNS HOPKINS,ROLLEND DEREK M;;KATYAL KAPIL D;;WOLFE KEVIN C;;KLEISSAS DEAN M;;PARA MATTHEW P;;ROSENDALL PAUL E;;HELDER JOHN B;;BURLINA PHILIPPE M;;CORNISH DUANE C;;MURPHY RYAN J;;JOHANNES MATTHEW S;;ROY ARUP;;BILLINGS SETH D;;OBEN JONATHAN M;;GREENBERG ROBERT J,THE JOHNS HOPKINS UNIVERSITY (2016-08-17),https://lens.org/118-631-943-326-293,Granted Patent,yes,6,0,2,2,0,G06F3/011;;G06F3/013;;G06F3/0304;;A61N1/36046;;G06F1/163;;G06V40/161;;G06T5/40;;G06F1/163;;G06T2207/10004;;G06T2207/30201;;G06F3/011;;G06F3/013;;G06F3/0304;;A61N1/36046;;G06V40/161;;G06T7/11,G06K9/00;;A61N1/36;;G06F1/16;;G06F3/01;;G06F3/03;;G06T5/40;;G06T7/11,,2,2,115-038-203-045-852;;052-104-972-727-451,25307496;;10.1088/1741-2560/11/6/066002;;10.1088/1741-2560/10/2/026017;;23449023,"Kiral-Kornek et al. “Improved visual performance in letter perception through edge orientation encoding in a retinal prosthesis simulation”, Journal of Neural Engineering, vol. 11, No. 6, Published Oct. 13, 2014, Available online at: http://iopscience.iop.org/article/10.1088/1741-2560/11/6/066002/meta.;;Parih et al., “Performance of visually guided tasks using simulated prosthetic vision and saliency-based cues”, Journal of Neural Engineering, vol. 10, No. 2, Published Feb. 28, 2013, Available online at: http://iopscience.iop.org/article/10.1088/1741-2560/10/2/026017/meta.",ACTIVE
